<SEC-DOCUMENT>0001104659-25-050983.txt : 20250520
<SEC-HEADER>0001104659-25-050983.hdr.sgml : 20250520
<ACCEPTANCE-DATETIME>20250520171016
ACCESSION NUMBER:		0001104659-25-050983
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250520
FILED AS OF DATE:		20250520
DATE AS OF CHANGE:		20250520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DarioHealth Corp.
		CENTRAL INDEX KEY:			0001533998
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				452973162
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37704
		FILM NUMBER:		25969865

	BUSINESS ADDRESS:	
		STREET 1:		322 W 57TH ST. #33B
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		972-4-770-6377

	MAIL ADDRESS:	
		STREET 1:		322 W 57TH ST. #33B
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LabStyle Innovations Corp.
		DATE OF NAME CHANGE:	20111101
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>tm2515450d1_pre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 19 17:09:12 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:drio="http://dariohealth.com/20250520" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-sec-ix-hidden: hidden-fact-0">SCHEDULE 14A</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(RULE 14a-101)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCHEDULE 14A INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proxy Statement Pursuant to Section&#160;14(a)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filed by the Registrant&#8239;&#8239;<span>&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filed by a Party other than the Registrant&#8239;&#8239;<span>&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the Appropriate Box:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span>&#9746;</span></td>
    <td style="text-align: justify">Preliminary Proxy Statement</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span>&#9744;</span></td>
    <td style="text-align: justify">Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2))</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"/></tr>
  <tr style="vertical-align: top">
    <td><span>&#9744;</span><span style="font-family: Wingdings; color: #0070C0"> </span></td>
    <td style="text-align: justify">Definitive Proxy Statement</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span>&#9744;</span></td>
    <td style="text-align: justify">Definitive Additional Materials</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span>&#9744;</span></td>
    <td>Soliciting Material Pursuant to &#167; 240.14a-12</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-102"><b>DARIOHEALTH CORP.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant as Specified in Its Charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Person(s)&#160;Filing Proxy Statement,
if other than the Registrant)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of Filing Fee (Check the appropriate box):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span>&#9746;</span></td>
    <td>No fee required</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span>&#9744;</span></td>
    <td>Fee paid previously with preliminary materials:</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding: 0.25pt"><span>&#9744;</span></td>
    <td style="padding: 0.25pt">Fee computed on table in exhibit required by Item 25(b)&#160;per Exchange Act Rules&#160;14a-6(i)(1)&#160;and 0-11</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DarioHealth Corp.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>322 W. 57th St.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>New York, New York 10019</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">To Be Held On Wednesday, July&#160;23, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are cordially invited to attend an annual
meeting of the stockholders (the &#8220;<b>Meeting</b>&#8221;) of DarioHealth Corp. (the &#8220;<b>Company</b>&#8221;), which will be
held at 4:00 p.m.&#160;(Israel Time) on Wednesday, July&#160;23, 2025, at our Israeli office, located at 5 Tarshish St., 2<sup>nd</sup>&#160;Floor,
Caesarea Industrial Park, 3088900,&#160;Israel. We intend to hold the annual meeting for the following purposes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">1.</td>
    <td style="width: 95%; text-align: justify">To re-elect Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure and Adam K. Stern as directors to serve on the Company&#8217;s Board of Directors (the &#8220;<b>Board</b>&#8221;) for a one-year term that expires at the 2026 Annual Meeting of Stockholders, or until their successors are elected and qualified or until their earlier resignation or removal;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>2.</td>
    <td style="text-align: justify">To ratify the appointment by the Audit Committee of the Board of Kesselman&#160;&amp; Kesselman, a member of PricewaterhouseCoopers International Limited&#160;as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2025; </td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>3.</td>
    <td style="text-align: justify">To consider and vote to amend and restate the Company&#8217;s 2020 Equity Compensation Plan, as amended; </td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>4.</td>
    <td style="text-align: justify">To authorize the Board to amend the Company&#8217;s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company&#8217;s issued and outstanding shares of common stock, $0.0001 par value per share (the &#8220;<b>Common Stock</b>&#8221;), at a ratio of not less than one (1)&#160;to two (2)&#160;and not greater than one (1)&#160;to twenty five (25), to be implemented no later than September&#160;15, 2025, as determined by the Board in its sole discretion;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>5.</td>
    <td style="text-align: justify">To approve an amendment to the Articles of Incorporation of the Company to increase the number of authorized shares Common Stock from one hundred sixty million (160,000,000) shares, $0.0001 par value per share, to four hundred million (400,000,000) shares, $0.0001 par value per share; and</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>6.</td>
    <td style="text-align: justify">To transact any other business as may properly come before the Meeting or any adjournments thereof.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All stockholders are cordially
invited to attend the Meeting.&#160;If your shares are registered in your name, please bring the admission ticket attached to your proxy
card.&#160;If your shares are registered in the name of a broker, trust, bank or other nominee, you will need to bring a proxy or a letter
from that broker, trust, bank or other nominee or your most recent brokerage account statement, that confirms that you are the beneficial
owner of those shares. If you do not have either an admission ticket or proof that you own shares of the Company, you will not be admitted
to the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has fixed the close
of business on May&#160;&#160;&#160;, 2025 as the record date for the Meeting. Only stockholders on the record date are entitled to notice of and
to vote at the Meeting and at any adjournment or postponement thereof. <span>In addition, shareholders
who intend to solicit proxies in support of director nominees other than the Company&#8217;s nominees must also comply with the additional
requirements of Rule&#160;14a-19(b).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your vote is important regardless
of the number of shares you own.&#160;The Company requests that you complete, sign, date and return the enclosed proxy card without delay
in the enclosed postage-paid return envelope, even if you now plan to attend the Meeting.&#160;You may revoke your proxy at any time prior
to its exercise by delivering written notice or another duly executed proxy bearing a later date to the Secretary of the Company, or by
attending the Meeting and voting in person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 100%; border: black 1pt solid; padding: 2pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Important Notice Regarding the Availability
    of Proxy Materials for the Meeting to be held on July&#160;23, 2025</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The proxy statement, proxy card and Annual Report
    are also available at</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">http://www.dariohealth.com/DH2025Proxy.pdf</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Stockholders may also obtain additional paper or
    e-mail copies of these materials at no cost by writing to<br/>
    DarioHealth Corp., 322 W. 57th St., New York, New York, 10019, and/or via electronic mail to ir@dariohealth.com,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Secretary.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities and Exchange Commission
rules&#160;allow us to furnish proxy materials to our stockholders over the internet. You may also have access to the materials for the
Meeting by visiting the website: https://dariohealth.investorroom.com. You may also cast your vote by visiting www.proxyvote.com if you
hold your shares in &#8220;street name,&#8221; or www.vstocktransfer.com/proxy if you are a registered stockholder. You may also authorize
a proxy to vote your shares over the internet. In order to vote over the internet, you must have your stockholder identification number,
which is set forth in the Notice of Internet Availability of Proxy Materials mailed to you. You may also request a paper proxy card to
submit your vote by mail. If you have any questions regarding the completion of the enclosed&#160;proxy&#160;card&#160;or&#160;would&#160;like&#160;directions&#160;to&#160;the&#160;Meeting,&#160;please&#160;call
(972)-4770-6377, and/or via electronic mail to ir@dariohealth.com.&#160;You&#160;may&#160;also&#160;find&#160;directions&#160;at <span style="text-decoration:underline">https://dariohealth.investorroom.com/SECFilings</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%"><b>By order of the Board</b>,</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">/s/ Erez Raphael</td></tr>
  <tr>
    <td>&#160;</td>
    <td>Erez Raphael</td></tr>
  <tr>
    <td>&#160;</td>
    <td>Chief Executive Officer</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caesarea,&#160;Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160; , 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IMPORTANT: In order to secure a quorum and
to avoid the expense of additional proxy solicitation, please either vote by internet or sign, date and return your proxy promptly in
the enclosed envelope even if you plan to attend the Meeting personally. Your cooperation is greatly appreciated.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION
OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF EACH OF THE PROPOSALS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 95%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 5%; text-align: center"><b>Page</b>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_001">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_001">2</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_002">THE ANNUAL MEETING</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_002">2</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_003">PROPOSAL 1&#160;ELECTION OF DIRECTORS</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_003">9</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="#a_004">PROPOSAL 2-&#160;RATIFICATION OF THE APPOINTMENT OF THE COMPANY&#8217;S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER
    31, 2025</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_004">13</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_005">PROPOSAL 3-&#160;INCENTIVE PLAN PROPOSAL</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_005">14</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_006">PROPOSAL 4- REVERSE STOCK SPLIT PROPOSAL</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_006">21</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_007">PROPOSAL 5- INCREASE THE NUMBER OF AUTHORIZED SHARES</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_007">28</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_008"><span style="text-transform: uppercase">Beneficial Ownership of Principal Stockholders, Officers
    and Directors</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_008">45</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_009">STOCKHOLDER PROPOSALS</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_009">48</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_010">HOUSEHOLDING OF MEETING MATERIALS</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_010">48</a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_011">OTHER MATTERS</a></td>
    <td style="vertical-align: bottom; text-align: right"><a href="#a_011">48</a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROXY STATEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>DarioHealth
</b></span><b>CORP.</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANNUAL MEETING OF STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>to be held at 4:00 p.m.&#160;(Israel Time)
on July&#160;23, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5 Tarshish St., 2<sup>nd</sup> Floor,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Caesarea Industrial Park, 3088900,&#160;Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Why am I receiving this Proxy Statement?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy Statement describes
the proposals on which our Board of Directors (the &#8220;<b>Board</b>&#8221;) would like you, as a stockholder, to vote at an annual
meeting of the stockholders (the &#8220;<b>Meeting</b>&#8221;), which will take place at 4:00 p.m.&#160;(Israel Time) on Wednesday, July&#160;23,
2025, at our Israeli office, located at 5 Tarshish Street, 2<sup>nd</sup> floor, Caesarea Industrial Park,&#160;3088900,&#160;Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy Statement also
gives you information on these proposals so that you can make an informed decision. We intend to mail this Proxy Statement and accompanying
proxy card on or about June&#160;6, 2025, to all stockholders of record entitled to vote at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this proxy statement, we
refer to DarioHealth Corp. as the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221; or similar terminology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Website addresses included
in this proxy statement are textual references only, and the information in any website is not incorporated by reference into this proxy
statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>How many shares must be present in order to
hold the Meeting?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that a
quorum shall consist of the holders of thirty-three and one-third (33 1/3<sup>rd</sup>) of the stock issued and outstanding and entitled
to vote thereat, present in person or represented by proxy at the Meeting. A quorum will be present if stockholders holding at least a
majority of the outstanding shares entitled to vote are present at the Meeting in person or represented by proxy. On May&#160;29, 2025
(the &#8220;<b>Record Date</b>&#8221;), there were 44,449,424 shares of our common stock, $0.0001 par value per share (the &#8220;<b>Common
Stock</b>&#8221;), 1,882 shares of Series&#160;A-1 Convertible Preferred Stock (convertible into 464,693 shares of Common Stock), with
a conversion price of $4.05 per share (the &#8220;<b>Series&#160;A-1 Preferred Stock</b>&#8221;), 4,946 shares of Series&#160;B-1 Convertible
Preferred Stock (convertible into 1,483,503 shares of Common Stock), with a conversion price of $3.334 per share (the &#8220;<b>Series&#160;B-1
Preferred Stock</b>&#8221;), 16,912 shares of Series&#160;C Convertible Preferred Stock (convertible into 8,388,352 shares of Common Stock),
with a conversion price of $2.02 per share (the &#8220;<b>Series&#160;C Preferred Stock</b>&#8221;), 4,000 shares of Series&#160;C-1 Convertible
Preferred Stock (convertible into 1,984,000 shares of Common Stock), with a conversion price of $2.02 per share (the &#8220;<b>Series&#160;C-1
Preferred Stock</b>&#8221;), 1,115 shares of Series&#160;C-2 Convertible Preferred Stock (convertible into 521,820 shares of Common Stock),
with a conversion price of $2.14 per share (the &#8220;<b>Series&#160;C-2 Preferred Stock</b>&#8221;), 7,055 shares of Series&#160;D Preferred
Stock (convertible into 9,665,350 shares of Common Stock), with a conversion price of $0.73 per share (the &#8220;<b>Series&#160;D Preferred
Stock</b>&#8221;), 11,750 shares of Series&#160;D-1 Preferred Stock (convertible into 16,097,500 shares of Common Stock), with a conversion
price of $0.73 per share (the &#8220;<b>Series&#160;D-1 Preferred Stock</b>&#8221;), 4,950 shares of Series&#160;D-2 Preferred Stock (convertible
into 5,964,750 shares of Common Stock), with a conversion price of $0.83 per share (the &#8220;<b>Series&#160;D-2 Preferred Stock</b>&#8221;)
and 1,850 shares of Series&#160;D-3 Preferred Stock (convertible into 2,229,250 shares of Common Stock), with a conversion price of $0.83
per share (the &#8220;<b>Series&#160;D-3 Preferred Stock</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Common Stock
and preferred stock, except for the Series&#160;A-1 Preferred Stock, Series&#160;B-1 Preferred Stock, Series&#160;C-1 Preferred Stock,
Series&#160;D-1 Preferred Stock, and Series&#160;D-3 Preferred Stock is entitled to one vote per share on an as-converted basis. The Series&#160;A-1
Preferred Stock, Series&#160;B-1 Preferred Stock, Series&#160;C-1 Preferred Stock, Series&#160;D-1 Preferred Stock, and Series&#160;D-3
Preferred Stock do not possess any voting rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Thus, the holders of the aggregate
number of 22,997,026 shares of Common Stock, inclusive of the shares of Common Stock issuable upon conversion of the Series&#160;C Preferred
Stock, Series&#160;C-2 Preferred Stock, Series&#160;D Preferred Stock and Series&#160;D-2 Preferred Stock (on an as-converted basis) must
be present in person or represented by proxy at the Meeting to have a quorum. If such quorum shall not be present or represented, the
stockholders entitled to vote thereat, present in person or represented by proxy, shall have the power to adjourn the Meeting, without
notice other than announcement at the Meeting, until a quorum shall be present or represented. Your shares will be counted towards the
quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person
at the Meeting. Abstentions may be specified on all proposals. Abstentions and broker non-votes will be counted towards the quorum requirement.
Submitted proxies which are left blank will also be counted as present for purposes of determining a quorum but are not counted for purposes
of determining whether a proposal has been approved in matters where the proxy does not confer the authority to vote on such proposal,
and thus have no effect on its outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Who can vote at the Meeting?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders who owned shares of our Common Stock,
Series&#160;C Preferred Stock, Series&#160;C-2 Preferred Stock, Series&#160;D Preferred Stock, Series&#160;D-2 Preferred Stock on the
Record Date may attend and vote at the Meeting. There were 44,449,424 shares of Common Stock, 16,912 shares of Series&#160;C Preferred
Stock (convertible into 8,388,352 shares of Common Stock), 1,115 shares of Series&#160;C-2 Preferred Stock (convertible into 521,820 shares
of Common Stock), 7,055 shares of Series&#160;D Preferred Stock (convertible into 9,665,350 shares of Common Stock), and 4,950 shares
of Series&#160;D-2 Preferred Stock (convertible into 5,964,750 shares of Common Stock), outstanding on the Record Date. All shares of
Common Stock and preferred stock, aside from the Series&#160;A-1 Preferred Stock, Series&#160;B-1 Preferred Stock, Series&#160;C-1 Preferred
Stock, Series&#160;D-1 Preferred Stock, and Series&#160;D-3 Preferred Stock, have one vote per share and vote together as a single class.
The Series&#160;A-1 Preferred Stock, Series&#160;B-1 Preferred Stock, Series&#160;C-1 Preferred Stock, Series&#160;D-1 Preferred Stock,
and Series&#160;D-3 Preferred Stock do not possess any voting rights. Information about the stockholdings of our directors and executive
officers is contained in the section of this Proxy Statement entitled &#8220;Beneficial Ownership of Principal Stockholders, Officers
and Directors&#8221; on page&#160;45 of this Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>What is the proxy card?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proxy card enables you
to appoint Erez Raphael, our Chief Executive Officer, and/or Chen Franco-Yehuda, our Chief Financial Officer, Secretary and Treasurer,
as your representative at the Meeting. By completing and returning the proxy card or voting online as described herein, you are authorizing
these persons to vote your shares at the Meeting in accordance with your instructions on the proxy card. This way, your shares will be
voted whether or not you attend the Meeting. Even if you plan to attend the Meeting, please complete and return your proxy card before
the Meeting date just in case your plans change. If a proposal comes up for vote at the Meeting that is not on the proxy card, the proxies
will vote your shares, under your proxy, according to their best judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What am I voting on?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are being asked to vote:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">1.</td>
    <td style="text-align: justify">To re-elect Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure and Adam K. Stern as directors to serve on the Company&#8217;s Board for a one-year term that expires at the 2026 Annual Meeting of Stockholders, or until their successors are elected and qualified or until their earlier resignation or removal (the &#8220;<b>Election of Directors Proposal</b>&#8221;);</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>2.</td>
    <td style="text-align: justify">To ratify the appointment by the Audit Committee of the Board of Kesselman&#160;&amp; Kesselman, a member of PricewaterhouseCoopers International Limited (the &#8220;<b>Auditor</b>&#8221;) as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2025; </td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>3.</td>
    <td style="text-align: justify">To consider and vote to amend the Company&#8217;s 2020 Equity Compensation Plan, as amended (the &#8220;<b>2020 Equity Incentive Plan</b>&#8221; and the &#8220;<b>Incentive Plan Proposal</b>&#8221; respectively)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>4.</td>
    <td style="text-align: justify">To authorize the Board to amend the Company&#8217;s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company&#8217;s issued and outstanding shares of Common Stock at a ratio of not less than one (1)&#160;to two (2)&#160;and not greater than one (1)&#160;to twenty five (25), to be implemented no later than September&#160;15, 2025, as determined by the Board in its sole discretion (the &#8220;<b>Reverse Stock Split Proposal</b>&#8221;);</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>5.</td>
    <td style="text-align: justify">To approve an &#160;amendment to the Articles of Incorporation of the Company to increase the number of authorized Common Stock from one hundred sixty million (160,000,000) shares, $0.0001 par value per share, to four hundred million (400,000,000) shares, par value $0.0001 par value per share (the &#8220;<b>Increase in Authorized Shares Proposal</b>&#8221;); and</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">6.</td>
    <td style="text-align: justify">To transact any other business as may properly come before the Meeting or any adjournments thereof.</td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>How does the Board recommend that I vote?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board unanimously recommends
that the stockholders vote <b>&#8220;FOR&#8221;</b> all proposals being put before our stockholders at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the difference between holding shares
as a stockholder of record and as a beneficial owner?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of our stockholders hold
their shares in an account at a brokerage firm, bank or other nominee holder, rather than holding share certificates in their own name.
As summarized below, there are some distinctions between shares held of record and those owned beneficially.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stockholder of Record</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, on the Record Date, your
shares were registered directly in your name with our transfer agent, VStock Transfer LLC, you are a &#8220;stockholder of record&#8221;
who may vote at the Meeting, and we are sending these proxy materials directly to you. As the stockholder of record, you have the right
to direct the voting of your shares by returning the enclosed proxy card to us or to vote in person at the Meeting. Whether or not you
plan to attend the Meeting, please complete, date and sign the enclosed proxy card to ensure that your vote is counted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Beneficial Owner</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, on the Record Date, your
shares were held in an account at a brokerage firm or at a bank or other nominee holder, you are considered the beneficial owner of shares
held &#8220;in street name,&#8221; and these proxy materials are being forwarded to you by your broker or nominee who is considered the
stockholder of record for purposes of voting at the Meeting. As the beneficial owner, you have the right to direct your broker on how
to vote your shares and to attend the Meeting. However, since you are not the stockholder of record, you may not vote these shares in
person at the Meeting unless you receive a valid proxy from your brokerage firm, bank or other nominee holder. To obtain a valid proxy,
you must make a special request of your brokerage firm, bank or other nominee holder. If you do not make this request, you can still vote
by using the voting instruction card enclosed with this proxy statement; however, you will not be able to vote in person at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>How do I vote?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;You
may vote by mail.</b> You may vote by mail by completing, signing and dating your proxy card and returning it in the enclosed, postage-paid
and addressed envelope. If we receive your proxy card prior to the Meeting and if you mark your voting instructions on the proxy card,
your shares will be voted:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>as you instruct, and</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style=" font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">according to the best judgment of the proxies if a proposal comes up for a vote at the Meeting that is not on the proxy card.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>If you return a signed card, but do not provide
voting instructions, your shares will be voted:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>for the Election of Directors Proposal;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>for the ratification of the appointment of the Auditor as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>for the Incentive Plan Proposal;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>for the Reverse Stock Split Proposal;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>for the Increase in Authorized Shares Proposal; and</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td>according to the best judgment of either Mr.&#160;Raphael or Ms.&#160;Franco-Yehuda if a proposal comes up for a vote at the Meeting that is not on the proxy card.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;You
may vote in person at the Meeting.</b> We will pass out written ballots to anyone who wants to vote at the Meeting. However, if you hold
your shares in street name, you must bring to the Meeting a valid proxy from the broker, bank or other nominee holding your shares that
confirms your beneficial ownership of the shares and gives you the right to vote your shares. Holding shares in street name means you
hold them through a brokerage firm, bank or other nominee, and therefore the shares are not held in your individual name. We encourage
you to examine your proxy card closely to make sure you are voting all of your shares in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160;You
may vote online.</b> You may also have access to the materials for the Meeting by visiting the website: https://dariohealth.investorroom.com.
You may also cast your vote by visiting www.proxyvote.com if you hold your shares in &#8220;street name,&#8221; or www.vstocktransfer.com/proxy
if you are a registered stockholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What does it mean if I receive more than one
proxy card?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may have multiple accounts
at the transfer agent and/or with brokerage firms. Please sign and return all proxy cards to ensure that all of your shares are voted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What if I change my mind after I return my
proxy?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may revoke your proxy
and change your vote at any time before the polls close at the Meeting. You may do this by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style=" font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">sending a written notice to Chen Franco-Yehuda, our corporate Secretary, stating that you would like to revoke your proxy of a particular date;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style=" font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">signing another proxy card with a later date and returning it before the polls close at the Meeting; or</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style=" font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">attending the Meeting and voting in person.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please note, however, that
if your shares are held of record by a brokerage firm, bank or other nominee, you must instruct your broker, bank or other nominee that
you wish to change your vote by following the procedures on the voting form provided to you by the broker, bank or other nominee. If your
shares are held in street name, and you wish to attend and vote at the Meeting, you must bring to the Meeting a legal proxy from the broker,
bank or other nominee holding your shares, confirming your beneficial ownership of the shares and giving you the right to vote your shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Will my shares be voted if I do not sign and return my proxy card?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your shares are held in
street name or in your name and you do not sign and return your proxy card, your shares will not be voted unless you vote in person at
the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>How are votes counted?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may vote &#8220;for,&#8221;
 &#8220;against,&#8221; or &#8220;abstain&#8221; on each of the proposals being placed before our stockholders. Abstentions and broker
non-votes (<i>i.e.</i>, shares held by brokers on behalf of their customers, which may not be voted on certain matters because the brokers
have not received specific voting instructions from their customers with respect to such matters) will be counted solely for the purpose
of determining whether a quorum is present at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What are broker non-votes?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker non-votes occur when
a beneficial owner of shares held in &#8220;street name&#8221; does not give instructions to the broker or nominee holding the shares
as to how to vote on matters deemed &#8220;non-routine.&#8221; Generally, if shares are held in street name, the beneficial owner of the
shares is entitled to give voting instructions to the broker or nominee holding the shares. If the beneficial owner does not provide voting
instructions, the broker or nominee can&#8239;still vote the shares with respect to matters that are considered to be &#8220;routine,&#8221;
but not with respect to &#8220;non-routine&#8221; matters. In the event that a broker, bank, or other agent indicates on a proxy that
it does not have discretionary authority to vote certain shares on a non-routine proposal, then those shares will be treated as broker
non-votes. Proposals No.&#160;1, and 3, are non-routine proposals; therefore, your broker, bank or other agent is not entitled to vote
your shares on Proposals No.&#160;1, and 3 without your instructions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management believes that
Proposals 2, 4 and 5 are &#8220;routine&#8221; matters for which brokers will have authority to vote your shares at the Meeting if you
do not give instruction on how to vote your shares. Consequently, if customers do not give any direction, brokers will be permitted to
vote your shares at the Meeting in relation to these matters. Nevertheless, we encourage you to submit your voting instructions to your
broker to ensure your shares are voted at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>How many votes are required to elect the Director Nominees as directors
of the Company?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock represented in person or by proxy and entitled
to vote is required for approval of the election of each of the Director Nominees. Abstentions are considered present for purposes of
establishing a quorum but will have no effect on the election of directors. Broker non-votes will not affect the outcome of the vote on
this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>How many votes are required to ratify the Company&#8217;s independent
public accountants?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock represented in person or by proxy and entitled
to vote is required to ratify the Auditor as our independent registered public accounting firm for the year ending December&#160;31, 2025.
Abstentions are considered present for purposes of establishing a quorum but will have no effect on the ratification of our independent
public accountants. There are no broker non-votes on this matter since it is a &#8220;routine&#8221; matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>How many votes are required to approve the Incentive Plan Proposal?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock represented in person or by proxy and entitled to vote is required
for approval of the Incentive Plan Proposal. Abstentions are considered present for purposes of establishing a quorum but will have no
effect on the approval of the Incentive Plan Proposal. Broker non-votes will not affect the outcome of the vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>How many votes are required to approve the
Reverse Stock Split Proposal?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock (voting together as a single class) represented
in person or by proxy and entitled to vote is required for approval of the Reverse Stock Split Proposal. Abstentions are considered present
for purposes of establishing a quorum as to this matter&#160;but will have no effect on the approval of the Reverse Stock Split Proposal.
Broker non-votes are considered present for purposes of establishing a quorum as to this matter but will not affect the outcome of the
vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>How many votes are required to approve the
Increase in Authorized Shares Proposal?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock (voting together as a single class) represented
in person or by proxy and entitled to vote is required for approval of the Increase in Authorized Shares Proposal <b>and</b>&#160;the
affirmative vote of a majority of the votes cast at the Meeting by the holders of Common Stock&#160;(voting separately as a class)&#160;represented
in person or by proxy. Abstentions by holders of Common Stock&#160;are considered present for purposes of establishing a quorum&#160;as
to this matter&#160;but will have no effect on the approval of the Increase in Authorized Shares Proposal. Broker non-votes with respect
to Common Stock are considered present for purposes of establishing a quorum as to this matter but&#160;will not affect the outcome of
the vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What happens if I don&#8217;t indicate how
to vote my proxy?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you just sign your proxy
card without providing further instructions, your shares will be counted as a &#8220;for&#8221; vote for all of the proposals being placed
before our stockholders at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Is my vote kept confidential?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proxies, ballots and voting
tabulations identifying stockholders are kept confidential and will not be disclosed except as may be necessary to meet legal requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Where do I find the voting results of the Meeting?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will announce preliminary
voting results at the Meeting and file a Current Report on Form&#160;8-K announcing the final voting results of the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Who can help answer my questions?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can contact our Chief
Financial Officer, Secretary and Treasurer, Chen Franco-Yehuda, at (972) 4770-6377 or by sending a letter to Ms.&#160;Franco-Yehuda at
offices of the Company at 322 W. 57th St., New York, New York 10019, with any questions about proposals described in this Proxy Statement
or how to execute your vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Who is paying for this proxy solicitation?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay for the entire
cost of soliciting proxies. In addition to these mailed proxy materials, our directors and employees may also solicit proxies in person,
by telephone or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>No Right of Appraisal</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of Delaware law, our
Certificate of Incorporation or our Bylaws provides for appraisal or other similar rights for dissenting stockholders in connection with
any of the proposals to be voted upon at this Meeting. Accordingly, our stockholders will have no right to dissent and obtain payment
for their shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>ALL PROXIES RECEIVED WILL
BE VOTED IN ACCORDANCE WITH THE CHOICES SPECIFIED ON SUCH PROXIES. PROXIES WILL BE VOTED IN FAVOR OF A PROPOSAL IF NO CONTRARY SPECIFICATION
IS MADE. ALL VALID PROXIES OBTAINED WILL BE VOTED AT THE DISCRETION OF THE PERSONS NAMED IN THE PROXY WITH RESPECT TO ANY OTHER BUSINESS
THAT MAY&#160;COME BEFORE THE MEETING. THE BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR EACH OF PROPOSALS 1, 2, 3, 4, AND 5.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROPOSAL 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ELECTION OF DIRECTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Introduction</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has nominated the
Director Nominees, each of whom currently serves as a director, to stand for election at the Meeting. Stockholders will be asked to elect
each of the Director Nominees, each to hold office until the 2026 Annual Meeting of Stockholders or until his or her successor is elected
and qualified or until his or her earlier resignation or removal. The enclosed proxy, if returned, and unless indicated to the contrary,
will be voted for the election of each of the Director Nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been advised by each
of the Director Nominees that they are willing to be named as a nominee and each are willing to continue to serve as a director if elected.
If some unexpected occurrence should make necessary, in the discretion of the Board, the substitution of some other person for the nominees,
it is the intention of the persons named in the proxy to vote for the election of such other person as may be designated by the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Board Qualifications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the collective
skills, experiences and qualifications of our directors provide our Board with the expertise and experience necessary to advance the interests
of our stockholders. While the Nominating and Corporate Governance Committee of our Board does not have any specific, minimum qualifications
that must be met by each of our directors, the Nominating and Corporate Governance Committee uses a variety of criteria to evaluate the
qualifications and skills necessary for each member of the Board. In addition to the individual attributes of each of our current directors
described below, we believe that our directors should have the highest professional and personal ethics and values, consistent with our
longstanding values and standards. They should have broad experience at the policy-making level in business, exhibit commitment to enhancing
stockholder value and have sufficient time to carry out their duties and to provide insight and practical wisdom based on their past experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Nominee and Executive Officer Information</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Listed below are the names of the directors and
executive officers of the Company, their ages as of the Record Date and positions held:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><b>Name</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Age</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Position(s)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 20%">Erez Raphael</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: center">51</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 73%">Chief Executive Officer and Director</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Chen Franco-Yehuda</td>
    <td>&#160;</td>
    <td style="text-align: center">41</td>
    <td>&#160;</td>
    <td>Chief Financial Officer, Treasurer and Secretary</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>Steven Nelson</td>
    <td>&#160;</td>
    <td style="text-align: center">52</td>
    <td>&#160;</td>
    <td>Chief Commercial Officer</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Yoav Shaked</td>
    <td>&#160;</td>
    <td style="text-align: center">53</td>
    <td>&#160;</td>
    <td>Chairman of the Board</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>Dennis Matheis</td>
    <td>&#160;</td>
    <td style="text-align: center">64</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Hila Karah</td>
    <td>&#160;</td>
    <td style="text-align: center">56</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCECFF">
    <td>Lawrence Leisure</td>
    <td>&#160;</td>
    <td style="text-align: center">74</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Dennis M. McGrath</td>
    <td>&#160;</td>
    <td style="text-align: center">68</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCECFF">
    <td>Adam Stern</td>
    <td>&#160;</td>
    <td style="text-align: center">60</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="ecd:PeoName" id="ixv-1143"><b><i>Erez Raphael</i></b></ix:nonNumeric>&#160;has
served as our Chief Executive Officer since August&#160;9, 2013. Mr.&#160;Raphael served as Chairman of the Board from November&#160;2014
to July&#160;2018, and as a director from November&#160;2014 to the present. He previously and until October&#160;2012 served as our Vice
President of Research and Development. Mr.&#160;Raphael has over 17 years of industry experience, having been responsible in his career
for product delivery, technology and business development. Prior to joining us, from 2010 to 2012, Mr.&#160;Raphael served as Head of
Business Operations for Nokia Siemens Networks, where he was responsible for establishing and implementing a new portfolio business unit
directed towards marketing and sales of complimentary products. Prior to that, from 1998 to 2010, he held increasingly senior positions
at Amdocs Limited (Nasdaq: DOX) where he was ultimately responsible for advising the Chief Technology Officer and implementing matters
of overall business strategy. Mr.&#160;Raphael holds a B.A. in economics and business management from Haifa University. We believe Mr.&#160;Raphael
is qualified to serve on our Board because of his extensive experience with technology companies and in sales and marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Chen Franco-Yehuda </i></b>has
served as the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, since May&#160;15, 2025. Prior to joining our company,
Ms.&#160;Franco-Yehuda served as Chief Financial Officer, Treasurer and Secretary of Pluri Inc. (Nasdaq, TASE: PLUR), from March&#160;2019
to October&#160;2024. Prior to that, Ms.&#160;Franco-Yehuda served as Pluri&#8217;s Head of Accounting and Financial Reporting since July&#160;2016,
and Pluri&#8217;s Corporate Controller since May&#160;2013. Before joining Pluri, from October&#160;2008 to April&#160;2013, Ms.&#160;Franco-Yehuda
served as a manager of audit groups relating to public and private companies in various industries at PricewaterhouseCoopers (PwC) and
also as a lecturer of accounting classes at the Open University of Israel from 2009 to 2014. Ms.&#160;Franco-Yehuda also serves as a board
member and a member of the audit and compensation committee at Brenmiller Energy Ltd. (Nasdaq: BRNG). Ms.&#160;Franco-Yehuda holds a bachelor's
degree in economics and accounting with high honors from Haifa University and is a certified public accountant in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Steven C. Nelson</i></b>&#160;has
served as our Chief Commercial Officer since June&#160;5, 2024. From October&#160;2018 to September&#160;2023, Mr.&#160;Nelson served
as President and Chief Executive Officer of Contigo Health, a Premier Inc. subsidiary, where he previously served as Chief Operating Officer
from 2017 to 2018, Vice President of Strategy, Planning,&#160;&amp; Innovation from 2015 to 2016 and Chief of Staff in 2016. From 2007
to 2014, he served as Senior Vice President of Strategy, Product,&#160;&amp; Marketing at Highmark Inc., a healthcare company. Prior to
Highmark, from 2012 to 2014, he served as the Senior Vice President of Executive Oversight at Allegheny Health Network, a healthcare company.
Earlier in his career, Mr.&#160;Nelson was a Senior Vice President for GNC Holdings, LLC, General Manager of Brand Marketing and Promotions
for MET-Rx Nutrition Inc., Vice President of International Marketing for 141 Communicator, and Director of Marketing&#160;&amp; Omnicom
Integration for GMR Marketing LCC. Mr.&#160;Nelson holds a Bachelor of Science in education from the University of Pittsburgh at Johnstown
and a Master of Arts in business administration from Ohio University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yoav Shaked</i></b>
has served as the Chairman of our Board since July&#160;5, 2018. Since 2011, Mr.&#160;Shaked has served as a partner at Sequoia Capital,
a leading global venture capital firm. In 2005, he co-founded Medpoint Ltd., a private medical device distribution company offering a
wide range of medical products. Previously, he founded and served as Chief Executive Officer of Y-Med Inc. from May&#160;2004 until its
sale to C.R. Bard,&#160;Inc. in November&#160;2009. After the sale of Y-Med Inc., Mr.&#160;Shaked served as the director of research at
ThermopeutiX, a developer of innovative products for strokes and peripheral artery diseases. Mr.&#160;Shaked currently serves on the board
of directors of several biotechnology companies, including Endospan Ltd., Vibrant &#160;Ltd., G&amp;G Biotechnology Ltd., and Orasis Pharmaceuticals,&#160;Ltd.,
the latter of which he serves as Chairman of the board. Mr.&#160;Shaked has a B.A. in biology from The Hebrew University of Jerusalem.
We believe that Mr.&#160;Shaked is qualified to serve as Chairman of the Board because of his extensive experience both in biotechnology
companies and in the venture capital realm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dennis Matheis&#160;</i></b>has
been a director of our company since July&#160;2, 2020. Mr.&#160;Matheis spent nearly 30 years in various senior leadership roles in health
insurance and healthcare. Since September&#160;2022 he serves as the President and Chief Executive Officer of Sentara Healthcare,&#160;Inc.
Prior to that, he served for 5 years as the President of Optima Health,&#160;Inc. and spent 13 years in leadership roles at Anthem,&#160;Inc.,
serving as President of Central Region and Exchanges encompassing six states and representing $12 billion in annual revenue. Mr.&#160;Matheis
also served in senior leadership roles at Anthem Blue Cross and Blue Shield of Missouri, CIGNA Healthcare and Humana Health Plan, as well
as Advocate Health Care in Chicago. Mr.&#160;Matheis has a B.S. in accounting from the University of Kentucky and practiced as a Certified
Public Accountant before entering the healthcare industry. We believe that Mr.&#160;Matheis is qualified to serve on our Board because
of his experience in the healthcare business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Hila Karah</i></b>&#160;has
been a director of our company since November&#160;23, 2014. Ms.&#160;Karah is an independent business consultant and an investor in several
high-tech, biotech, and internet companies. From 2006 to 2013, she served as a partner and Chief Investment Officer of Eurotrust Ltd.,
a family office. From 2002 to 2005, she served as a research analyst at Perceptive Life Sciences Ltd., a New York-based hedge fund. Prior
to that, Ms.&#160;Karah served as research analyst at Oracle Partners Ltd., a health care-focused hedge fund. Ms.&#160;Karah has served
as a director in several private and public companies including Intec Pharma, since 2009 and Cyren Ltd since 2008. Ms.&#160;Karah holds
a B.A. in molecular and cell biology from the University of California, Berkeley, and studied at the University of California, Berkeley-University
of California, San Francisco Joint Medical Program. We believe Ms.&#160;Karah is qualified to serve on our Board because of her experience
as an investor in and advisor to high-tech, biotech, and internet companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Lawrence Leisure</i></b>&#160;has
been a director of our company since February&#160;25, 2025. Mr.&#160;Leisure has extensive business experience consulting and advising
in the senior living, provider services, value based care and technology enabled services sectors. Since 2014, Mr.&#160;Leisure has served
as the Co-Founder and Co-Managing Partner of Chicago Pacific Founders, a private equity firm focused on digital and AI-enabled businesses,
and those serving the senior population. Mr.&#160;Leisure is serving on the board of directors and the compensation committee of P3 Health
Partners Inc. (NASDAQ: PIII), a publicly traded health management company. Mr.&#160;Leisure has also served on the board of directors
of several private companies backed by Chicago Pacific Founders as well as several venture capital backed companies. Since 2009, he has
served as Co-Founder and Chairman of Healthspottr, a strategic networking and consulting firm focused on health innovation and collaboration
in the healthcare industry and he also served as the Co-Founder of the Employer Health Innovation Roundtable since 2015. Prior to Chicago
Pacific Partners, Mr.&#160;Leisure held senior management roles at Accenture, PricewaterhouseCoopers, Towers Perrin, Kaiser Foundation
Health Plans and UnitedHealth Group. Mr.&#160;Leisure was also employed by the venture capital firm, Kleiner Perkins, as an Operating
Partner within the Life Sciences&#160;&amp; Digital Health Practice. Mr.&#160;Leisure is Chairman of the UCSF Rosenman Institute, member
of the UCLA Anderson School of Management Board of Advisors, and a Senior Advisor at the Mussalem Center for BIODESIGN at Stanford University.
Mr.&#160;Leisure holds a B.A. from Stanford University and an MBA from the University of California-Los Angeles Anderson School of Management.
We believe Mr.&#160;Leisure is qualified to serve on our Board because of his accounting expertise and his experiences serving as an officer
and director of public and private companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dennis M. McGrath</i></b>&#160;has
been a director of our company since November&#160;12, 2013. Mr.&#160;McGrath is a seasoned medical device industry executive with extensive
public company leadership experience possessing a broad range of skills in corporate finance, business development, corporate strategy,
operations, and administration. After an 18 year career at PhotoMedex,&#160;Inc. (Nasdaq: PHMD), he recently joined PAVmed,&#160;Inc (Nasdaq:
PAVM, PAVMW) as its Executive Vice President and Chief Financial Officer. Previously, from 2000 to 2017 Mr.&#160;McGrath served in several
senior level positions of PhotoMedex, a global manufacturer and distributor of medical device equipment and services, including from 2011
to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex&#8217;s reverse merger with Radiancy,&#160;Inc. in December&#160;2011,
he also served as Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000
to 2009. Mr.&#160;McGrath received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment
Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst&#160;&amp;
Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, and
particularly involving public company acquisitions, including Surgical Laser Technologies,&#160;Inc, (formerly, Nasdaq: SLTI), ProCyte
Corporation (formerly, Nasdaq: PRCY), LCA Vision,&#160;Inc. (formerly, Nasdaq: LCAV) and Think New Ideas,&#160;Inc. (formerly, Nasdaq:
THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group,&#160;Inc. (then, Nasdaq: ANSR,
now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief
Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group,&#160;Inc., while concurrently during
the merger of the companies, serving as the acting&#160;Chief Financial Officer of Think New Ideas,&#160;Inc. (then, Nasdaq: THNK, now,
Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr.&#160;McGrath also served from 1996 until 1999 as
Chief Financial Officer, Executive Vice President and director of TriSpan,&#160;Inc., an internet commerce solutions and technology consulting
company, which was acquired by AnswerThink Consulting Group,&#160;Inc. in 1999. During his tenure at Arthur Andersen&#160;&amp; Co., where
he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle
University. In addition to serving as the audit and compensation committee chair and director of several biopharmaceutical and medical
device companies, including our Company, Citius Pharmaceuticals,&#160;Inc. (Nasdaq: CTXR), Citius Oncology,&#160;Inc (Nasdaq: CTOR), and
LIV Process,&#160;Inc. formerly BioVector,&#160;Inc. Previously from 2014 to 2024 Mr.&#160;McGrath served as a director and audit chair
of Cagent Vascular,&#160;Inc, and from 2007 to 2009 he served as a director of Embrella Cardiovascular,&#160;Inc. (sold to Edwards Lifesciences
Corporation, NYSE: EW). He also serves on the board of trustees for Manor College and the board of visitors for Taylor University. We
believe Mr.&#160;McGrath is qualified to serve on our Board because of his accounting expertise and his experiences serving as an officer
and director of public and private companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Adam Stern</i></b>&#160;has
been a director of our company since March&#160;1, 2020. Mr.&#160;Stern has been the head Private Equity Banking at Aegis Capital Corp.
and CEO of SternAegis Ventures since 2012 and was a member of our Board between October&#160;2011 and May&#160;2014. Prior to Aegis, from
1997 to November&#160;2012, he was with Spencer Trask Ventures,&#160;Inc., most recently as a Senior Managing Director, where he managed
the structured finance group, focusing primarily on the technology and life science sectors. Mr.&#160;Stern held increasingly responsible
positions from 1989 to 1997 with Josephthal&#160;&amp; Co.,&#160;Inc., members of the New York Stock Exchange, where he served as Senior
Vice President and Managing Director of Private Equity Marketing. He has been a FINRA licensed securities broker since 1987 and a General
Securities Principal since 1991. Mr.&#160;Stern is a director of Aerami Therapeutics Holdings (formerly Dance Biopharm,&#160;Inc.), Matinas
BioPharma Holdings,&#160;Inc. Adgero Biopharmaceuticals Holdings and Hydrofarm Holdings Group,&#160;Inc. Mr.&#160;Stern is a former director
of InVivo Therapeutics Holdings Corp. (OTCQB: NVIV), Organovo Holdings,&#160;Inc. (NYSE MKT: ONVO) and PROLOR Biotech Ltd., which was
sold to Opko Health,&#160;Inc. (NYSE: OPK) for approximately $600 million in 2013. Mr.&#160;Stern holds a Bachelor of Arts degree with
honors from The University of South Florida in Tampa. We believe Mr.&#160;Stern is qualified to serve on our Board because of his experience
in the capital markets, his experiences serving as a director of public and private companies and his experience with life sciences companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the
terms of the placement agency agreement between us and Aegis Capital Corp. (&#8220;<b>Aegis</b>&#8221;), dated October&#160;22, 2019,
we granted Aegis the right to nominate an individual to the Board for a period of three years, which resulted in the appointment of Mr.&#160;Stern
to serve on our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for the foregoing,
there are no arrangements between our directors and any other person pursuant to which our directors were nominated or elected for their
positions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth herein,
none of our directors or executive officers have been involved, in the past ten years and in a manner material to an evaluation of such
director&#8217;s or officer&#8217;s ability or integrity to serve as a director or executive officer, in any of those &#8220;Certain Legal
Proceedings&#8221; more fully detailed in Item 401(f)&#160;of Regulation S-K, which include but are not limited to, bankruptcies, criminal
convictions and an adjudication finding that an individual violated federal or state securities laws. Additionally, none of our directors
or executive officers have been involved in any material proceedings to which such director or executive officer was a party adverse to
us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Required Vote</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The election of each of the
Director Nominees requires the affirmative vote of a majority of the shares of Common Stock and preferred stock (voting together as a
single class) represented in person or by proxy and entitled&#8239;to vote in the election of directors at the Meeting. Abstentions are
considered present for purposes of establishing a quorum but will have no effect on the election of directors. Broker non-votes will not
affect the outcome of the vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Recommendation of the Board</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE BOARD UNANIMOUSLY RECOMMENDS
A VOTE &#8220;FOR&#8221; ELECTION OF EACH OF THE NOMINEES FOR DIRECTOR.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROPOSAL 2</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RATIFICATION OF THE APPOINTMENT OF THE COMPANY&#8217;S
INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May&#8239;19, 2025, the Audit
Committee of the Board appointed the firm of Kesselman&#160;&amp; Kesselman, a member of PricewaterhouseCoopers International Limited
(&#8220;<b>PwC</b>&#8221;) to serve as our independent auditors for our fiscal year ending December&#160;31, 2025. Stockholders will be
asked to ratify the Auditor to serve as our independent auditors. The Board&#8217;s Audit Committee (the &#8220;<b>Audit Committee</b>&#8221;)
is directly responsible for appointing our independent registered public accounting firm. The Audit Committee is not bound by the outcome
of this vote but will consider these voting results when selecting the Company&#8217;s independent auditor for fiscal year 2025. The Auditor
has been our auditor since May&#160;12, 2025. A representative of the Auditor is not expected to be present at the Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
fees billed to us by Kost Forer Gabbay&#160;&amp; Kasierer, a member of Ernst&#160;&amp; Young Global, our prior independent registered
public accounting firm that was replaced by PwC, during the fiscal years ended December&#160;31, 2024 and December&#160;31, 2023 for:
(i)&#160;services rendered for the audit of our annual financial statements and the review of our quarterly financial statements; (ii)&#160;services
by our independent registered public accounting firms that are reasonably related to the performance of the audit or review of our financial
statements and that are not reported as audit fees; (iii)&#160;services rendered in connection with tax compliance, tax advice and tax
planning; and (iv)&#160;all other fees for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December&#160;31,&#160;2024</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December&#160;31,&#160;2023</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">Audit Fees</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">487,573</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">303,296</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Audited Related Fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Tax Fees (1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">82,535</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">16,686</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">All Other Fees (2)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">273,150</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">102,250</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Total</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">843,258</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">422,232</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px">(1)</td>
    <td style="text-align: justify">Consists of fees relating to our tax compliance and tax planning.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">(2)</td>
    <td>Consists of fees relating to our private placements.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Audit Committee Policies</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee of our
Board is solely responsible for the approval in advance of all audit and permitted non-audit services to be provided by the independent
auditors (including the fees and other terms thereof), subject to the de minimis exceptions for non-audit services provided by Section&#160;10A(i)(1)(B)&#160;of
the Securities Exchange Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;), which services are subsequently approved by the
Board prior to the completion of the audit. None of the fees listed above are for services rendered pursuant to such de minimis exceptions.
The audit, tax and non-audit services provided by the Auditor in 2023 and 2024 set forth above were pre-approved by our Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Required Vote</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the shares of Common Stock and preferred stock (voting together as a single class) represented in person or by proxy and entitled
to vote is required to ratify the Auditor as our independent registered public accounting firm for the year ending December&#160;31, 2025.
Abstentions are considered present for purposes of establishing a quorum but will have no effect on the ratification of our independent
public accountants. There are no broker non-votes on this matter since it is a &#8220;routine&#8221; matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Recommendation of the Board</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE BOARD UNANIMOUSLY RECOMMENDS
A VOTE &#8220;FOR&#8221; THE <span style="text-transform: uppercase">Ratification of the appointment by the Audit Committee of the Board
of the Auditor as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2025.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROPOSAL 3</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APPROVAL OF INCENTIVE PLAN PROPOSAL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May&#160;19, 2025, the
Board, upon the recommendation of the Board&#8217;s Compensation Committee (the &#8220;<b>Compensation Committee</b>&#8221;), unanimously
approved an amendment and restatement of the 2020 Equity Incentive Plan (the &#8220;<b>Plan Amendment</b>&#8221;), subject to stockholder
approval. The principal amendments (i)&#160;provide that for each of the calendar years ending on December&#160;31, 2026, December&#160;31,
2027, December&#160;31, 2028, December&#160;31, 2029 and December&#160;31, 2030, the number of shares available under the 2020 Equity
Incentive Plan shall be increased by an additional number of shares of Common Stock equal to six percent (6%) of the number of shares
of Common Stock issued and outstanding on a Fully Diluted Basis on the immediately preceding December&#160;31; and (ii)&#160;authorize
the grant of restricted stock units (&#8220;<b>RSUs</b>&#8221;) as a permissible form of award under the 2020 Equity Incentive Plan. The
full text of the proposed Plan Amendment is set out in&#160;<span style="text-decoration:underline">Annex A</span>&#160;to this Proxy Statement. Stockholders are being asked
to approve the Plan Amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reasons for the Plan Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of our 2020 Equity
Incentive Plan is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable,
to encourage a sense of proprietorship and to stimulate an active interest of such persons in our development and financial achievements.
We also intend to use part of the increased number of shares that may become available pursuant to the Plan Amendment to issue awards
to board members, employees, consultants, advisors and service providers in lieu of cash payments that are, or may be, owed, as a way
to preserve our cash. (Recipients of awards under the Plan are referred to below as &#8220;Participants.&#8221;) Our Board believes that
the number of shares of Common Stock subject to the 2020 Equity Incentive Plan remaining available is insufficient to achieve the purpose
of the 2020 Equity Incentive Plan. In addition, the Board believes the authorization of RSUs under the 2020 Equity Incentive Plan is in
the best interests of the Company and its stockholders for the following reasons: (i)&#160;RSUs are a commonly used, flexible form of
equity compensation that can effectively align the interests of employees and stockholders; (ii)&#160;RSUs help conserve share usage compared
to stock options, as fewer RSUs are typically granted to deliver an equivalent dollar value; (iii)&#160;RSUs provide retention value due
to time-based or performance-based vesting requirements; (iv)&#160;adding RSUs broadens the Company&#8217;s ability to attract and retain
talent, particularly in a competitive hiring environment; and (v)&#160;the change reflects evolving best practices in equity compensation.
Therefore, our Board believes the Plan Amendment is necessary to increase the number of shares of Common Stock available under the 2020
Equity Incentive Plan and to enable the grant of RSUs, which will allow flexibility in granting awards to attract and retain key personnel
and to provide a means for directors, officers, employees, consultants and advisors to preserve our cash, to acquire and maintain an interest
in us, which interest may be measured by reference to the value of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Effects of the Plan Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Plan Amendment,
there will be an increase in the total number of shares of Common Stock reserved for issuance under the 2020 Equity Incentive Plan. This
will provide us with the ability to grant more awards than are currently available under the 2020 Equity Incentive Plan to eligible recipients
including employees, directors, consultants and advisors. The Plan Amendment will also authorize the grant of RSUs as a permissible form
of award under the 2020 Equity Incentive Plan. The inclusion of RSUs will provide the Company with additional flexibility in its equity
compensation program, enabling the grant of full-value awards alongside stock options and other types of equity grants. The issuance in
the future of awards under the 2020 Equity Incentive Plan consisting of full-value awards, including RSUs, options to purchase shares
of Common Stock, and stock grants, may have the effect of diluting the earnings per share and book value per share, as well as the stock
ownership and voting rights of the holders of the currently outstanding shares of Common Stock. The effective increase in the number of
authorized but unissued shares of Common Stock that may be issued as awards under the 2020 Equity Incentive Plan may be construed as having
an anti-takeover effect by permitting the issuance of shares to purchasers who might oppose a hostile takeover bid or oppose any efforts
to amend or repeal certain provisions of our Certificate of Incorporation or Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the Common Stock
have no preemptive or other subscription rights with respect to the shares issuable under the 2020 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Description of the 2020 Equity Incentive Plan
Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Shares Subject to the
2020 Equity Incentive Plan</i></b>. The 2020 Equity Incentive Plan currently provides for&#160;17,897,652&#160;shares of Common Stock
reserved for grant of awards, which if the proposal for the Plan Amendment is approved, then the maximum number of shares of Common Stock
reserved for grant of awards under the 2020 Equity Incentive Plan will be subject to future increases&#160;for the calendar years ending
on December&#160;31, 2026, December&#160;31, 2027, December&#160;31, 2028, December&#160;31, 2029 and December&#160;31, 2030, by an additional
number of shares of Common Stock equal to six percent (6%) of the number of shares of Common Stock issued and outstanding on a Fully Diluted
Basis on the immediately preceding December&#160;31. For purposes of the&#160;2020 Equity Incentive Plan, the term &#8220;Fully Diluted
Basis&#8221; means all issued and outstanding share capital (where options shall be deemed outstanding share capital until exercised)
and all rights to acquire share capital including, without limitation, all securities convertible or exercisable into shares of Common
Stock being deemed so converted and exercised, the&#160;conversion of any convertible stockholder loans into share capital, with all outstanding
warrants, options or any other right granted by the Company to receive shares of the Company&#8217;s share capital being deemed exercised
in full. The foregoing notwithstanding, the maximum number of shares that may be subject to incentive stock options (&#8220;<b>ISOs</b>&#8221;)&#160;granted
under the&#160;2020 Equity Incentive Plan&#160;shall be 3,000,000, subject to adjustment as provided in the&#160;2020 Equity Incentive
Plan. To the extent that an award granted&#160;under the 2020 Equity Incentive Plan&#160;lapses or is forfeited, the shares subject to
such award will again become available for grant under the terms of the&#160;2020 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Purpose and Eligible
Individuals</i></b>. The purpose of the 2020 Equity Incentive Plan is to retain the services of valued key employees, directors and consultants
of ours and its affiliates, thereby strengthening their incentive to achieve the objectives of our stockholders, to serve as an aid and
inducement in the hiring of new employees and to provide an equity incentive to consultants and other persons selected by the Compensation
Committee. In addition, we intend to use part of the increased number of shares available under the 2020 Equity Incentive Plan to issue
awards to board members, employees, consultants, advisors and service providers in lieu of cash payments that are, or may be, owed, as
a way to preserve our cash. Finally, we believe we will need to issue equity incentive to potential new employees in the coming fiscal
years as we ramp up our business-to-business-to-consumer go-to market strategy. Under the 2020 Equity Incentive Plan, awards may be granted
to officers, directors, employees and consultants of ours or of our affiliates (each, a &#8220;<b>Participant</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Administration</i></b>.
The Board has the authority to administer the 2020 Equity Incentive Plan or may delegate administration of the 2020 Equity Incentive Plan
to a committee of not less than two (2)&#160;non-employee directors, in accordance with Rule&#160;16b-3 promulgated under the Exchange
Act or the rules&#160;of the applicable trading market on which the Common Stock is then traded. Our Board has delegated its administrative
powers to administer the 2020 Equity Incentive Plan to our Compensation Committee. As such, our Compensation Committee has the power,
among other things, to (a)&#160;determine terms and conditions of any equity award granted, including the exercise price and the vesting
schedule, (b)&#160;select persons who are to receive equity awards, (c)&#160;interpret the 2020 Equity Incentive Plan and prescribe rules&#160;and
regulations for its administration and (d)&#160;delegate to a subcommittee any of the administrative powers the Compensation Committee
is authorized to exercise, subject, however, to such resolutions, not inconsistent with the provisions of the 2020 Equity Incentive Plan,
as may be adopted from time to time by the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Stock Options</i></b>.
The Compensation Committee may grant ISOs, nonqualified stock options or options under Section&#160;102 or 3(i)&#160;of the Israeli Tax
Ordinance (New Version) 1961 (&#8220;<b>ITO</b>&#8221;) (collectively referred to as &#8220;<b>Options</b>&#8221;). The Compensation Committee
determines the number of shares of Common Stock subject to each Option, provided that the aggregate fair market value of the shares of
Common Stock with respect to which ISOs are exercisable for the first time by a Participant during any calendar year shall not exceed
$100,000. The Compensation Committee determines the exercise price of an Option, its duration and the manner and time of exercise. However,
in no event shall an Option be exercisable more than ten (10)&#160;years following the grant date thereof. A more than ten percent (10%)
by vote stockholder of the Company or a corporate subsidiary shall not be granted an ISO unless the exercise price of such ISO is at least
110% of the fair market value of the Common Stock at the date of grant and such ISO is not exercisable after the expiration of five (5)&#160;years
from the date of grant. ISOs may be issued only to employees of the Company or of a corporate subsidiary of ours, and the exercise price
must be at least equal to the fair market value of the Common Stock as of the date the Option is granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee,
in its discretion, may provide the vesting terms of any Option. The vesting of one (1)&#160;or more outstanding Options may be accelerated
by the Board at such times and in such amounts as it shall determine in its sole discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price of an Option
may be paid in any form or method authorized by the Board and permitted by the option agreement and 2020 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ISOs granted under the 2020
Equity Incentive Plan and the rights and privileges conferred by the 2020 Equity Incentive Plan may not be transferred, assigned, pledged
or hypothecated in any manner (whether by operation of law or otherwise) other than by will or by applicable laws of descent and distribution.
Nonqualified stock options shall not be transferred, assigned, pledged or hypothecated in any manner (whether by operation of law or otherwise)
other than by will or by applicable laws of descent and distribution or as otherwise provided in the option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Stock Grants and RSUs</i></b>.
The Compensation Committee may award shares of Common Stock with or without restrictions, as well as RSUs to a Participant subject to
such conditions and restrictions as the Compensation Committee may determine. RSUs are similar to restricted shares except that no shares
are actually awarded to the Participant on the grant date. No monetary payment, other than for applicable taxes, is due by the Participant
in connection with the grant of restricted stock or issuance of shares in connection with an RSU, except that the Participant must pay
the Company the par value of the restricted stock or the shares of Common Stock underlying the RSU. Restrictions could include conditions
that require the Participant to forfeit the shares in the event that the Participant ceases to provide services to us or any of our affiliates
thereof before a stated time. The period of restriction, the number of shares of restricted stock granted, the purchase price, if any,
and such other conditions and/or restrictions as the Compensation Committee may establish will be set forth in an award agreement. After
all conditions and restrictions applicable to restricted shares have been satisfied or have lapsed, shares of restricted stock will become
freely transferable, as determined by the Compensation Committee and stated in the award agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted, the Compensation
Committee may make a stock award without any restrictions and the Compensation Committee may award dividend equivalents with respect to
RSUs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Effect of Certain Corporate
Transactions</i></b>. If a recapitalization or similar transaction occurs that does not alter the existing proportionate ownership of
the Common Stock, appropriate adjustments shall be made to the exercise price, the purchase price, if any, and number of outstanding awards.
In the case of a change of control (as defined in the 2020 Equity Incentive Plan), such as a merger, acquisitive transaction, reorganization,
liquidation or other transaction (a &#8220;<b>Major Transaction</b>&#8221;) that does alter such proportionate ownership, vested awards
generally may be exercised before such transaction and persons owning Common Stock as a result of awards made under the 2020 Equity Incentive
Plan will participate on the same basis as other owners of Common Stock. Alternatively, the Board may determine in the case of a Major
Transaction that awards will continue in effect on a basis similar to that in effect prior to such Major Transaction, including with respect
to vesting, except that such rights shall apply with respect to the surviving entity or shall be assumed by the surviving or acquiring
corporation (in accordance, as applicable, with the requirements of Section&#160;409A of the Internal Revenue Code of 1986, as amended
(the &#8220;<b>Code</b>&#8221;), or Section&#160;424 of the Code). The Board may, in its discretion, accelerate vesting and/or settlement
in whole or in part in connection with a Major Transaction. The 2020 Equity Incentive Plan also provides that Awards may be liquidated
for a cash payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Further Amendments to
the 2020 Equity Incentive Plan</i></b>. The Board or the Compensation Committee may, at any time, modify, amend or terminate the 2020
Equity Incentive Plan or modify or amend awards granted under the 2020 Equity Incentive Plan, including, without limitation, such modifications
or amendments as are necessary to maintain compliance with applicable laws. However, the Board or the Compensation Committee may not,
without approval of our stockholders: (1)&#160;increase the total number of shares covered by the 2020 Equity Incentive Plan, except by
adjustments upon certain changes in capitalization; (2)&#160;change the class of persons eligible to receive awards under the 2020 Equity
Incentive Plan; or (3)&#160;make other changes in the 2020 Equity Incentive Plan that require stockholder approval under applicable law
(including any rules&#160;of any applicable stock exchange or stock quotation system of which our shares of Common Stock are traded).
Except as otherwise provided in the 2020 Equity Incentive Plan or an Award agreement, no amendment will adversely affect outstanding awards
without the consent of the Participant. Any termination of the 2020 Equity Incentive Plan will not terminate awards then outstanding,
without the consent of the Participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Term of the 2020
      Equity Incentive Plan</i></b>. Unless sooner terminated by the Board, the 2020 Equity Incentive Plan will terminate on the day prior
      to the tenth anniversary of its adoption by the Board, or May 18, 2035. No award may be granted after such termination or during
      any suspension of the 2020 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>U.S. Tax Treatment</i></b>.
The following description of the U.S. federal income tax consequences of awards. It is general and does not purport to be comprehensive
nor does it address state and/or local tax consequences of awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Incentive Stock Options</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, a Participant incurs
no federal income tax liability on either the grant or the exercise of an ISO, although a Participant will generally have taxable income
for alternative minimum tax purposes at the time of exercise equal to the excess of the fair market value of the shares subject to the
Option over the exercise price. Provided that the shares are held for at least one (1)&#160;year after the date of exercise of the Option
and at least two (2)&#160;years after its date of grant, any gain realized on a subsequent sale of the shares will be taxed as long-term
capital gain. If the shares are disposed of within a shorter period of time, the Participant will recognize ordinary income in an amount
equal to the difference between the fair market value of the shares on the date of exercise (or the sale price of the shares sold, if
less) over the exercise price. We receive no tax deduction on the grant or exercise of an ISO, but we may be entitled to a tax deduction,
subject in the case of certain executives to limitations on the deductibility of compensation under Section&#160;162(m)&#160;of the Code,
if the Participant recognizes ordinary income on account of a premature disposition of shares acquired on exercise of an ISO, in the same
amount and at the same time as the participant recognizes income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nonqualified Stock Options</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Participant realizes no
taxable income when a nonqualified stock option is granted. Instead, the difference between the fair market value of the shares acquired
pursuant to the exercise of the Option and the exercise price paid is taxed as compensation income (subject to income and employment taxes
and withholding) when the Option is exercised. The difference is measured and taxed as of the date of exercise, if the shares are not
subject to a &#8220;substantial risk of forfeiture,&#8221; or as of the date or dates on which the risk terminates in other cases. A Participant
may elect (as described under Restricted Stock below) to be taxed on the difference between the exercise price and the fair market value
of the shares on the date of exercise, even though some or all of the shares acquired are subject to a substantial risk of forfeiture.
When the shares are subsequently sold, the Participant generally will recognize capital gain or loss (short-term or long-term, as applicable)
equal to the difference between the amount realized upon the sale of the shares and his or her tax basis (generally the exercise price
plus any compensation income recognized).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We receive no tax deduction
on the grant of a nonqualified stock option, but may be entitled to a tax deduction when a Participant recognizes ordinary compensation
income on or after exercise of the Option, subject in the case of certain executives to limitations on the deductibility of compensation
under Section&#160;162(m)&#160;of the Code, in the same amount as the income recognized by the Participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Grants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to stock grants
under our 2020 Equity Incentive Plan that are made without any restrictions, a Participant generally recognizes compensation income (subject
to income and employment taxes and withholding) equal to the excess of the fair market value of the shares received over the amount paid
(if any). We generally will be entitled to a deduction in an amount equal to the ordinary compensation income recognized by a Participant,
subject in the case of certain executives to limitations on the deductibility of compensation under Section&#160;162(m)&#160;of the Code.
When the stock is subsequently sold, the Participant generally will recognize capital gain or loss (short-term or long-term, as applicable)
equal to the difference between the amount realized upon the sale of the shares and his or her tax basis (generally the amount paid plus
any compensation income recognized).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If stock is awarded subject
to restrictions, a Participant generally will not recognize income at the time of the award, but will instead recognize compensation income
(subject to income and employment taxes and withholding) equal to the excess of the fair market value of the shares received over the
amount paid (if any) when restrictions on transferability or that otherwise constitute a substantial risk of forfeiture lapse. A Participant
may elect to be taxed at the time of the receipt of the shares, rather than upon the lapse of restrictions on transferability or substantial
risk of forfeiture, but if the Participant subsequently forfeits such shares, the Participant would not be entitled to any tax deduction
for the amount of previously recognized compensation income (he or she will be entitled to a capital loss for the amount paid (if any)
for the shares). To make this election, the Participant must file a so-called Section&#160;83(b)&#160;election with the Internal Revenue
Service within thirty (30) days of the receipt of the shares. We generally will be entitled to a deduction at the time, subject in the
case of certain executives to limitations on the deductibility of compensation under Section&#160;162(m)&#160;of the Code, and in an amount
equal to, the compensation income is recognized by the Participant. When the stock is subsequently sold, the Participant generally will
recognize capital gain or loss (short-term or long-term, as applicable) equal to the difference between the amount realized upon the sale
of the shares and his or her tax basis (generally the amount paid plus any compensation income recognized).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>RSUs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Participant recognizes no
income until the issuance of the shares at or shortly after vesting. At that time, the Participant must generally recognize compensation
income (subject to income and employment taxes and withholding) equal to the fair market value of the shares received less the amount
paid (if any). We generally will be entitled to a deduction , subject in the case of certain executives to limitations on the deductibility
of compensation under Section&#160;162(m)&#160;of the Code, in an amount equal to the compensation income is recognized by the Participant.
When the stock is subsequently sold, the Participant generally will recognize capital gain or loss (short-term or long-term, as applicable)
equal to the difference between the amount realized upon the sale of the shares and his or her tax basis (generally the amount paid plus
any compensation income recognized).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Participant will generally
not receive the benefit of dividends prior to the exercise of an option or settlement of RSUs, unless the Compensation Committee has,
in the case of RSUs, awarded dividend equivalents. The full amount of dividends or other distributions of property made with respect to
Restricted Stock and RSUs before the lapse of any applicable restrictions will constitute compensation income, and we are generally entitled
to a deduction, subject in the case of certain executives to limitations on the deductibility of compensation under Section&#160;162(m)&#160;of
the Code, at the same time and in the same amount as the income is realized by the Participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Additional federal tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After an award has been settled,
a Participant holding Common Stock may be required to pay a 3.8% tax with respect to his or her net investment income, including dividends
on and gains from the sale or other disposition of our Common Stock, to the extent that his or her modified adjusted gross income exceeds
applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Section&#160;162(m)&#160;of the Code</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Tax Cuts and
Jobs Act of 2017 (&#8220;<b>TCJA</b>&#8221;), Section&#160;162(m)&#160;of the Code disallows an income tax deduction to public companies
for compensation in excess of $1,000,000 paid in any year to the principal executive officer, the principal financial officer and the
three other most highly compensated executive officers. Each person covered by Section&#160;162(m)&#160;of the Code for a particular year
after 2016 remains subject to this limit in subsequent years, even if not included in that group for the year. TCJA also eliminated the
performance-based compensation exception,, which may have applied to one or more of our outstanding options or other forms of equity awards.
As a result, it is expected that certain of our compensation arrangements will result in non-deductible compensation when the total exceeds
$1,000,000, except certain historical awards that meet transition rules&#160;for continued deductibility under the TCJA. Nevertheless,
the deductibility of compensation is but one of the critical factors in the design and implementation of any compensation arrangement,
and the Compensation Committee and our Board reserve the right to pay nondeductible compensation when appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Israeli Tax Treatment</i></b>.
The following is a summary of the Israeli income tax consequences of certain transactions under the 2020 Equity Incentive Plan with regard
to the granting of awards to Israeli Participants. It is general and does not purport to be comprehensive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, the 2020 Equity
Incentive Plan provides for the granting of awards to employees, directors and consultants under either Section&#160;102 or Section&#160;3(i)&#160;of
the ITO. The awards granted under the 2020 Equity Incentive Plan to employees and officeholders, who are not controlling shareholders
(as defined in the ITO) are subject to the &#8220;capital gains tax route&#8221; under Section&#160;102 of the ITO (the &#8220;<b>Capital
Gains Tax Route</b>&#8221;), and the awards granted to Participants in the 2020 Equity Incentive Plan who do not qualify to receive awards
under the Capital Gains Tax Route, including consultants, service providers and controlling shareholders, are subject to Section&#160;3(i)&#160;of
the ITO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Capital Gains Tax Route
generally provides for a reduced tax rate of twenty-five percent (25%) on gains realized upon the sale of the award&#8217;s underlying
shares, subject to the fulfillment of certain procedures and conditions including the deposit of such awards (or shares issued upon their
exercise or shares in case restricted stock was granted) for a requisite period of time with a trustee approved by the Israeli Tax Authority
(currently, twenty-four (24) months from the date of grant). Notwithstanding the above, in any event where the exercise price of the underlying
shares subject to the awards is less than the fair market value of the underlying shares at the time of grant of the awards (calculated
as the average value of a company&#8217;s shares on the thirty (30) trading days preceding the date of grant), such amount will be deemed
ordinary income of the award holder, taxed at the applicable marginal tax rate (up to fifty percent (50%) in 2016) together with health
insurance and social security insurance payments, on the date of sale of the underlying shares and/or the date of the release of such
underlying shares from trust. In the event the requirements of Section&#160;102 of the ITO for the allocation of awards according to the
Capital Gains Tax Route are not met, the benefit attributed to the Participant as a result of the grant of such awards will be taxed as
ordinary work income at applicable marginal income tax rates (together with health insurance and social security insurance payments).
For as long as the restricted stock or the shares issued upon exercise of awards are registered in the name of the trustee, the voting
rights with respect to such shares will remain with the trustee. Under the Capital Gains Tax Route, a company, or its Israeli subsidiary,
as the case may be, is generally not entitled to recognize a deduction for Israeli tax purposes on the gain recognized by the Participant
upon sale of the shares underlying the awards (except for such amount that will be deemed ordinary income of the Participant as explained
above). Our Israeli subsidiary will be required to withhold applicable tax (and social security and national health insurance charges,
if applicable) at source on behalf of the Participant and may be required to pay social security and national health insurance charges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, with respect to
a holder of an award under Section&#160;3(i)&#160;of the ITO that is not registered for trade, the taxable event shall take place on the
date of exercise of the award into shares, and the income will be classified as regular employment or work income subject to marginal
tax rates (if the Participant is an individual) or corporate tax rates (if the Participant is a corporation).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2012 Plan and Other Equity Compensation Arrangements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the 2020 Equity
Incentive Plan, we also maintain the Amended and Restated 2012 Equity Incentive Plan (the &#8220;<b>2012 Equity Incentive Plan</b>&#8221;).
Under the 2012 Equity Incentive Plan, Awards may be granted to our&#160;officers, directors, employees&#160;and consultants or the officers,
directors, employees and consultants of our subsidiary. Pursuant to the 2012 Plan, the total number of shares of Common Stock authorized
for issuance thereunder may not exceed 1,968,650. The 2012 Equity Incentive Plan expired on January&#160;23, 2022. We may issue awards
under the 2012 Equity Incentive Plan up to the amount available under the 2012 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information as of December&#160;31, 2024, with respect to options outstanding under the Company&#8217;s 2012 Equity Incentive Plan, the
Company&#8217;s 2020 Equity Incentive Plan, and the Company&#8217;s other equity compensation arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt"><b>&#160;</b></td><td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number&#160;of&#160;securities</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt"><b>&#160;</b></td><td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">to&#160;be&#160;issued&#160;upon</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Weighted-average</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt"><b>Forfeited</b></td><td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">exercise&#160;of</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">exercise&#160;price&#160;of</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number&#160;of&#160;securities</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><b>shares</b></td><td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">outstanding options,</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">outstanding&#160;options,</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">remaining&#160;available</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Plan category</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>(6)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">warrants and&#160;rights</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">warrants&#160;and&#160;rights</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">for future&#160;issuance</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%; font-size: 10pt; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 8%; font-size: 10pt; text-align: right">334,522</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt; text-align: right">5,881,675</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">3.24</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt; text-align: right">7,583,836</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders <sup>(1)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">90,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8.41</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders <sup>(2)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">50,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5.75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders <sup>(3)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">20,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">18.62</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders <sup>(4)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">1,931,074</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.55</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders <sup>(5)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">2,250,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.35</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Total</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">334,522</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">10,222,749</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">7,583,836</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&#160;2013, our Board adopted
a non-employee director&#8217;s remuneration policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.5in">(1)</td><td style="text-align: justify">In January&#160;2020, our Board approved the grant of non-plan options as a material inducement for employment,
in accordance with Nasdaq Listing Rule&#160;5635(c)(4), to our newly hired President and General Manager for North America. The options
have an exercise price of $8.41 per share. 90,000 options are time based and vest over a three-year period. One third vests after one
year and the balance vests over eight quarterly installments after the first anniversary; these options have a cashless exercise feature
and a six-year term. An additional 90,000 options are performance based, and vest over a three-year period. One third vest after one year
and the balance vest over eight quarterly installments after the first anniversary; these options have a cashless exercise feature and
a six-year term. 22,500 options will commence vesting every calendar year for the next four years, commencing in 2021, and only if certain
performance milestones were met in the immediately preceding year. 22,500 of these options have expired on each of January&#160;1, 2021,
January&#160;1, 2022, January&#160;1, 2023 and January&#160;1, 2024 as the performance milestones were not met.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.5in">(2)</td><td style="text-align: justify">In March&#160;2020, our Board approved the grant of certain non-plan options as a material inducement
for employment, in accordance with Nasdaq Listing Rule&#160;5635(c)(4), to our newly hired Chief Medical Officer. The options have an
exercise price of $5.75 per share, and vest over a three-year period with one third vesting after one year and the balance vesting over
eight quarterly installments after the first anniversary; these options have a cashless exercise feature and a six-year term.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.5in">(3)</td><td style="text-align: justify">In July&#160;2021, our Board approved the grant of certain non-plan options as a material inducement for
employment, in accordance with Nasdaq Listing Rule&#160;5635(c)(4), to our newly hired Special Vice President of Market Access. The options
have an exercise price of $18.62 per share, and vest over a three-year period with one third vesting after one year and the balance vesting
over eight quarterly installments after the first anniversary; these options have a cashless exercise feature and a ten-year term. The
option expired on February&#160;4, 2025 following the departure of the employee.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.5in">(4)</td><td style="text-align: justify">In February&#160;2024, our Board approved the grant of certain non-plan options as a material inducement
for employment, in accordance with Nasdaq Listing Rule&#160;5635(c)(4), to the employees of Twill,&#160;Inc. The options have an exercise
price of $2.55 per share, the options are time based and vest over a two-year period in eight equal amounts. These options have a cashless
exercise feature and a ten-year term.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.5in">(5)</td><td style="text-align: justify">In June&#160;2024, our Board approved the grant of certain non-plan options as a material inducement for
employment, in accordance with Nasdaq Listing Rule&#160;5635(c)(4), to our newly hired Chief Commercial Officer. The options have an exercise
price of $1.35 per share, 500,000 options are time based and vest over a three-year period. One third vests after one year and the balance
vests over eight quarterly installments after the first anniversary; these options have a cashless exercise feature and a ten-year term.
An additional 1,750,000 options are performance based, and vest upon achieving personal objective during the years 2025 to 2028.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.5in">(6)</td><td style="text-align: justify">334,522 restricted shares of common stock issued to certain of our employees were forfeited, as they were
not vested upon certain employee departures.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Required Vote</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock (voting together as a single class) represented
in person or by proxy and entitled to vote is required for approval of the Incentive Plan Proposal. Abstentions are considered present
for purposes of establishing a quorum but will have no effect on the approval of the Incentive Plan Proposal. Broker non-votes will not
affect the outcome of the vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recommendation of the Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE &#8220;FOR&#8221;
THE INCENTIVE PLAN PROPOSAL.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROPOSAL 4</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REVERSE STOCK SPLIT PROPOSAL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board has adopted and
is recommending that our stockholders approve an amendment to our Certificate of Incorporation, as amended, and thereby authorize the
Board to effect a reverse stock split of our outstanding shares of Common Stock. Our stockholders are being asked to approve the proposal
that Article&#160;FOURTH of our Certificate of Incorporation be amended to effect a reverse stock split of the issued and outstanding
shares of Common Stock within a range of one-for-two (1:2) shares of our Common Stock to one-for-twenty five (1:25) shares of our Common
Stock (the &#8220;<b>Reverse Stock Split</b>&#8221;), with the exact reverse split ratio to be decided and publicly announced by the Board
prior to the effective time of the reverse stock split amendment. Pursuant to the General Corporation Law of the State of Delaware, our
state of incorporation, the Board must adopt any amendment to our Certificate of Incorporation and submit the amendment to stockholders
for their approval. The form of amendment to our Certificate of Incorporation to effect the Reverse Stock Split (the &#8220;<b>Reverse
Stock Split Amendment</b>&#8221;) is attached as&#160;<span style="text-decoration:underline">Annex B</span>&#160;to this proxy statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the stockholders approve
the Reverse Stock Split Amendment, the Board will have the authority to decide, at any time prior to September&#160;15, 2025, whether
to implement the reverse stock split and the precise ratio of the reverse stock split within a range of one-for-two (1:2) shares of our
Common Stock to one-for-twenty five (1:25) shares of our Common Stock. If the Board decides to implement the reverse stock split, the
reverse stock split will become effective upon the filing of the Reverse Stock Split Amendment with the Delaware Secretary of State.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split would
reduce the number of shares of Common Stock outstanding without reducing the total number of authorized shares of Common Stock. As a result,
we would have a larger number of authorized but unissued shares from which to issue additional shares of Common Stock, or securities convertible
or exercisable into shares of Common Stock, in equity financing transactions. The Reverse Stock Split will not change the number of authorized
shares of preferred stock, or the par value of Common Stock or preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board reserves the right,
even after stockholder approval, to abandon or postpone the filing of the Reverse Stock Split Amendment if the Board determines that it
is not in the best interests of the Company and the stockholders. If the Reverse Stock Split Amendment is not filed by the Company by
September&#160;15, 2025 the proposal will be deemed abandoned, without any further effect. In that case, the Board may again seek stockholder
approval at a future date for a reverse stock split if it deems a reverse stock split to be advisable at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reasons for the Reverse Stock Split</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September&#160;16, 2024,
we received a written notice from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that we are not in compliance with Nasdaq
Listing Rule&#160;5550(a)(2), as our closing bid price for our common stock was below $1.00 per share for the last 30 consecutive business
days. Pursuant to Nasdaq Listing Rule&#160;5810(c)(3)(A), we have been granted a 180-calendar day compliance period, or until March&#160;17,
2025, to regain compliance with the minimum bid price requirement. On March&#160;18, 2025, we received a letter from Nasdaq approving
an extension of an additional 180 calendar days to regain compliance with the minimum bid price requirement, or until September&#160;15,
2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time during the
additional compliance period, the bid price of our Common Stock closes at or above $1.00 per share for a minimum of ten (10)&#160;consecutive
trading days, Nasdaq will provide us with written confirmation of compliance with the minimum bid price requirement and the matter will
be closed. If we do not regain compliance within the additional compliance period or do not comply with the terms of the extension, Nasdaq
will provide notice that our securities will be delisted from The Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The primary objective in proposing the Reverse
Stock Split is to maintain our listing on the Nasdaq Capital Market, if needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reducing the number of outstanding
shares of our Common Stock through the Reverse Stock Split is intended, absent other factors, to increase the per share market&#160;price&#160;of
our Common Stock in order to attract new investors and meet the $1.00 per share minimum bid&#160;price requirement&#160;of Nasdaq. However,
other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the market&#160;price&#160;of
our Common Stock. As a result, we cannot assure you that the Reverse Stock Split, if completed, will result in the intended benefits described
above, that the market&#160;price&#160;of our Common Stock will increase following the Reverse Stock Split or that the market&#160;price&#160;of
our Common Stock will not decrease in the future. Additionally, we cannot assure you that the market&#160;price&#160;per share of our
Common Stock after a Reverse Stock Split will increase in proportion to the reduction in the number of shares of our Common Stock outstanding
before the Reverse Stock Split. Accordingly, the total market capitalization of our Common Stock after the Reverse Stock Split may be
lower than the total market capitalization before the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Determination of Reverse Stock Split Ratio</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board believes that stockholder
approval of an amendment that would allow the Board to determine the exact reverse stock split ratio within a specified range of one-for-two
(1:2) to one-for-twenty five (1:25) (rather than stockholder approval of a fixed reverse stock split ratio) provides the flexibility to
achieve the desired results of the reverse stock split. In determining the range of reverse stock split ratios to be submitted for stockholder
approval, the Board considered numerous factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the projected impact of the reverse stock split ratio on the trading liquidity in our Common Stock and
the Company&#8217;s ability to continue our Common Stock&#8217;s listing on Nasdaq;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the potential devaluation of the Company&#8217;s market capitalization as a result of a reverse stock
split;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the historical and projected performance of our Common Stock and volume level before and after the reverse
stock split;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">prevailing market conditions;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">general economic and other related conditions prevailing in the Company&#8217;s industry and in the marketplace
generally;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the Company&#8217;s capitalization (including the number of shares of our Common Stock issued and outstanding);
and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the prevailing trading prices for our Common Stock and its trading volume.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board will consider the
conditions, information and circumstances existing at the time when it determines whether to implement a Reverse Stock Split and, if it
decides to implement a Reverse Stock Split, the precise reverse stock split ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Principal Effects of the Reverse Stock Split</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the stockholders approve
the proposal to authorize the Board to implement the reverse stock split and the Board implements the reverse stock split, we will amend
Article&#160;FOURTH of our Certificate of Incorporation (which sets forth our authorized capital), to materially read as set forth in&#160;<span style="text-decoration:underline">Annex
B</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split will
be effected simultaneously for all issued and outstanding shares of Common Stock. The Reverse Stock Split will affect all of our common
stockholders uniformly and will not affect any stockholder&#8217;s percentage ownership interests in the Company, except to the extent
that the reverse stock split results in any of our stockholders owning a fractional share. After the Reverse Stock Split, the shares of
our Common Stock will have the same proportional voting rights and rights to dividends and distributions and will be identical in all
other respects to our Common Stock now authorized. The reverse stock split will not affect the Company continuing to be subject to the
periodic reporting requirements of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split may
result in some stockholders owning &#8220;odd-lots&#8221; of less than 100 shares of our Common Stock. Brokerage commissions and other
costs of transactions in odd-lots are generally higher than the costs of transactions in &#8220;round-lots&#8221; of even multiples of
100 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional principal effect of the Reverse Stock Split would be
to decrease the number of outstanding shares of our Common Stock. Except for de minimis adjustments that may result from the treatment
of fractional shares as described below, the Reverse Stock Split will not have any dilutive effect on our stockholders since each stockholder
would hold the same percentage of our Common Stock outstanding immediately following the Reverse Stock Split as such stockholder held
immediately prior to the Reverse Stock Split. The relative voting and other rights that accompany the shares of Common Stock would not
be affected by the Reverse Stock Split. The table below sets forth, for informational purposes only, an example the number of shares of
our Common Stock outstanding before and after a Reverse Stock Split assuming a one-for-two ratio and a one-for-twenty five ratio (although
the Board may choose another ratio in its sole discretion) based on shares of Common Stock outstanding as of the Record Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: center; font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prior to<br/> the<br/> Reverse<br/> Split</b></span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming a<br/> one-for-<br/> two Reverse<br/> Split (1)</b></span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming a<br/> one-for-<br/> five Reverse<br/> Split (1)</b></span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming a<br/> one-for-<br/> ten Reverse<br/> Split (1)</b></span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming a<br/> one-for-<br/> fifteen Reverse<br/> Split (1)</b></span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assuming a<br/> one-for-</b></span><br/> <b>twenty five<br/> Reverse Split<br/> (1)</b></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; font: 10pt Times New Roman, Times, Serif">Aggregate Number of Shares of Common Stock</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]</span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]</span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]</span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]</span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]</span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]</span></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numbers are approximate and do not take into account rounding for fractional shares.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Reverse Stock
Split will not have any dilutive effect on our stockholders, the proportion of shares owned by our stockholders relative to the number
of shares authorized for issuance will decrease because the Reverse Stock Split does not change the current authorized number of shares
of Common Stock (160,000,000 shares). The remaining authorized shares may be used for various purposes, including, without limitation,
raising capital, providing equity incentives to employees, officers or directors, effecting stock dividends, establishing strategic relationships
with other companies and expanding our business through the acquisition of other businesses or products. We do not currently have any
plans, proposals or arrangements to issue any of the newly available authorized shares that result from the Reverse Stock Split for any
purposes. In order to support our projected need for additional equity capital and to provide flexibility to raise the capital as necessary,
our Board believes the number of authorized shares of Common Stock should not be reduced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board will retain the
authority not to effect the Reverse Stock Split even though it has already obtained stockholder approval. Thus, the Board, at its discretion,
may cause the filing of the Reverse Stock Split Amendment to effect a Reverse Stock Split or abandon it and effect no Reverse Stock Split
if it determines that such action is not in the best interests of the Company and stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Effecting the Reverse Stock Split</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt of stockholder
approval for the Reverse Stock Split Amendment, if our Board concludes that it is in the best interests of our Company and our stockholders
to effect the Reverse Stock Split, the Reverse Stock Split Amendment will be filed with the Secretary of State of Delaware. The actual
timing of the filing of the Amendment with the Secretary of State of Delaware to effect the Reverse Stock Split will be determined by
our Board. In addition, if for any reason our Board deems it advisable to do so, the Reverse Stock Split may be abandoned at any time
prior to the filing of the Reverse Stock Split Amendment, without further action by our stockholders. In addition, our Board may deem
it advisable to effect the Reverse Stock Split even if the price of our Common Stock is above the $1.00 per share minimum bid&#160;price
requirement&#160;of Nasdaq at the time the Reverse Stock Split is to be effected. The Reverse Stock Split will be effective as of the
date of filing with the Secretary of State of Delaware (the &#8220;<b>Effective Time</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the filing of the Reverse
Stock Split Amendment, without further action on our part or our stockholders, the outstanding shares of Common Stock held by stockholders
of record as of the Effective Time would be converted into a lesser number of shares of Common Stock based on a Reverse Stock Split ratio
as determined by the Board. For example, if you presently hold 100 shares of our Common Stock, you would hold 50 shares of our Common
Stock following the Reverse Stock Split if the ratio is one-for-two or you would hold 5 shares of our Common Stock if the ratio is one-for-twenty
five.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Effect on Outstanding Shares, Options and Certain
Other Securities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Reverse Stock Split
is implemented, the number of shares of our Common Stock owned by each stockholder will be reduced in the same proportion as the reduction
in the total number of shares outstanding, such that the percentage of our Common Stock owned by each stockholder will remain unchanged
except for any de minimis change resulting from rounding up to the nearest number of whole shares so that we are not obligated to issue
cash in lieu of any fractional shares that such stockholder would have received as a result of the Reverse Stock Split. The number of
shares of our Common Stock that may be purchased upon exercise of outstanding options or other securities convertible into, or exercisable
or exchangeable for, shares of our Common Stock, and the exercise or conversion prices for these securities, will also be ratably adjusted
in accordance with their terms as of the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Prior to<br/> the<br/> Reverse <br/> Split</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Assuming a<br/> one-for -<br/> two Reverse<br/> Split(1)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Assuming a <br/> one-for-<br/> five Reverse<br/> Split(1)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Assuming a<br/> one-for-<br/> ten Reverse<br/> Split(1)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Assuming a<br/> one-for-<br/> fifteen Reverse <br/> Split(1)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Assuming a<br/> one-for-<br/> twenty five <br/> Reverse Split(1)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; font-size: 10pt">Warrants</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">[_]</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">[_]</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">[_]</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">[_]</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">[_]</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">[_]</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Pre-funded - Warrants</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Plan Options</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Non-Plan Options and RSUs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Preferred Stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">[_]</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">(1)</td>
    <td>Numbers are approximate and do not take into account rounding for fractional shares.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fractional Shares; Exchange of Stock Certificates</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board does not currently
intend to issue fractional shares in connection with the Reverse Stock Split. Therefore, we do not expect to issue certificates representing
fractional shares. In lieu of any fractional shares, we will issue to stockholders of record who would otherwise hold a fractional share
because the number of shares of Common Stock they hold before the Reverse Stock Split is not evenly divisible by the Reverse Stock Split
ratio that number of shares of Common Stock as rounded up to the nearest whole share. For example, if a stockholder holds 150.25 shares
of Common Stock following the Reverse Split, that stockholder will receive certificate representing 151 shares of Common Stock. No stockholders
will receive cash in lieu of fractional shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Record Date, we had holders of record of our Common Stock
(although we have significantly more beneficial holders). We do not expect the Reverse Stock Split and the rounding up of fractional shares
to whole shares to result in a significant reduction in the number of record holders. We presently do not intend to seek any change in
our status as a reporting company for federal securities law purposes, either before or after the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On or after the Effective
Time, we will mail a letter of transmittal to each stockholder. Each stockholder will be able to obtain a certificate evidencing his,
her or its post-Reverse Stock Split shares only by sending the exchange agent (who will be the Company&#8217;s transfer agent) the stockholder&#8217;s
old stock certificate(s), together with the properly executed and completed letter of transmittal and such evidence of ownership of the
shares as we may require. Stockholders will not receive certificates for post-Reverse Stock Split shares unless and until their old certificates
are surrendered. Stockholders should not forward their certificates to the exchange agent until they receive the letter of transmittal,
and they should only send in their certificates with the letter of transmittal. The exchange agent will send each stockholder, if elected
in the letter of transmittal, a new stock certificate after receipt of that stockholder&#8217;s properly completed letter of transmittal
and old stock certificate(s). A stockholder that surrenders his, her or its old stock certificate(s)&#160;but does not elect to receive
a new stock certificate in the letter of transmittal will be deemed to have requested to hold that stockholder&#8217;s shares electronically
in book-entry form with our transfer agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our registered
holders of Common Stock hold some or all of their shares electronically in book-entry form with our transfer agent. These stockholders
do not have stock certificates evidencing their ownership of our Common Stock. They are, however, provided with a statement reflecting
the number of shares registered in their accounts. If a stockholder holds registered shares in book-entry form with our transfer agent,
the stockholder may return a properly executed and completed letter of transmittal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders who hold shares
in street name through a nominee (such as a bank or broker) will be treated in the same manner as stockholders whose shares are registered
in their names, and nominees will be instructed to effect the Reverse Stock Split for their beneficial holders. However, nominees may
have different procedures and stockholders holding shares in street name should contact their nominees. Stockholders will not have to
pay any service charges in connection with the exchange of their certificates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Authorized Shares</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If and when our Board elects
to effect the Reverse Stock Split, the authorized number of shares of our Common Stock will remain at 160,000,000, subject to the approval
of proposal No.&#160;5, which will provide for the increase in our authorized shares. Accordingly, there will be no reduction in the number
of authorized shares of our Common Stock in proportion to the Reverse Stock Split ratio. As a result, the proportion of shares owned by
our stockholders relative to the number of shares authorized for issuance will decrease and the additional authorized shares of Common
Stock will be available for issuance at such times and for such purposes as our Board may deem advisable without further action by our
stockholders, except as required by applicable laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Reverse Split will have no effect on our authorized
preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with our Certificate of Incorporation
and Delaware law, our shareholders do not have any preemptive rights to purchase or subscribe for any of our unissued or treasury shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Anti-Takeover and Dilutive Effects</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of maintaining
our authorized Common Stock at 160,000,000, or increasing the authorized shares as elaborated under Proposal No.&#160;5, after the Reverse
Stock Split is to facilitate our ability to raise additional capital to support our operations, not to establish any barriers to a change
of control or acquisition of our Company. The shares of Common Stock that are authorized but unissued provide our Board with flexibility
to effect, among other transactions, public or private refinancings, acquisitions, stock dividends, stock splits and the granting of equity
incentive awards. However, these authorized but unissued shares may also be used by our Board, consistent with and subject to its fiduciary
duties, to deter future attempts to gain control of us or make such actions more expensive and less desirable. The Reverse Stock Split
would give our Board authority to issue additional shares from time to time without delay or further action by the stockholders except
as may be required by applicable law or the rules&#160;of Nasdaq. The Reverse Stock Split is not being recommended in response to any
specific effort of which we are aware to obtain control of us, nor does our Board have any present intent to use the authorized but unissued
Common Stock to impede a takeover attempt. There are no plans or proposals to adopt other provisions or enter into any arrangements that
have material anti-takeover effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the issuance
of additional shares of Common Stock for any of the corporate purposes listed above could have a dilutive effect on earnings per share
and the book or market value of our outstanding Common Stock, depending on the circumstances, and would likely dilute a stockholder&#8217;s
percentage voting power in us. Holders of our Common Stock are not entitled to preemptive rights or other protections against dilution.
Our Board intends to take these factors into account before authorizing any new issuance of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Accounting Consequences</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Effective Time,
the stated capital attributable to Common Stock on our balance sheet will be reduced proportionately based on the Reverse Stock Split
ratio (including a retroactive adjustment of prior periods), and the additional paid-in capital account will be credited with the amount
by which the stated capital is reduced. Reported per share net income or loss will be higher because there will be fewer shares of our
Common Stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Federal Income Tax Consequences</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary describes
certain material U.S. federal income tax consequences of the Reverse Stock Split to holders of our Common Stock. This summary addresses
the tax consequences only to a beneficial owner of our Common Stock that is a citizen or individual resident of the United States, a corporation
organized in or under the laws of the United States or any state thereof or the District of Columbia or otherwise subject to U.S. federal
income taxation on a net income basis in respect of our Common Stock (a &#8220;<b>U.S. holder</b>&#8221;). This summary does not address
all of the tax consequences that may be relevant to any particular stockholder, including tax considerations that arise from rules&#160;of
general application to all taxpayers or to certain classes of taxpayers or that are generally assumed to be known by investors. This summary
also does not address the tax consequences to persons that may be subject to special treatment under U.S. federal income tax law or persons
that do not hold our Common Stock as &#8220;capital assets&#8221; (generally, property held for investment). This summary is based on
the provisions of the Internal Revenue Code of 1986, as amended, U.S. Treasury regulations, administrative rulings and judicial authority,
all as in effect as of the date hereof. Subsequent developments in U.S. federal income tax law, including changes in law or differing
interpretations, which may be applied retroactively, could have a material effect on the U.S. federal income tax consequences of the Reverse
Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a partnership (or other
entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our Common Stock, the U.S. federal
income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership.
Partnerships that hold our Common Stock, and partners in such partnerships, should consult their own tax advisors regarding the U.S. federal
income tax consequences of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Each stockholder should consult his, her or
its own tax advisor regarding the U.S. federal, state, local and foreign income and other tax consequences of the Reverse Stock Split.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Stock Split should
be treated as a recapitalization for U.S. federal income tax purposes. Therefore, no gain or loss should be recognized by a U.S. holder
upon the Reverse Stock Split. Accordingly, the aggregate tax basis in the Common Stock received pursuant to the Reverse Split should equal
the aggregate tax basis in the Common Stock surrendered and the holding period for the Common Stock received should include the holding
period for the Common Stock surrendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Text of Proposed Amendment; Effectiveness</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The text of the proposed Reverse Stock Split Amendment
is set forth in&#160;<span style="text-decoration:underline">Annex B</span>&#160;to this Proxy Statement. If and when effected by our Board, the Reverse Stock Split Amendment
will become effective upon its filing with the Secretary of State of Delaware.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Required Vote</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock (voting together as a single class) represented
in person or by proxy and entitled to vote is required for approval of the Reverse Stock Split Proposal. Abstentions are considered present
for purposes of establishing a quorum as to this matter&#160;but will have no effect on the approval of the Reverse Stock Split Proposal.
Broker non-votes are considered present for purposes of establishing a quorum as to this matter but will not affect the outcome of the
vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recommendation of the Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE BOARD RECOMMENDS THAT
THE STOCKHOLDERS VOTE &#8220;FOR&#8221; THE REVERSE STOCK SPLIT PROPOSAL.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROPOSAL 5</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INCREASE IN AUTHORIZED SHARES AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has approved an
amendment to our Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of
common stock from one hundred sixty million (160,000,000) to four hundred million (400,000,000) (the &#8220;<b>Authorized Shares Amendment</b>&#8221;).
The Authorized Shares Amendment will not change the number of authorized shares of preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the 160,000,000 shares
of common stock that are currently authorized, as of May&#160;16, 2025, 44,449,424 shares of common stock were issued and outstanding,
19,277,880 shares of common stock were reserved for issuance upon the exercise of outstanding warrants and prefunded warrants, 55,734,113
shares of common stock were reserved for issuance upon the exercise of preferred shares (including dividend shares) 5,596,183 shares of
common stock were reserved for issuance upon the exercise of outstanding stock options pursuant to our equity incentive plans, including
our employee stock purchase plan, 3,766,383 shares of common stock were reserved for issuance upon the exercise of outstanding non plan
stock options and RSUs, and 5,563,391 shares were reserved for future issuance pursuant to our equity incentive plans, including our employee
stock purchase plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The additional shares of common
stock authorized for issuance by the Authorized Shares Amendment would be a part of the existing class of common stock and, if and when
issued, would have the same rights and privileges as the common stock presently issued and outstanding. The full text of the proposed
Authorized Shares Amendment, which would be filed as a Certificate of Amendment to our Amended and Restated Certificate of Incorporation
with the Secretary of State of the State of Delaware, is attached to this Proxy Statement as Annex C. However, the text of the Authorized
Shares Amendment is subject to revision as may be required by the Secretary of State of the State of Delaware or as the Board deems necessary
and advisable to effect the Authorized Shares Amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provided our stockholders
approve the Authorized Shares Amendment, the increased number of shares would be authorized for issuance, but such shares would remain
unissued until such time as the Board approves a specific issuance of shares. We currently have no plans or arrangements to issue the
additional authorized shares of common stock resulting from the Authorized Shares Amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the proposed Authorized
Shares Amendment is approved by our stockholders, it will become effective upon the filing of the Certificate of Amendment with the Secretary
of State of the State of Delaware. We plan to file such Certificate of Amendment as soon as practicable after the Meeting. However, the
Board reserves its right to elect not to proceed with and abandon the Authorized Shares Amendment if it determines, in its sole discretion
at any time, that this proposal is no longer in the best interests of our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Background and Purpose of the Authorized Shares Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred net losses
since our inception. We expect to incur future net losses and our transition to profitability is dependent upon, among other things, the
successful development and commercialization of our products and the achievement of a level of revenues adequate to support the cost structure.
Until we achieve profitability or generate positive cash flows, we will continue to be dependent on raising additional funds. We intend
to fund our future operations through cash on hand, additional private and/or public offerings of debt or equity securities or a combination
of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success in achieving our
business objectives depend on our ability to raise additional capital in the future, and the Board believes it is in the best interests
of the Company and its stockholders to have sufficient flexibility to issue additional shares in the future on a timely basis if such
need arises in connection with potential financings or other corporate purposes. Approval of the Authorized Shares Amendment would enable
us to take advantage of market conditions, the availability of more favorable financings and other strategic transactions, without the
potential delay and expense associated with convening a special stockholders&#8217; meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our success also
depends in part on our continued ability to attract, retain and motivate highly qualified management and key personnel, which is of particular
concern in the competitive biopharmaceutical industry. If the Authorized Shares Amendment is not approved by our stockholders, the lack
of unissued and unreserved authorized shares of common stock to provide future equity incentive opportunities could adversely impact our
ability to achieve these goals to retain employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Effect of the Authorized Shares Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The additional common stock
to be authorized by adoption of the Authorized Shares Amendment would have rights identical to our currently outstanding common stock.
Adoption of the Authorized Shares Amendment would not affect the rights of the holders of currently outstanding common stock, except for
effects incidental to increasing the number of shares of our common stock outstanding, such as dilution of the earnings per share, if
any, book value per share and voting power and percentage interest of the current holders of common stock, in each case to the extent
that any additional shares of common stock are ultimately issued out of the increase in authorized shares proposed in the Authorized Shares
Amendment. The proposed increase in the number of authorized shares of common stock will not, by itself, have an immediate dilutive effect
on our current stockholders. However, if the Authorized Shares Amendment is approved, unless otherwise required by applicable law or stock
exchange rule, the Board will be able to issue the additional shares of common stock from time to time in its discretion without further
action or authorization by the stockholders. We currently have no specific plans, arrangements or understandings to issue additional shares
of common stock. The newly authorized shares of common stock would be issuable for any proper corporate purpose, including capital raising
transactions of equity or convertible debt securities, the establishment of collaborations or other strategic agreements, stock splits,
stock dividends, issuance under current or future equity incentive plans, future acquisitions, investment opportunities or for other corporate
purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Potential Anti-Takeover Effect of the Authorized Shares Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An increase in the number
of authorized but unissued shares of common stock relative to the number of outstanding shares of common stock may also, under certain
circumstances, be construed as having an anti-takeover effect. Although not designed or intended for such purposes, the effect of the
Authorized Shares Amendment might be to render more difficult or to discourage a merger, tender offer, proxy contest or change in control
of us and the removal of management, which stockholders might otherwise deem favorable. For example, the authority of the Board to issue
common stock might be used to create voting impediments or to frustrate an attempt by another person or entity to effect a takeover or
otherwise gain control of us because the issuance of additional common stock would dilute the voting power of the common stock then outstanding.
Our common stock could also be issued to purchasers who would support the Board in opposing a takeover bid which our Board determines
not to be in our best interests and those of our stockholders. In addition to the Authorized Shares Amendment, the Amended and Restated
Certificate of Incorporation and our Bylaws also include other provisions that may have an anti-takeover effect. These provisions, among
other things, permit the Board to issue preferred stock with rights senior to those of the common stock without any further vote or action
by the stockholders, provide that special meetings of stockholders may only be called by the majority of our Board and certain of our
officers and do not provide for cumulative voting rights, all of which could make it more difficult for stockholders to effect certain
corporate actions and may delay or discourage a change in control. The Board is not presently aware of any attempt, or contemplated attempt,
to acquire control of the Company, and the Authorized Shares Amendment is not part of any plan by the Board to recommend or implement
a series of anti-takeover measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Vote Required</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast at the Meeting by the holders of Common Stock and preferred stock (voting together as a single class) represented
in person or by proxy and entitled to vote is required for approval of the Increase in Authorized Shares Proposal and&#160;the affirmative
vote of a majority of the votes cast at the Meeting by the holders of Common Stock&#160;(voting separately as a class)&#160;represented
in person or by proxy. Abstentions by holders of Common Stock&#160;are considered present for purposes of establishing a quorum&#160;as
to this matter&#160;but will have no effect on the approval of the Increase in Authorized Shares Proposal. Broker non-votes with respect
to Common Stock are considered present for purposes of establishing a quorum as to this matter but&#160;will not affect the outcome of
the vote on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recommendation of the Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE &#8220;FOR&#8221;
THE&#160;INCREASE IN AUTHORIZED SHARES PROPOSAL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Director Independence</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board has reviewed the
materiality of any relationship that each of our directors has with us, either directly or indirectly. Based on this review, our Board
has determined that, Messrs.&#160;Shaked, Matheis and McGrath, and Ms.&#160;Karah are &#8220;independent directors&#8221; as defined in
the Nasdaq Listing Rules&#160;and Rule&#160;10A-3 promulgated under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Meetings of the Board</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board met telephonically
8 times during the fiscal year ended December&#160;31, 2024 and also acted by unanimous written consent on 8 occasions. Each member
of our then current Board was present for at least 88% percent or more of the Board meetings held.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Board Committees</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board has three standing committees: an Audit
Committee, a Compensation Committee and a Nominating and Corporate Governance Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Audit Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee is comprised
of Messrs.&#160;Shaked, McGrath and Matheis, each of whom is an independent director. Mr.&#160;McGrath is the Chairman of the Audit Committee.
Mr.&#160;McGrath is an &#8220;audit committee financial expert&#8221; as defined in Item 407(d)(5)(ii)&#160;of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee oversees
our corporate accounting, financial reporting practices and the audits of financial statements. For this purpose, the Audit Committee
has a charter (which is reviewed annually) and performs several functions. The Audit Committee charter is available on our website at
https://dariohealth.investorroom.com under the &#8220;For Investors&#8212;Corporate Governance&#8221; section. The Audit Committee:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">evaluates the independence and performance of, and assesses the qualifications of, our independent auditor
and engage such independent auditor;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">approves the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services
and approve in advance any non-audit service to be provided by our independent auditor;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">monitors the independence of our independent auditor and the rotation of partners of the independent auditor
on our engagement team as required by law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">reviews the financial statements to be included in our Annual Report on Form&#160;10-K and Quarterly Reports
on Form&#160;10-Q and reviews with management and our independent auditor the results of the annual audit and reviews of our quarterly
financial statements; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style=" font-size: 10pt">&#9679;</span></td><td style="text-align: justify">oversees all aspects our systems of internal accounting control and corporate governance functions on
behalf of the Board.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee met telephonically
on 4 occasions during the fiscal year ended December&#160;31, 2024 and also acted by unanimous written consent on 8 occasions. Each of
the members of the Audit Committee attended 100% of the meetings held by the Audit Committee during the time each director served as a
member of the committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee
is comprised of Messrs.&#160;Shaked, McGrath and Ms.&#160;Karah. Mr.&#160;McGrath is the Chairman of the Compensation Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
reviews or recommends the compensation arrangements for our management and employees and also assists our Board in reviewing and approving
matters such as company benefit and insurance plans, including monitoring the performance thereof. The Compensation Committee has a charter
(which is reviewed annually) and performs several functions. The Compensation Committee charter is available on our website at https://dariohealth.investorroom.com
under the &#8220;For Investors&#8212;Corporate Governance&#8221; section.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
has the authority to directly engage, at our expense, any compensation to consultants, or other advisers as it deems necessary to carry
out its responsibilities in determining the amount and form of employee, executive and director compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
met telephonically on 1 occasions during the fiscal year ended December&#160;31, 2024 and acted by unanimous written consent on 14 occasion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Nominating and Corporate Governance Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Nominating and Corporate
Governance Committee is currently comprised of Messrs.&#160;Matheis and Shaked. Mr.&#160;Matheis is the Chairman of the Nominating and
Corporate Governance Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nominating and Corporate
Governance Committee is charged with the responsibility of reviewing our corporate governance policies and with proposing potential director
nominees to the Board for consideration. This committee also has the authority to oversee the hiring of potential executive positions
in our company. The Nominating and Corporate Governance Committee operates under a written charter, which will be reviewed and evaluated
at least annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the fiscal year ended
December&#160;31, 2024, we did not pay a fee to any third party to identify or evaluate, or assist in identifying or evaluating, potential
nominees for our Board. We have not received any recommendations from stockholders for Board nominees. All of the nominees for election
at the Meeting are current members of our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nominating and Corporate
Governance Committee will review a reasonable number of candidates for director recommended by stockholders who satisfy the notice, information
and consent provisions set forth in the Company&#8217;s Bylaws. The Board will use the same evaluation criteria and process for director
nominees recommended by stockholders as it uses for other director nominees. A stockholder wishing to formally nominate an individual
for election to the Board must do so by following the procedures described in the Company&#8217;s Bylaws. There has been no change to
the procedures by which stockholders may recommend nominees to our Board. For information concerning stockholder proposals, see &#8220;Stockholder
Proposals&#8221; below in this Proxy Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board believes that all
of its directors should have the highest personal integrity and have a record of exceptional ability and judgment. The Board also believes
that its directors should ideally reflect a mix of experience and other qualifications. There is no firm requirement of minimum qualifications
or skills that candidates must possess. The Nomination and Corporate Governance Committee evaluates director candidates based on a number
of qualifications, including their independence, judgment, leadership ability, expertise in the industry, experience developing and analyzing
business strategies, financial literacy, risk management skills, and, for incumbent directors, his or her past performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nomination and Corporate
Governance Committee acted by unanimous written consent on 1 occasion during the fiscal year ended December&#160;31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the nominees for election
at this Meeting was recommended to the Board by the Nominating and Corporate Governance Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Board Leadership Structure and Role in Risk Oversight</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board&#8217;s, including
our Audit and Compensation Committees&#8217;, as appropriate, role in risk oversight includes risk analysis and assessment in connection
with each financial and business review, update and decision-making proposal and is an integral part of all Board deliberations. Each
of our Board committees is focused on specific risks within their areas of responsibility, but the Board believes that the overall enterprise
risk management process is more properly overseen by all of the members of the Board. The Audit Committee is responsible for overseeing
the management of financial and accounting risks. The Compensation Committee is responsible for overseeing the management of risks relating
to executive compensation plans and arrangements. While each Committee is responsible for the evaluation and management of such risks,
the entire Board is regularly informed through Committee reports. The Board incorporates the insight provided by these reports into its
overall risk management analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board&#8217;s role in
our risk oversight is consistent with our leadership structure, with our Chief Executive Officer and other members of senior management
having responsibility for assessing and managing our risk exposure, and the Board providing oversight in connection with those efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Code of Conduct</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&#160;5, 2013, our
Board adopted a Code of Conduct which is available on our internet website at https://dariohealth.investorroom.com/CorporateGovernance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Procedures for Contacting Directors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has established
a process for stockholders to send communications to the Board. Stockholders may communicate with the Board generally or a specific director
at any time by writing to: DarioHealth Corp., at 322 W. 57th St. New York, New York 10019, Attention: Chen Franco-Yehuda. We review all
messages received, and forward any message that reasonably appears to be a communication from a stockholder about a matter of stockholder
interest that is intended for communication to the Board. Communications are sent as soon as practicable to the director to whom they
are addressed, or if addressed to the Board generally, to the Chairman of the Board. Because other appropriate avenues of communication
exist for matters that are not of stockholder interest, such as general business complaints or employee grievances, communications that
do not relate to matters of stockholder interest are not forwarded to the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Attendance at Special and Annual Stockholder Meetings</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We encourage our directors
to attend our special and annual stockholder meetings. Mr.&#160;Erez Raphael, our Chief Executive Officer and Zvi Ben David, our former
Chief Financial Officer, Secretary and Treasurer, attended our last annual stockholder meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Executive Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes compensation of
our named executive officers, as of December&#160;31, 2023 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Name
    and</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-<br/>
    qualified</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">All&#160;Other</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Principal</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Awards</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">incentive&#160;plan</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">incentive&#160;plan</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Compensation</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: left; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Position</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Year</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Salary&#160;($)*</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Bonus&#160;($)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock&#160;Awards</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">($)**</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">compensation</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">compensation</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">($)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">($)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Erez
    Raphael</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2024</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">448,293</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,344,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">169,791</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,962,084</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Chief
    Executive Officer)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">446,307</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">101,939</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">173,941</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">722,187</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Zvi
    Ben David</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">327,311</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">672,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">87,144</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,086,455</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(former
    Chief Financial Officer)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">243,419</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">31,479</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">67,686</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">342,584</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Richard
    Anderson</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">345,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(9)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(10)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(11)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">962,250</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">59,074</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,366,324</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Former
    President)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">400,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(9)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">80,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(10)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(11)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">56,648</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(12)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">536,648</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Steven
    Nelson</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">212,308</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(13)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">532,500</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(14)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">44,564</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(15)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">789,372</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Chief
    Commercial Officer) (20)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(13)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(14)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(15)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tomer
    Ben Kiki</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2024</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">384,041</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(16)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,573,421</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(17)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">38,690</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(18)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,996,152</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Former
    Chief Operations Officer) (20)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(16)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(17)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(18)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>








</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">*</td><td>Certain compensation paid by the company is denominated in New Israeli Shekel (or the NIS). Such compensation is calculated for purposes
of this table based on the annual average currency exchange for such period.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">**</td><td>Amount shown does not reflect dollar amount actually received. Instead, this amount reflects the aggregate grant date fair value of
each stock option granted in the fiscal years ended December&#160;31, 2024, and December&#160;31, 2023, computed in accordance with the
provisions of ASC 718 &#8220;Compensation-Stock Compensation&#8221; (&#8220;<b>ASC 718</b>&#8221;). Assumptions used in accordance with
ASC 718 are included in Note 16 to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the fiscal
year ended December&#160;31, 2024 (the &#8220;<b>Annual Report</b>&#8221;).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">In accordance with his second amendment to the employment agreement with our company effective August&#160;11,
2013, Mr.&#160;Raphael was initially entitled to a monthly salary of NIS 44,000. Since August&#160;2013, the Compensation Committee has
approved several increases to Mr.&#160;Raphael&#8217;s monthly salary, most recently on April&#160;1, 2021, when his monthly salary was
increased to NIS 137,466 (approximately $37,078 per month).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">In March&#160;2023, Mr.&#160;Raphael was paid a bonus of $101,939 for his performance during 2022.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">On March&#160;6, 2024, Mr.&#160;Raphael was granted 800,000 restricted shares of our common stock under
our 2020 Equity Incentive Plan.</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(4)</td><td style="text-align: justify">In addition to his salary, Mr.&#160;Raphael is entitled to receive a leased automobile and mobile phone
during his employment as well as reimbursements for expenses accrued. These benefits, as well as other social benefits under Israeli law,
are included as part of his &#8220;All Other Compensation.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(5)</td><td style="text-align: justify">In accordance with his employment agreement with our company effective January&#160;8, 2015, Mr.&#160;Ben
David was initially entitled to a monthly salary and additional compensation (excluding social benefits under applicable Israeli law)
of NIS 31,200 (approximately $8,415) for providing eighty percent of his working time to our company. Beginning on March&#160;1, 2015,
Mr.&#160;Ben David began working for us on a full-time basis pursuant to the terms of his employment agreement at which point Mr.&#160;Ben
David&#8217;s salary was increased to NIS 39,000 (approximately $10,519 per month. Since March&#160;2015, the Compensation Committee has
approved several increases to Mr.&#160;Ben David&#8217;s salary, most recently on March&#160;1, 2024, when his monthly salary was updated
to NIS 105,000 (approximately $28,471).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(6)</td><td style="text-align: justify">In March&#160;2023, Mr.&#160;Ben David was paid a bonus of $31,479 for his performance during 2022.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(7)</td><td style="text-align: justify">On March&#160;6, 2024, Mr.&#160;Ben David was granted 400,000 restricted shares of our common stock under
our 2020 Equity Incentive Plan.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(8)</td><td style="text-align: justify">In addition to his salary, Mr.&#160;Ben David is entitled to receive a mobile phone during his employment
as well as reimbursements for expenses accrued. These benefits, as well as other social benefits under Israeli law, are included as part
of his &#8220;All Other Compensation.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(9)</td><td style="text-align: justify">In accordance with his employment agreement, effective in January&#160;2020, Mr.&#160;Anderson was entitled
to a monthly salary of $27,916.67. As of April&#160;2022, Mr.&#160;Anderson was entitled to a monthly salary of $33,333.33.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(10)</td><td style="text-align: justify">In April&#160;2023, Mr.&#160;Anderson was paid a bonus of $80,000 for his performance during 2022.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(11)</td><td style="text-align: justify">On March&#160;6, 2024, Mr.&#160;Anderson was granted 750,000 options to purchase shares of our common
stock under our 2020 Equity Incentive Plan, at an exercise price of $1.68 per share.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(12)</td><td style="text-align: justify">In addition to his salary, Mr.&#160;Anderson was entitled to participate in any and other benefit plans
and programs that we may offer to our employees from time to time according to the terms of such plans and our practices and policies
as well as reimbursements for expenses accrued. These benefits are included as part of his &#8220;All Other Compensation.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(13)</td><td style="text-align: justify">In accordance with his employment agreement, effective in June&#160;2024, Mr.&#160;Nelson was entitled
to a monthly salary of $33,333.33.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(14)</td><td style="text-align: justify">On June&#160;5, 2024, Mr.&#160;Nelson was granted 500,000 options to purchase shares of our common stock
as an inducement grant pursuant to Nasdaq Listing Rule&#160;5635 (c)(4), at an exercise price of $1.35 per share.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(15)</td><td style="text-align: justify">In addition to his salary, Mr.&#160;Nelson is entitled to participate in any and other benefit plans and
programs we may offer to our employees from time to time according to the terms of such plans and the Company&#8217;s practices and policies
as well as reimbursements for expenses accrued. These benefits are included as part of his &#8220;All Other Compensation.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(16)</td><td style="text-align: justify">In accordance with his employment agreement, effective in February&#160;2024, Mr.&#160;Ben-Kiki was entitled
to a monthly salary of $35,417.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(17)</td><td style="text-align: justify">On February&#160;15, 2024, Mr.&#160;Ben-Kiki was granted 717,946 options to purchase shares of our common
stock as an inducement grant pursuant to Nasdaq Listing Rule&#160;5635 (c)(4), at an exercise price of $2.55 per share. On November&#160;4,
2024, Mr.&#160;Ben-Kiki was granted a Warrant to purchase 319,653 shares of our common stock at an exercise price of $0.9475 per share.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(18)</td><td style="text-align: justify">In addition to his salary, Mr.&#160;Ben-Kiki was entitled to participate in any and other benefit plans
and programs that we may offer to our employees from time to time according to the terms of such plans and our practices and policies
as well as reimbursements for expenses accrued. These benefits are included as part of his &#8220;All Other Compensation.&#8221;</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All compensation awarded to
our executive officers was independently reviewed by our Compensation Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Employment and Related Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth below,
we currently have no other written employment agreements with any of our officers and directors. The following is a description of our
current executive employment agreements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Erez Raphael</i>,&#160;<i>Chief
Executive Officer and a Member of the Board </i>&#8211; On August&#160;30, 2013, LabStyle Innovation Ltd., our Israeli subsidiary, entered
into an amendment to a Personal Employment Agreement with Mr.&#160;Raphael in connection with his August&#160;2013 appointment as our
President and Chief Executive Officer. Pursuant to the terms of his employment agreement as amended, Mr.&#160;Raphael is entitled to a
monthly salary of NIS 137,466 (approximately $37,275) and a target bonus equal to 75% of his annual base salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July&#160;25, 2017, we,
through our Israeli subsidiary, LabStyle Innovation Ltd., executed an Amended and Restated Employment Agreement with Mr.&#160;Raphael.
Pursuant to the agreement, Mr.&#160;Raphael kept his monthly salary and shall be eligible for an annual bonus equal to up to 60% of his
annual base salary. Mr.&#160;Raphael&#8217;s employment agreement expired on December&#160;31, 2020. In the event Mr.&#160;Raphael&#8217;s
employment agreement is terminated by us at will, by Mr.&#160;Raphael for good reason as provided thereby, or in conjunction with a change
of control, Mr.&#160;Raphael shall be entitled to receive 24 months base salary and severance payment pursuant to applicable Israeli severance
law, provided, however, that in the event such termination occurs during the final year of the term, or within the last 6 months of a
renewal period of the term, Mr.&#160;Raphael shall be entitled to receive 12 months base salary and severance payment pursuant to applicable
Israeli severance law. In the event the employment agreement is terminated by us for cause, Mr.&#160;Raphael will only be entitled to
a severance pay under applicable Israeli severance law. Mr.&#160;Raphael&#8217;s employment agreement also includes a one-year non-competition
and non-solicitation provision, certain confidentiality covenants and assignment of any of his company-related inventions. Under the terms
of the agreement, Mr.&#160;Raphael is entitled to certain expense reimbursements and other standard benefits, including vacation, sick
leave, contributions to a manager&#8217;s insurance policy and study fund and car and mobile phone allowances. On February&#160;12, 2020,
we extended the term of Mr.&#160;Raphael&#8217;s employment to expire on December&#160;31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chen Franco-Yehuda, Chief
Financial Officer, Treasurer and Secretary</i>&#160;&#8211; On April&#160;18, 2025, the Board appointed Ms.&#160;Franco-Yehuda, as our
Chief Financial Officer, Treasurer and Secretary. In connection with her appointment, we through our wholly owned subsidiary Labstyle
Innovation Ltd., entered into an employment agreement and a standard indemnification agreement with Ms.&#160;Franco-Yehuda. Pursuant to
the terms of her Employment Agreement, we agreed to pay Ms.&#160;Franco-Yehuda a monthly salary of NIS 82,000 (approximately $22,245),
as well as a target bonus equal to a gross amount of up to six times her base salary, subject to meeting certain milestones as annually
approved by the Compensation Committee and/or the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms.&#160;Franco-Yehuda&#8217;s
employment agreement may be terminated by either party at will upon 90 days prior written notice or terminated by us for cause, as defined
under the employment agreement. In the event the employment agreement is terminated by us at will,&#160;Ms.&#160;Franco-Yehuda shall be
entitled to receive a minimum of 90 days of severance plus any required severance payment pursuant to applicable Israeli severance law,
including an adjustment period where she will continue to receive severance (whereby Ms.&#160;Franco will accrue one month of an adjustment
period for each year of her employment, commencing as of April&#160;27, 2025, but in no event will the adjustment period exceed six (6)&#160;months
in the aggregate). In the event the employment agreement is terminated by the Company for cause, Ms.&#160;Franco-Yehuda will only be entitled
to a severance pay under applicable Israeli severance law. In the event of a change of control of the Company, Ms.&#160;Franco-Yehuda
will be entitled to a six (6)&#160;month adjustment period and a full acceleration of any unvested awards. The Employment Agreement also
includes a twelve-month non-competition and non-solicitation provision, certain confidentiality covenants and assignment of any of her
company-related inventions to the company. Under the terms of the Employment Agreement, Ms.&#160;Franco-Yehuda is entitled to certain
expense reimbursements and other standard benefits, including vacation, sick leave, contributions to a manager&#8217;s insurance policy
and study fund and mobile phone allowances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreed to
issue Ms.&#160;Franco-Yehuda 500,000 restricted shares Common Stock, pursuant to our Amended and Restated 2020 Equity Incentive Plan,
as amended. The restricted shares vest over three years, with one third of such shares vesting on April&#160;27, 2026, and the remaining
shares vesting in equal quarterly amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Zvi Ben David</i>,&#160;<i>Former
Chief Financial Officer, Treasurer and Secretary</i>&#160;&#8211; On January&#160;8, 2015, LabStyle Innovation Ltd., our Israeli subsidiary,
entered into a Personal Employment Agreement with Mr.&#160;Ben David. Pursuant to the terms of his employment agreement, as amended, Mr.&#160;Ben
David is entitled to a monthly salary of NIS 105,000 (approximately $28,471) and a target bonus equal to 40% of his base salary. Mr.&#160;Ben
David's employment agreement may be terminated by either party at will upon 90 days prior written notice or terminated by us for cause,
as defined under the employment agreement. In the event the employment agreement is terminated by us at will,&#160;Mr.&#160;Ben David
shall be entitled to receive 90 days of severance plus any required severance payment pursuant to applicable Israeli severance law. In
the event the employment agreement is terminated by us for cause, Mr.&#160;Ben David will only be entitled to a severance pay under applicable
Israeli severance law. The employment agreement also includes a twelve-month non-competition and non-solicitation provision, certain confidentiality
covenants and assignment of any of his company-related inventions to the company. Under the terms of the employment agreement, Mr.&#160;Ben
David is entitled to certain expense reimbursements and other standard benefits, including vacation, sick leave, contributions to a manager&#8217;s
insurance policy and study fund and mobile phone allowances. On April&#160;18, 2025, the Company, through its wholly owned subsidiary
Labstyle Innovation Ltd., executed a Termination of Employment and Separation Agreement with Mr.&#160;Ben David, pursuant to which Mr.&#160;Ben
David&#8217;s position as Chief Financial Officer, Secretary and Treasurer, terminated effective May&#160;15, 2025. Pursuant to the terms
of the agreement, Mr.&#160;Ben-David will remain a member of our advisory board. We also agreed to pay Mr.&#160;Ben-David, in lieu of
his notice period and accrued vacation, a reduced monthly payment of 52,500 NIS (approximately $14,266) for the period from July&#160;1,
2025 through December&#160;31, 2025, and 47,775 NIS (approximately $12,982) for the period January&#160;1, 2026 through October&#160;31,
2027.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Steven Nelson, Chief Commercial
Officer</i>&#160;&#8211; On June&#160;5, 2024, we appointed Mr.&#160;Nelson as our Chief Commercial Officer. In connection with Mr.&#160;Nelson&#8217;s
appointment, we agreed to pay Mr.&#160;Nelson an annual base salary of $400,000. Mr.&#160;Nelson shall also be subject to a six-month
non-competition and one-year non-solicitation provision, certain confidentiality covenants and assignment of any of his company-related
inventions. Mr.&#160;Nelson will also be entitled to certain expense reimbursements and other standard benefits, including vacation and
sick leave. In addition, Mr.&#160;Nelson will be entitled to receive an annual incentive bonus of up to $400,000, subject to certain milestones
and performance targets. In conjunction with his appointment as Chief Commercial Officer, we agreed to issue Mr.&#160;Nelson a stock option
to purchase up to 500,000 shares of common stock, with such shares vesting over three years, with one third of such shares vesting on
June&#160;1, 2025, and the remaining shares vesting in equal quarterly amounts. In addition, we agreed to issue Mr.&#160;Nelson a stock
option to purchase 400,000 shares of common stock, of which 150,000 shares commence vest upon our achieving 92% of a targeted revenue
amount for the year ended December&#160;31, 2024, and the remaining balance of 250,000 shares if the annual revenue is 100% or more of
a targeted amount, provided, however that such options shall be canceled if the annual revenue does not reach at least 92% of the targeted
amount. We also agreed to issue Mr.&#160;Nelson a stock option to purchase 450,000 shares of common stock, for each of the years ending
December&#160;31, 2025, December&#160;31, 2026 and December&#160;2027, of which 150,000 shares commence vesting if the Company&#8217;s
annual revenue is at least 92% of a targeted amount, 150,000 shares commence vesting if the Company&#8217;s annual revenue is 100% or
more of the targeted amount and an additional 150,000 shares will commence vesting upon reaching certain annual goals as determined by
the Board for such fiscal year, provided, however that such options shall be canceled if the annual revenue does not reach at least 92%
of the targeted amount. Each of the performance options vests over a three-year period commencing on the first day of the following fiscal
year to which such option relates, at the rate of 8.33% per quarter, at the last day of the relevant fiscal quarter. All options were
granted as an inducement material to Mr.&#160;Nelson becoming an employee of the Company, in accordance with Nasdaq Listing Rule&#160;5635(c)(4).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Richard Anderson, Former
President and General Manager of North America</i>&#160;&#8211; On January&#160;7, 2020, we appointed Mr.&#160;Anderson as our President
and General Manager of North America. In connection with Mr.&#160;Anderson&#8217;s appointment, we agreed to pay Mr.&#160;Anderson an
annual base salary of $335,000. Mr.&#160;Anderson was also entitled to certain expense reimbursements and other standard benefits, including
vacation and sick leave. On April&#160;1, 2022, Mr.&#160;Anderson&#8217;s base salary was increased to $400,000. In addition, Mr.&#160;Anderson
was entitled to receive an annual incentive bonus of up to $250,000, subject to certain milestones and performance targets. In addition,
and in conjunction with his appointment as President and General Manager of North America, we agreed to issue Mr.&#160;Anderson a stock
option to purchase up to 90,000 shares of common stock at an exercise price of $8.41 per share, subject to vesting. Mr.&#160;Anderson
was also issued a stock option to purchase up to 90,000 shares of common stock at an exercise price of $8.41 per share, subject to vesting
and the achievement of certain business revenue targets. In that regard, Mr.&#160;Anderson&#8217;s option will vest as follows: (i)&#160;22,500
shares shall vest following fiscal year 2020 if our business-to-business revenues reach or exceed $6 million in the aggregate, or a pro-rated
amount equal to the percentage achievement of such target, assuming the Company&#8217;s GAAP revenues in 2020 will reach at least $11
million in the aggregate; (ii)&#160;22,500 shares shall vest following fiscal year 2021 if our business-to-business revenues reach or
exceed $15 million in the aggregate, or a pro-rated amount equal to the percentage achievement of such target, assuming the Company&#8217;s
GAAP revenues in 2021 will reach at least $19.5 million in the aggregate; (iii)&#160;22,500 shares shall vest following fiscal year 2022
if our business-to-business revenues reach or exceed $40 million in the aggregate, or a pro-rated amount equal to the percentage achievement
of such target, assuming the Company&#8217;s GAAP revenues in 2022 will reach at least $38 million in the aggregate; and (iv)&#160;22,500
shares shall vest following fiscal year 2023 if our business-to-business revenues reach or exceed $80 million in the aggregate, or a pro-rated
amount equal to the percentage achievement of such target, assuming the Company&#8217;s GAAP revenues in 2023 will reach at least $62
million in the aggregate. The performance options for 2020, 2021, 2022 and 2023 did not vest and have expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May&#160;30, 2024, we and
Mr.&#160;Anderson, mutually agreed that Mr.&#160;Anderson would cease serving in his role as President of the Company and would continue
as a consultant and member of our advisory board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tomer Ben-Kiki, Former
Chief Operating Officer</i>. Mr.&#160;Ben-Kiki acted as the Company&#8217;s Chief Operating Officer between February&#160;15, 2024, and
August&#160;7, 2024. Under Mr.&#160;Ben-Kiki&#8217;s employment agreement he was entitled to earn an annual salary of $212,000 for his
work in the United States, and 65,000 NIS per month for his work in Israel. Mr.&#160;Ben-Kiki was also entitled to a bonus of up to 20%
of his base salary, subject to certain performance objectives as defined by the Board. In addition, he was entitled to receive a stock
option to purchase up to 1,017,947 shares of Common Stock, at an exercise price of $2.55 per share, which were granted as an inducement
material to Mr.&#160;Ben-Kiki becoming an employee of the company, in accordance with Nasdaq Listing Rule&#160;5635(c)(4). On August&#160;7,
2024, we and Tomer Ben-Kiki, mutually agreed that Mr.&#160;Ben-Kiki would be relieved from his role as Chief Operating Officer and re-assigned
to serve in a non-executive management role as our Chief Technology Officer. In connection with his departure from his role, we made a
consulting agreement with Mr.&#160;Ben-Kiki.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Outstanding Equity
Awards on December&#160;31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Equity</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">incentive</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">plan&#160;awards:</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number&#160;of</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number&#160;of</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number&#160;of</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">securities</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">securities</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">securities</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">underlying</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">underlying</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">underlying</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">unexercised</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">unexercised</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">unexercised</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">options&#160;(#)</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">options&#160;(#)</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">unearned</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">exercise</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; white-space: nowrap; font-size: 10pt; font-weight: bold">Name</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">exercisable</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">unexercisable</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">options&#160;(#)</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">price&#160;($)</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">Zvi Ben David</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">27,827</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7.74</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 12%; font-size: 10pt; text-align: right">February&#160;12, 2026</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">(Chief Financial Officer, Secretary and Treasurer)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Richard Anderson</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">90,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8.410</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">January&#160;30, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">(President and General Manager of North America)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">91,652</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">17.890</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">January&#160;19, 2031</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112,500</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,500</td><td style="font-size: 10pt; text-align: left">(1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7.190</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">May&#160;18, 2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">515,625</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">234,375</td><td style="font-size: 10pt; text-align: left">(1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.680</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">March&#160;6, 2034</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Steven Nelson</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">500,000</td><td style="font-size: 10pt; text-align: left">(2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.35</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">June&#160;5, 2034</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">(Chief Commercial Officer)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Tomer Ben-Kiki</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">398,293</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">319,654</td><td style="font-size: 10pt; text-align: left">(3)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.55</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">February&#160;15, 2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">(Former Chief Operating Officer)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Total Option Shares</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,235,897</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,076,529</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">Vests in 12 equal quarterly installments over a three-year period.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">One third vests after one year followed by 8 equal quarterly amounts over the following two years.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">Unvested options were cancelled.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AwardTmgMnpiDiscTextBlock-c0_cont_1" escape="true" name="ecd:AwardTmgMnpiDiscTextBlock" id="ixv-5000"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any formal
policy that requires us to grant, or avoid granting, equity-based compensation at certain times. <ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMethodTextBlock" id="ixv-8328">We do not grant equity awards in anticipation
of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time
the public release of such information based on award grant dates.</ix:nonNumeric> The timing of any equity grants to executive officers or directors
in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such as an executive
officer&#8217;s commencement of employment or promotion effective date).</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AwardTmgMnpiDiscTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December&#160;31,
2024, there were no equity grants made to our executive officers during any period beginning four business days before the filing of a
periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing
of such report with the Securities and Exchange Commission that were likely to result in changes to the price of our common stock, and
do not time the public release of such information based on award grant dates.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pay Versus Performance Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Section&#160;953(a)&#160;of
the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v)&#160;of Regulation S-K, we are providing the following
information about the relationship between executive compensation actually paid to our CEO and our other Named Executive Officer (&#8220;<b>NEO</b>&#8221;)
and certain financial performance of the Company for each of the fiscal years ended December&#160;31, 2023, and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ecd:PvpTableTextBlock" id="ixv-5034"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Summary<br/> Compensation<br/> Table Total<br/> for CEO</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Compensation<br/> Actually Paid <br/>
to CEO</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Summary<br/> Compensation<br/> Table Total <br/>
for Other<br/> NEOs</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Compensation<br/> Actually Paid<br/> to Other<br/> NEOs</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Value of <br/> Initial Fixed <br/> $100 <br/>
Investment<br/> Based on<br/> Total<br/> Shareholder<br/> Return</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Income<br/> (Loss)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: center">2024</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-8329">1,962,084</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-8330">1,678,609</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-8331">5,238,304</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-8332">3,782,931</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd" id="ixv-8333">45.70</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-8334">42,747,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-8335">722,187</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-8336">274,283</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-8337">879,232</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-8338">576,066</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd" id="ixv-8339">40.13</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-8340">59,427,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">Compensation
actually paid to our Chief Executive Officer represents the total compensation reported in the Summary Compensation Table for the applicable
fiscal year, as adjusted as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ecd:AdjToPeoCompFnTextBlock" id="ixv-5131"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Adjustments to Determine Compensation &#8220;Actually Paid&#8221; to our Chief Executive Officer</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Total Compensation in the Summary Compensation Table</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-8341">1,962,084</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-8342">722,187</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8343">1,344,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under &#8220;Option Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-8344">157,220</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-8345">903,305</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8346">351,996</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8347">95,908</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8348">283,475</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8349">447,904</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Compensation Actually Paid to the CEO</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-8350">1,678,609</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-8351">274,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="ixv-5239"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Adjustments to Determine Compensation &#8220;Actually Paid&#8221; to our Other Named Executive Officers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Total Compensation in the Summary Compensation Table</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-8352">5,238,304</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-8353">879,232</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8354">672,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under &#8220;Option Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8355">3,068,171</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-8356">596,365</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" unitRef="usd" id="ixv-8357">1,688,434</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8358">157,758</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8359">145,408</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8360">1,455,373</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-8361">303,166</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Compensation Actually Paid to our other Named Executive Officers</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-8362">3,782,931</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-8363">576,066</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Relationship Between
Financial Performance Measures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
relationships between the compensation actually paid to our CEO and the compensation actually paid to our other NEOs, with (i)&#160;our
cumulative total shareholder return (&#8220;<b>TSR</b>&#8221;), and (ii)&#160;our net income (loss), in each case, for the fiscal years
ended December&#160;31, 2024, and 2023 is described as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>From
2023 to 2024, the compensation actually paid to our Chief Executive Officer increased by approximately 512%, from $274,283 to $1,678,609.
From 2023 to 2024, the compensation actually paid to our other Named Executive Officers, including Richard Anderson, Zvi Ben-David, Steven
Nelson and Tomer Ben Kiki, increased by approximately 557%, from $</span>576,066 <span>to $3,782,931.
Over this same period, the Company&#8217;s TSR decreased by approximately 54.30% from $100 to $45.70. Our cumulative TSR for the two-years
period ended December&#160;31, 2024, was $18.37. Our net loss decreased by 28.1%, from approximately $(59,427,000</span>) <span>to
$(42,747,000), due largely to the increase in our gross profit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Non-Employee Director Remuneration Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March&#160;2013, our Board
adopted the following non-employee director remuneration policy:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Awards</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our non-employee directors
(currently Messrs.&#160;Shaked, Matheis, McGrath, Leisure, Stern and Ms.&#160;Karah) will receive the following cash payments for each
fiscal year: (i)&#160;$50,000 per year, to be paid quarterly in arrears and (ii)&#160;$20,000 for Board committee service, to be paid
quarterly in arrears. Commencing the second quarter of 2024 Messrs Shaked, Mathies, Stern and Ms.&#160;Karah have waived their cash compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock and Option Awards</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&#160;6, 2024, the
Compensation Committee of our Board approved the following issuances, each was done under our 2020 Equity Incentive Plan: (i)&#160;90,000
restricted shares of our common stock to Mr.&#160;Shaked; (ii)&#160;80,000 restricted shares of our common stock to Mr.&#160;McGrath;
and (iii)&#160;70,000 restricted shares of our common stock to each of Ms.&#160;Karah, Mr.&#160;Matheis, Mr.&#160;Stern and Mr.&#160;Leisure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;24, 2025,
our Compensation Committee of our Board approved to accelerate the vesting of 35,000 restricted shares of our common stock as well as
approved the grant of 30,000 restricted shares of Common Stock to Mr.&#160;Leisure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Leisure is also a
Member of NearWater Growth, LLC (&#8220;<b>NearWater</b>&#8221;), which has provided investment and business consulting services to the
Company since 2021 pursuant to a consulting agreement, as amended, by and between the Company and NearWater effective as of September&#160;3,
2021, or the Consulting Agreement. As remuneration for such services, we agreed to pay NearWater a monthly cash retainer upon the successful
completion of an equity financing resulting in gross proceeds in excess of $25 million and we further agreed to issue NearWater shares
of Common Stock as equity compensation if certain milestones are met such as NearWater introducing entities to us for acquisition or partnership
purposes, provided certain revenue milestones are met. Further, the Consulting Agreement provides for the payment to NearWater of 150,000
shares of Common Stock which shall vest quarterly over a four-year period. To date, NearWater has received approximately 258,000 shares
of Common Stock and common stock purchase warrants to purchase up to 125,000 shares of common stock. On February&#160;24, 2025, NearWater
and we entered into a Second Amendment to the Consulting Agreement pursuant to which we agreed to pay NearWater a monthly retainer of
$10,000. Mr.&#160;Leisure has in interest in, and will receive, the compensation due to NearWater.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation Committee Review</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
shall, if it deems necessary or prudent in its discretion, reevaluate and approve in January&#160;of each such year (or in any event prior
to the first Board meeting of such fiscal year) the cash and equity awards (amount and manner or method of payment) to be made to non-employee
directors for such fiscal year. In making this determination, the Compensation Committee shall utilize such market standard metrics as
it deems appropriate, including, without limitation, an analysis of cash compensation paid to independent directors of our peer group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
shall also have the power and discretion to determine in the future whether non-employee directors should receive annual or other grants
of options to purchase shares of common stock or other equity incentive awards in such amounts and pursuant to such policies as the Compensation
Committee may determine utilizing such market standard metrics as it deems appropriate, including, without limitation, an analysis of
equity awards granted to independent directors of our peer group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Participation of Employee Directors; New Directors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless separately and specifically
approved by the Compensation Committee in its discretion, no employee director of our company shall be entitled to receive any remuneration
for service as a director (other than expense reimbursement as per prevailing policy).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New directors joining our
Board shall be entitled to a pro-rated portion (based on months to be served in the fiscal year in which they join) of cash and stock
option or other equity incentive awards (if applicable) for the applicable fiscal year at the time they join the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Prior Awards to Management</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&#160;4, 2024,
our Compensation Committee approved &#160;amendments to certain previously issued awards of restricted shares of common stock in the aggregate
amount of 68,750 and 250,000 shares of common stock, respectively, granted to Mr.&#160;Erez Raphael, our Chief Executive Officer, and
Mr.&#160;Zvi Ben David, our Chief Financial Officer, in the aggregate amount of 23,750 and 125,000 shares of common stock, respectively,
on May&#160;18, 2022 and March&#160;6, 2024 (collectively, the &#8220;<b>Prior Awards</b>&#8221;) to permit an immediate acceleration
of the unvested portion of the Prior Awards in the event of change in control of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&#160;18, 2025, our
Compensation Committee approved the issuance of 500,000 restricted shares of the Company&#8217;s common stock, to Ms.&#160;Chen Franco-Yehuda,
pursuant to our Amended and Restated 2020 Equity Incentive Plan, as amended. The restricted shares vest over three years, with one third
of such shares vesting on April&#160;27, 2026, and the remaining shares vesting in equal quarterly amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Director Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the annual compensation paid to our non-employee directors for the fiscal year ended December&#160;31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fees&#160;Paid</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">or</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-equity</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">qualified</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Name and</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Earned&#160;in</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">incentive</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">deferred</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">All&#160;other</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Principal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Cash</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Awards</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">plan</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">compensation</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">compensation</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Position</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">($)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Awards</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">($)*</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">compensation</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">earnings</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">($)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#160;($)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 12%">Dennis McGrath</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center">2024</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">134,400</td><td style="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">(1)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">204,400</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Kaplan&#8239;&#8239;<sup>(13)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">117,600</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(4)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">130,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dennis Matheis</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">117,600</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(5)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(6)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Hila Karah</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">117,600</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(7)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(8)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Yoav Shaked</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">151,200</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(9)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(10)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">168,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Adam Stern</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">117,600</td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(11)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(12)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">130,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>








</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">*</td><td>Amount shown does not reflect dollar amount actually received. Instead, this amount reflects the aggregate grant date fair value of
each stock option granted in the fiscal year ended December&#160;31, 2024, computed in accordance with the provisions of ASC 718. Assumptions
used in accordance with ASC 718 are included in Note 9 to our consolidated financial statements included in the Annual Report.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">154,744 stock awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">No option awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">70,000 stock awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(4)</td><td style="text-align: justify">No option awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(5)</td><td style="text-align: justify">102,620 stock awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(6)</td><td style="text-align: justify">55,000 option awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(7)</td><td style="text-align: justify">218,751 stock awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(8)</td><td style="text-align: justify">No option awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(9)</td><td style="text-align: justify">253,896 stock awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(10)</td><td style="text-align: justify">No option awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(11)</td><td style="text-align: justify">178,341 stock awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(12)</td><td style="text-align: justify">No option awards are outstanding as of December&#160;31, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(13)</td><td style="text-align: justify">Mr.&#160;Kaplan resigned from the Board on February&#160;23, 2025.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF THE AUDIT COMMITTEE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the course of our oversight
of the Company&#8217;s financial reporting process, we have: (1)&#160;reviewed and discussed with management the audited financial statements
for the fiscal year ended December&#160;31, 2024; (2)&#160;discussed with the Auditors the matters required to be discussed pursuant to
the applicable requirements of the Public Company Accounting Oversight Board (the &#8220;<b>PCOAB</b>&#8221;) and the SEC; (3)&#160;received
the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the
standards of the PCOAB regarding the independent accountant&#8217;s communications with the Audit Committee concerning independence, and
has discussed with the independent accountant the independent accountant&#8217;s independence; (4)&#160;discussed with the independent
registered public accounting firm its independence; and (5)&#160;considered whether the provision of non-audit services by the independent
registered public accounting firm is compatible with maintaining its independence and concluded that it is compatible at this time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing review
and discussions, the Audit Committee recommended to the Board that the audited financial statements be included in the annual report on
Form&#160;10-K for the fiscal year ended December&#160;31, 2024, for filing with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By the Audit Committee of the</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DarioHealth Corp.</p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dennis M. McGrath, Chairman</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yoav Shaked</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dennis Matheis</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Beneficial
Ownership of Principal Stockholders, Officers and Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of our Common Stock as of May&#160;19, 2025, by each person known by us to be the beneficial
owner of more than 5% of our outstanding shares of Common Stock, each of our named executive officers and directors; and all of our executive
officers and directors as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>The
following table shows the amount of our </span>Common Stock <span>beneficially owned as of May&#160;19,
2025, by (i)&#160;each person or group as those terms are used in Section&#160;13(d)(3)&#160;of the Exchange Act, believed by us to beneficially
own more than 5% of our Common Stock, (ii)&#160;each of our named executive officers and directors, and (iii)&#160;all our executive officers
and directors as a group. Except as otherwise noted, each person named in the table has sole voting and investment power with respect
to all shares shown as beneficially owned by them, subject to applicable community property laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><b>Percent&#160;of</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><b>Shares&#160;of</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><b>Common</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><b>Common</b></td><td style="text-align: center; font-size: 10pt"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><b>Stock</b></td><td style="text-align: center; font-size: 10pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold"><b>Stock&#160;Beneficially</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><b>Beneficially</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold"><b>Name&#160;of&#160;Beneficial&#160;Owner</b></td><td style="text-align: center; font-size: 10pt; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>Owned</b></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt"><b>&#160;</b></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><b>Owned&#160;<sup>(1)</sup></b></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Officers and Directors</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 74%; font-size: 10pt; text-align: left">Erez Raphael <sup>(2)</sup></td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">1,886.509</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">4.2</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Zvi Ben David<sup>(3)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">725,648</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Chen Franco-Yehuda <sup>(4)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Steven Nelson <sup>(5)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">221,667</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Dennis McGrath <sup>(6)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">134,744</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Lawrence Leisure <sup>(7)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">300,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Hila Karah <sup>(8)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">210,540</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Yoav Shaked <sup>(9)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">260,657</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Adam Stern <sup>(10)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,051,898</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2.3</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dennis Mathies <sup>(11)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">209,409</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">All Executive Officers and Directors as a group (10 persons)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,001,072</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">11.2</td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">5% Stockholders</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Nantahala Capital Management LLC <sup>(12)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,697,520</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">9.9</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left">Tasso Partners, LLC<sup>(13)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,009,043</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6.78</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Dana Carrera<sup>(14)</sup></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,519,043</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7.85</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">*</td>
    <td style="text-align: justify">Less than 1% </td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(1)</td>
    <td style="text-align: justify">Percentage ownership is based on 44,449,424 shares of our Common Stock outstanding as of May&#160;19, 2025 and, for each person or entity listed above, warrants or options to purchase shares of our Common Stock which exercisable within 60 days of such date.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Includes 1,388,158 vested restricted shares.
Also includes 37,876 shares of our Common Stock, held by Dicilyon Consulting and Investment Ltd. Erez Raphael is the natural person with
voting and dispositive power over our securities held by Dicilyon Consulting and Investment Ltd. The address of Dicilyon Consulting and
Investment Ltd. is 10 Nataf St., Ramat Hasharon 4704063,&#160;Israel.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(3)</td>
    <td>Includes 27,827 vested options to purchase Common
    Stock and 556,228 vested restricted shares. Includes 1,786 shares owned by his spouse, for which Mr.&#160;Ben David disclaims beneficial
    ownership except to the extent of his pecuniary interest therein.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(4)</td>
    <td style="text-align: justify">Excludes 500,000 restricted shares which are not vested.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(5)</td>
    <td style="text-align: justify">Excludes 333,000 options which are not vested.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(6)</td>
    <td>Includes 134,744 vested restricted shares.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(7)</td>
    <td>Includes 175,500 vested restricted shares, and warrants to purchase 125,000 shares.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(8)</td>
    <td>Includes 161,397 vested restricted shares.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(9)</td>
    <td style="text-align: justify">Includes 155,359 vested restricted shares. Includes 1,667 shares owned by his spouse, for which Mr.&#160;Shaked disclaims beneficial ownership except to the extent of his pecuniary interest therein.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(10)</td>
    <td style="text-align: justify">Includes 151,350 vested restricted shares. Includes warrants exercisable into 507,648 shares of Common Stock, Series&#160;C Preferred Stock and Series&#160;D Preferred Stock convertible into 244,500 of common stock, subject to a contractual beneficial ownership limitation of 4.99%.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(11)</td>
    <td style="text-align: justify">Includes 55,000 vested options to purchase Common Stock and 70,120 vested restricted shares. </td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(12)</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Based solely on information contained in Form&#160;13GA filed with
the SEC on March&#160;6, 2025, and data provided by the holder. Includes 183,289 pre-funded warrants to purchase Common Stock issued in
May&#160;2019, shares of Preferred Stock A-1 issued on November&#160;27, 2019, convertible into 673,807, 120,088 pre-funded warrants
to purchase Common Stock issued in July&#160;2020, 331,814 pre-funded warrants to purchase Common Stock issued in February&#160;2022,
shares of Series&#160;B-1 Preferred Stock issued on May&#160;05, 2023 convertible into 1,483,503 shares of Common Stock and shares of
Series&#160;C-1 Preferred Stock issued on February&#160;21, 2024 convertible into 207,777 shares of Common Stock, subject to a contractual
beneficial ownership limitation of 9.99% and excludes shares of Preferred Stock C-1 convertible into 1,772,420 shares of Common Stock
and shares of Preferred Stock D-1 convertible into 9,589,043 shares of Common Stock.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(13)</td>
    <td style="text-align: justify">Based solely on information contained in Form&#160;13G/A filed with the SEC on May&#160;13, 2025, and data provided by the holder. Includes (i)&#160;1,762,907 shares of Common Stock, (ii)&#160;shares of Series&#160;C Preferred Stock convertible into 1,222,772 shares of Common Stock, and (iii)&#160;shares of Series&#160;C-2 Preferred Stock convertible into 23,364 shares of Common Stock, and excluding (i)&#160;shares of Series&#160;D-1 Preferred Stock convertible into 6,506,849 shares of Common Stock with no voting rights, and (ii)&#160;shares of Series&#160;D-3 Preferred Stock convertible into 2,228,918 shares of Common Stock.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">(14)</td>
    <td style="text-align: justify">Based solely on information contained in Form&#160;13G/A filed with the SEC on May&#160;13, 2025, and data provided by the holder. Includes (i)&#160;1,887,907 shares of Common Stock, (iii)&#160;shares of Series&#160;C Preferred Stock convertible into 1,222,772 shares of Common Stock, (iii)&#160;shares of Series&#160;C-2 Preferred Stock convertible into 23,364 shares of Common Stock, and (iv)&#160;warrants to purchase 385,000 shares of Common Stock owned by the GCL Family Trust (the &#8220;Trust&#8221;), and excluding (i)&#160;shares of Series&#160;D-1 Preferred Stock convertible into 6,506,849 shares of Common Stock with no voting rights, and (ii)&#160;shares of Series&#160; D-3 Preferred Stock convertible into 2,228,918 shares of Common Stock, which are beneficially owned by Dana Carrera, the trustee of the Trust, and included pursuant to Rule&#160;13d-3(d)(1)(i)&#160;of the Securities Exchange Act of 1934, as amended.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stockholder Communications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders wishing to communicate
with the Board may direct such communications to the Board c/o the Company, Attn: Chen Franco-Yehuda. Ms.&#160;Franco-Yehuda will present
a summary of all stockholder communications to the Board at subsequent Board meetings. The directors will have the opportunity to review
the actual communications at their discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional Information</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are subject
to certain informational requirements of the Exchange Act and in accordance therewith files reports, proxy statements and other information
with the SEC. Such reports, proxy statements and other information are available on the SEC&#8217;s website at www.sec.gov. Stockholders
who have questions in regard to any aspect of the matters discussed in this Proxy Statement should contact Chen Franco-Yehuda, Chief Financial
Officer of the Company, at 322 W. 57th St. New York, New York 10019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STOCKHOLDER PROPOSALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposals of stockholders
intended to be included in the Company&#8217;s proxy statement and form of proxy for use in connection with the Company&#8217;s 2026 Annual
Meeting of Stockholders must be received by the Company&#8217;s Secretary at the Company&#8217;s principal executive offices at 322 W.
57th St. New York, New York 10019 and/or via electronic mail to ir@dariohealth.com, not less than 90 days nor more than 120 days prior
to the annual meeting of stockholders and must otherwise satisfy the procedures contained in the Company&#8217;s Bylaws or as prescribed
by Rule&#160;14a-8 under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholder proposals with
respect to director nominees for use in connection with the Company&#8217;s 2026 Annual Meeting of Stockholders must be received by the
Company&#8217;s Secretary at the Company&#8217;s principal executive offices at not less than 60 days before the date of the annual meeting
of stockholders. A stockholder wishing to formally nominate an individual for election to the Board must do so by following the notice,
information and consent provisions described in the Company&#8217;s Bylaws. In that regard, the stockholder must set forth the (a)&#160;the
name, age, business address and the primary legal residence address of each nominee proposed in such notice, (b)&#160;the principal occupation
or employment of such nominee, (c)&#160;the number of shares of capital stock of the Company which are owned directly or indirectly of
record and directly or indirectly beneficially owned by the nominee and each of its affiliates (within the meaning of Rule&#160;144 under
the Securities Act of 1933, as amended), including any shares of the Company owned or controlled via derivatives, hedged positions and
other economic and voting mechanisms, (d)&#160;any material agreements, understandings or relationships, including financial transactions
and compensation, between the nominating stockholder and the proposed nominees and (e)&#160;such other information concerning each such
nominee as would be required, under the rules&#160;of the SEC, in a proxy statement soliciting proxies in a contested election of such
nominees. The Board will use the same evaluation criteria and process for director nominees recommended by stockholders as it uses for
other director nominees. There has been no change to the procedures by which stockholders may recommend nominees to our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is suggested that any such
proposals be submitted by certified mail, return receipt requested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not receive notice
of a stockholder proposal within this timeframe, our management will use its discretionary authority to vote the shares they represent,
as the Board may recommend. We reserve the right to reject, rule&#160;out of order, or take other appropriate action with respect to any
proposal that does not comply with these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>HOUSEHOLDING OF MEETING MATERIALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some banks, brokers and other
nominee record holders may be participating in the practice of &#8220;householding&#8221; proxy statements and annual reports. This means
that only one copy of our proxy statement or annual report may have been sent to multiple stockholders in your household. We will promptly
deliver a separate copy of either document to you if you call or write us at the address shown on the first page&#160;of this proxy statement.
If you want to receive separate copies of the annual report and any proxy statement in the future or if you are receiving multiple copies
and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holders, or
you may contact us at the address shown on the first page&#160;of this proxy statement or by phone at (646) 665-4667.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OTHER MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement, our management knows of no matter not specifically described above as to any action which is expected to be taken at the Meeting.
The persons named in the enclosed proxy, or their substitutes, will vote the proxies, insofar as the same are not limited to the contrary,
in their best judgment, with regard to such other matters and the transaction of such other business as may properly be brought at the
Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>IF YOU HAVE NOT VOTED BY
INTERNET, PLEASE DATE, SIGN AND RETURN THE PROXY CARD AT YOUR EARLIEST CONVENIENCE IN THE ENCLOSED RETURN ENVELOPE. A PROMPT RETURN OF
YOUR PROXY CARD WILL BE APPRECIATED AS IT WILL SAVE THE EXPENSE OF FURTHER MAILINGS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%"><b>By order of the Board</b>,</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">/s/ Erez Raphael </td></tr>
  <tr>
    <td>&#160;</td>
    <td>Erez Raphael </td></tr>
  <tr>
    <td>&#160;</td>
    <td>Chief Executive Officer</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#160; , 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Annex A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">2020 Equity Incentive Plan</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DarioHealth Corp.<br/>
2020 Equity Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amended and Restated on ____________, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Purposes.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Eligible
Recipients.</b></span>&#160;The persons eligible to receive awards hereunder are the Employees, Directors and Consultants of the Company
and its Affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Available
Awards.</b></span>&#160;The purpose of the Plan is to provide a means by which eligible recipients of Awards may be given an opportunity
to benefit from increases in value of the Common Stock through the granting of: (i)&#160;Incentive Stock Options; (ii)&#160;Non statutory
Stock Options; (iii)&#160;Stock Grants (with restrictions, Restricted Stock); and (iv)&#160;Restricted Stock Units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;General
Purpose.</b></span>&#160;The Company, by means of the Plan, seeks to retain the services of the group of persons eligible to receive Awards,
to secure and retain the services of new members of this group and to provide incentives for such persons to exert maximum efforts for
the success of the Company and its Affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Definitions.&#160;</b></span>The following capitalized terms have the following meanings. Other capitalized terms are defined elsewhere
herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;<i>&#8220;Affiliate&#8221;</i></b></span>&#160;means
(i)&#160;any person or entity that directly or indirectly controls, is controlled by or is under common control with the Company and/or
(ii)&#160;to the extent provided by the Committee, any person or entity in which the Company has a significant interest as determined
by the Committee in its discretion. The term &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221;
and &#8220;under common control with&#8221;), as applied to any person or entity, means the possession, directly or indirectly, of the
power to direct or cause the direction of the management and policies of such person or entity, whether through the ownership of voting
or other securities, by contract or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;<i>&#8220;Award&#8221;</i></b></span><i>&#160;</i>means
an award of any Option, Stock Grant, Restricted Stock, or RSU granted under the Plan or any Sub Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;<i>&#8220;Award
Agreement&#8221;</i></b></span>&#160;means an Option Agreement, Restricted Stock Award Agreement, or RSU Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#160;<i>&#8220;Board&#8221;</i></b></span>&#160;means
the Board of Directors of the Company. If a Committee has been appointed to administer this Plan, references herein to the term &#8220;Board&#8221;
shall apply to such Committee to the extent such Committee has been delegated authority over the applicable subject matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)&#160;</b></span><i>&#8220;<b>Business
Day</b>&#8221;</i>&#160;means any day other than a Saturday, a Sunday, or a day on which banking institutions in New York City, New York
are authorized or obligated by federal law or executive order to be closed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)&#160;<i>&#8220;Cause&#8221;</i></b></span>&#160;means,
in the case of a particular Award, unless the applicable Award Agreement states otherwise (i)&#160;if the Participant is a party to an
employment or service agreement with the Company or its Affiliates and such agreement provides for a definition of &#8220;cause,&#8221;
the definition contained therein or (ii)&#160;if no such agreement exists, or if such agreement does not define &#8220;cause:&#8221; (A)&#160;conviction
of, or plea of guilty or no contest to, any felony or any crime involving moral turpitude or dishonesty or the commission of any other
act involving willful malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (B)&#160;participation in
a fraud, misappropriation, or embezzlement of Company and/or its Affiliate funds or property or act of dishonesty against the Company
and/or its Affiliate; (C)&#160;material violation of any rule, regulation, policy, or plan for the conduct of (as the case may be) any
director, officer, employee, member, manager, consultant, or service provider of or to the Company or its Affiliates or its or their business
(which, if curable, is not cured within five (5)&#160;Business Days after notice thereof is provided to the Participant); (D)&#160;conduct
that results in or is reasonably likely to result in harm to the reputation or business of the Company or any of its Affiliates; (E)&#160;gross
negligence or willful misconduct with respect to the Company or an Affiliate; (F)&#160;material violation of U.S. state, federal, or other
applicable (including non-U.S.) securities laws; or (G)&#160;material breach of Participant&#8217;s Proprietary Information and Inventions
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)&#160;<i>&#8220;Change
in Control</i></b></span>&#8221; shall, in the case of a particular Award, unless the applicable Award Agreement states otherwise or contains
a different definition of &#8220;Change in Control,&#8221; be deemed to occur upon:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)&#160;</b></span>An
acquisition (whether directly from the Company or otherwise) of any voting securities of the Company (the &#8220;<b><i>Voting Securities</i></b>&#8221;)
by any &#8220;Person&#8221; (as the term person is used for purposes of Section&#160;13(d)&#160;or 14(d)&#160;of the Exchange Act), immediately
after which such Person has &#8220;Beneficial Ownership&#8221; (within the meaning of Rule&#160;13d-3 promulgated under the Exchange Act)
of more than fifty percent (50%)&#160;of the combined voting power of the Company&#8217;s then outstanding Voting Securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ii)&#160;</b></span>The
individuals who constitute the members of the full Board of Directors of the Company cease, by reason of a financing, merger, combination,
acquisition, takeover, or other non-ordinary course transaction affecting the Company, to constitute at least fifty-one percent (51%)&#160;of
the members of the full Board of Directors of the Company; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(iii)&#160;</b></span>Approval
by the full Board of Directors of the Company and, if required, stockholders of the Company of, or execution by the Company of any definitive
agreement with respect to, or the consummation of (it being understood that the mere execution of a term sheet, memorandum of understanding,
or other non-binding document shall not constitute a Change of Control):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(A)&#160;</b></span>A
merger, consolidation, or reorganization involving the Company, where either or both of the events described in clauses (i)&#160;or (ii)&#160;above
would be the result;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(B)&#160;</b></span>A
liquidation or dissolution of or appointment of a receiver, rehabilitator, conservator, or similar person for, or the filing by a third
party of an involuntary bankruptcy against, the Company; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(C)&#160;</b></span>An
agreement for the sale or other disposition of all or substantially all of the assets of the Company to any Person (other than a transfer
to a subsidiary of the Company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)&#160;<i>&#8220;Code&#8221;</i></b></span>&#160;means
the Internal Revenue Code of 1986, as amended, and any successor thereto. Any reference to a section of the Code shall be deemed to include
any regulations promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)&#160;<i>&#8220;Committee&#8221;</i></b></span>&#160;means
a committee of members of the Board appointed by the Board in accordance with the provisions of Section&#160;3(c)&#160;to administer this
Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)&#160;<i>&#8220;Common
Stock&#8221;</i></b></span>&#160;means the common stock, par value $0.0001 of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(k)&#160;<i>&#8220;Company&#8221;</i></b></span>&#160;means
DarioHealth Corp., a Delaware corporation, and any successor thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(l)&#160;<i>&#8220;Consultant&#8221;</i></b></span>&#160;means
any person, including an advisor engaged by the Company or an Affiliate to render consulting or advisory services and who is compensated
for such services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(m)&#160;<i>&#8220;Continuous
Service&#8221;</i></b></span>&#160;means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee,
Director, or Consultant, is not interrupted or terminated. The Participant&#8217;s Continuous Service shall not be deemed to have terminated
merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant,
or Director or a change in the entity for which the Participant renders such service; <i>provided, that,</i>&#160;there is no interruption
or termination of the Participant&#8217;s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant
of an Affiliate or a Director will not constitute an interruption of Continuous Service. The Committee or its delegate, in its sole discretion,
may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including
sick leave, military leave, relocation, or any other personal or family leave of absence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(n)&#160;<i>&#8220;Director&#8221;</i></b></span>&#160;means
a member of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(o)&#160;<i>&#8220;Disability&#8221;</i></b></span>&#160;means
that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental
impairment;&#160;<i>provided, however,</i>&#160;for purposes of determining the term of an Incentive Stock Option, the term Disability
shall have the meaning ascribed to it in Section&#160;22(e)(3)&#160;of the Code. The determination of whether an individual has a Disability
shall be determined under procedures established by the Committee. Except in situations where the Committee is determining Disability
for purposes of the term of an Incentive Stock Option within the meaning of Section&#160;22(e)(3)&#160;of the Code, the Committee may
rely on any determination that a Participant is disabled for purposes of benefits under any long-term disability plan maintained by the
Company or any Affiliate in which a Participant participates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(p)&#160;<i>&#8220;Employee&#8221;</i></b></span>&#160;means
any person, including an Officer or Director, employed by the Company or an Affiliate;&#160;<i>provided, that,&#160;</i>for purposes of
determining eligibility to receive Incentive Stock Options, an Employee shall mean an employee of the Company or a parent or subsidiary
corporation within the meaning of Section&#160;424 of the Code (an &#8220;<b><i>ISO Entity</i></b>&#8221;<b>)</b>. Mere service as a Director
or payment of a director&#8217;s fee by the Company or an Affiliate shall not be sufficient to constitute &#8220;employment&#8221; by
the Company or an Affiliate for Incentive Stock Option purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(q)&#160;<i>&#8220;Exchange
Act&#8221;</i></b></span>&#160;means the Securities Exchange Act of 1934, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(r)&#160;&#8220;<i>Fair
Market Value&#8221;</i></b></span>&#160;means, as of any date, the value of the Common Stock determined as follows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Common Stock is listed on any established stock exchange or a national market system, including without limitation, the New York Stock
Exchange or the Nasdaq Stock Market, or quoted on a national exchange or other recognized securities quotation system (such as the OTC
Bulletin Board/OTCQB Market), the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock as quoted
on such exchange, market, or quotation system (or the exchange or market with the greatest volume of trading in the Common Stock) on the
last market trading day prior to the day of determination (or the closing price on the date immediately preceding such date if no sales
activity occurred on the day of determination), as reported by Bloomberg or such other source as the Board deems reliable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the absence of such markets for the Common Stock, the Fair Market Value shall be determined in good faith by the Board and such determination
shall be conclusive and binding on all persons;&#160;<i>provided, that</i>, (A)&#160;with respect to Options that are Incentive Stock
Options, the Board shall make such determination in accordance with the provisions of Section&#160;422 of the Code and subject to all
applicable regulations and any other applicable guidance promulgated pursuant thereto; (B)&#160;with respect to Options that are not Incentive
Stock Options, the determination shall be in accordance with and applicable to regulations under Section&#160;409A of the Code and any
other applicable guidance promulgated pursuant thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(s)&#160;<i>&#8220;Incentive
Stock Option&#8221;</i></b></span>&#160;means an Option intended to qualify as an incentive stock option within the meaning of Section&#160;422
of the Code and the regulations promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(t)&#160;<i>&#8220;Non-Employee
Director&#8221;&#160;</i></b></span>means a Director who either: (i)&#160;is not a current Employee or Officer of the Company or its Parent
or a Subsidiary, does not receive compensation (directly or indirectly) from the Company or its Parent or a Subsidiary for services rendered
as a Consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item
404(a)&#160;of Regulation S-K promulgated pursuant to the Securities Act (&#8220;<b><i>Regulation S-K</i></b>&#8221;)), does not possess
an interest in any other transaction as to which disclosure would be required under Item 404(a)&#160;of Regulation S-K and is not engaged
in a business relationship as to which disclosure would be required under Item&#160;404(b)&#160;of Regulation S-K; or (ii)&#160;is otherwise
considered a &#8220;non-employee director&#8221; for purposes of Rule&#160;16b-3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(u)&#160;<i>&#8220;Non
statutory Stock Option&#8221;</i></b></span>&#160;means an Option not intended to qualify as an Incentive Stock Option and does not meet
the requirements of, and is not governed by, the rules&#160;of Sections 421 through 424 of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(v)&#160;<i>&#8220;Officer&#8221;</i></b></span>&#160;means
a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act and the rules&#160;and regulations
promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(w)&#160;<i>&#8220;Option&#8221;</i></b></span>&#160;means
an Incentive Stock Option, a Non statutory Stock Option, or any other option granted pursuant to the Plan or any Sub Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(x)&#160;<i>&#8220;Option
Award&#8221;</i></b></span>&#160;means an award of any Option granted under the Plan or any Sub Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(y)&#160;<i>&#8220;Option
Agreement&#8221;</i></b></span>&#160;means an agreement between the Company and an Option holder evidencing the terms and conditions of
an individual Option Award. Each Option Agreement shall be subject to the terms and conditions of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(z)&#160;<i>&#8220;Option
holder&#8221;</i></b></span>&#160;means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person
who holds an outstanding Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(aa)
<i>&#8220;Parent</i></b></span>&#8221; means any corporation (other than the Company) in an unbroken chain of corporations or other entities
ending with the Company, if each of the corporations or other entities (other than the Company) owns stock possessing fifty percent (50%)
or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation or other
entity that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(bb)
<i>&#8220;Participant&#8221;</i></b></span>&#160;means a person to whom an Award is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(cc)
<i>&#8220;Plan&#8221;</i></b></span>&#160;means this 2020 Equity Incentive Plan, as amended and in effect from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(dd)
</b></span>&#8220;<b><i>Restricted Stock</i></b>&#8221; means an Award of shares of Common Stock subject to restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ee)
</b></span>&#8220;<b><i>Restricted</i></b>&#160;<b><i>Stock Award Agreement</i></b>&#8221; means a written agreement between the Company
and a Participant evidencing the terms and conditions of an individual Award of Restricted Stock. Each Restricted Stock Award Agreement
shall be subject to the terms and conditions of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ff)
<i>&#8220;Restricted Stock Units&#8221;</i></b></span> or <b><i>&#8220;RSUs&#8221;</i></b> means an Award that may be earned in whole
or in part upon the passage of time or the attainment of performance criteria established by the Committee and that may be settled for
cash, shares of Common Stock, or other securities or a combination of cash, shares of Common Stock, or other securities as established
by the Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(gg)
</b></span>&#8220;<b><i>RSU Agreement</i></b>&#8221; means a written agreement between the Company and a Participant evidencing the terms
and conditions of an Award of Restricted Stock Units. Each RSU Agreement shall be subject to the terms and conditions of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(hh)
<i>&#8220;Rule&#160;16b-3&#8221;</i></b></span>&#160;means Rule&#160;16b-3 promulgated under the Exchange Act or any successor to Rule&#160;16b-3,
as in effect from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ii)&#160;<i>&#8220;Securities
Act&#8221;</i></b></span>&#160;means the Securities Act of 1933, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(jj)
<i>&#8220;Stock Grant&#8221;</i></b></span> means an Award of shares of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(kk)
<i>&#8220;Subsidiary&#8221;</i></b></span>&#160;means any corporation (other than the Company) in an unbroken chain of corporations or
other entities beginning with the Company, if each of the corporations or other entities other than the last corporation or entity in
the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one
of the other corporations or entities in such chain. A corporation or other entity that attains the status of a Subsidiary on a date after
the adoption of the Plan shall be considered a Subsidiary commencing as of such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ll)
 &#8220;<i>Sub Plan</i>&#8221;&#160;</b></span>means any sub plan subject to the terms of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(mm)
<i>&#8220;Ten Percent Stockholder&#8221;</i></b></span>&#160;means a person who owns (or is deemed to own pursuant to Section&#160;424(d)&#160;of
the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of an ISO Entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. Administration.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Administration
by the Committee.</b></span>&#160;The Committee shall administer the Plan unless the Board provides otherwise. Any interpretation of the
Plan by the Committee and any decision by the Committee under the Plan shall be final and binding on all persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Powers
of the Committee.</b></span>&#160;The Committee shall have the power, subject to and within the limitations of, the express provisions
of the Plan:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
determine from time to time which of the persons eligible under the Plan shall be granted Awards; when and how each Award shall be granted;
what type or combination of types of Award shall be granted; the provisions and terms of each Award granted (which need not be identical),
including the time or times when a person shall be permitted to receive Common Stock pursuant to an Award; the number of shares of Common
Stock with respect to which an Award shall be granted to each such person; and to prescribe the terms and conditions of each Award, including,
without limitation, the exercise price and medium of payment (including Options exercisable via &#8220;cashless exercise&#8221;) and vesting
provisions, as appropriate, and to specify the provisions of the Award relating to such grant;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
construe and interpret (A)&#160;the Plan and apply its provisions and (B)&#160;Awards granted under it, and to establish, amend and revoke
rules&#160;and regulations for its administration. The Committee, in the exercise of this power, may correct any defect, omission, or
inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Plan
fully effective;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
promulgate, amend and rescind rules&#160;and regulations relating to the administration of the Plan or an Award;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
determine whether each Option is to be an Incentive Stock Option or a Non statutory Stock Option;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
amend any outstanding Award, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award;&#160;<i>provided,
however</i>, that if any such amendment impairs a Participant&#8217;s rights or increases a Participant&#8217;s obligations under his
or her Award or creates or increases a Participant&#8217;s federal income tax liability with respect to an Award, such amendment shall
also be subject to the Participant&#8217;s consent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
determine the duration and purpose of leaves of absences that may be granted to a Participant without constituting termination of their
employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company&#8217;s
employment policies;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers
anti-dilution adjustments;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
exercise discretion to make any and all other determinations that it determines to be necessary or advisable for the administration of
the Plan; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;generally,
to exercise such powers and to perform such acts as the Committee deems necessary or expedient to promote the best interests of the Company
that are not in conflict with the provisions of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c)&#160;Delegation to Committee.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b>General.</b>&#160;The
Plan shall be administered by a committee or committees of one (1)&#160;or more members of the Board (subject to the provisions of Section&#160;3(c)(ii)&#160;below),
and the term &#8220;<b><i>Committee</i></b>&#8221; shall apply to any person or persons to whom such authority has been delegated. The
Committee shall have, in connection with the administration of the Plan, the power to delegate to a subcommittee any of the administrative
powers the Committee is authorized to exercise, subject, however, to such resolutions, not inconsistent with the provisions of the Plan,
as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration
of the Plan. From time to time, the Board may increase or decrease the size of the Committee, add additional members to, remove members
(with or without cause) from, appoint new members in substitution therefor and fill vacancies, however caused, in the Committee. The Committee
shall act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only two (2)&#160;members, the
unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes shall be
kept of all of its meetings and copies thereof shall be provided to the Board. Subject to the limitations prescribed by the Plan and the
Board, the Committee may establish and follow such rules&#160;and regulations for the conduct of its business as it may determine to be
advisable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<b>Committee
Composition when Common Stock is Publicly Traded.</b>&#160;At such time as the Common Stock is publicly traded, unless otherwise determined
by the Board not to comply with the exemption requirements of Rule&#160;16b-3 or the rules&#160;of the applicable trading market on which
the Common Stock is then traded, a Committee shall consist solely of two (2)&#160;or more Non-Employee Directors, in accordance with Rule&#160;16b-3.
Within the scope of such authority, the Board or the Committee may delegate to a committee of one (1)&#160;or more members of the Board
who are not Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section&#160;16 of the
Exchange Act. Nothing herein shall create an inference that an Award is not validly granted under the Plan in the event Awards are granted
under the Plan by a compensation committee of the Board that does not at all times consist solely of two (2)&#160;or more Non-Employee
Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4.&#160;Shares Subject to the Plan.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Share
Reserve.</b></span>&#160;The Committee is authorized to grant Awards to acquire an aggregate number of shares of Common Stock, with the
current amount of such shares equal to an aggregate of 17,897,652 shares of Common Stock and an increase to such amount for each of the
calendar years ending on December&#160;31, 2026, December&#160;31, 2027, December&#160;31, 2028, December&#160;31, 2029 and December&#160;31,
2030 by an additional number of shares of Common Stock equal to six percent (6%) of the number of shares of Common Stock issued and outstanding
on a Fully Diluted Basis on the immediately preceding December&#160;31. For purposes of this Section&#160;4(a), the term <b><i>&#8220;Fully
Diluted Basis&#8221;</i></b> means all issued and outstanding share capital (where options shall be deemed outstanding share capital until
exercised) and all rights to acquire share capital including, without limitation, all securities convertible or exercisable into shares
of Common Stock being deemed so converted and exercised, the conversion of any convertible stockholder loans into share capital, with
all outstanding warrants, options, or any other right granted by the Company to receive shares of the Company&#8217;s share capital being
deemed exercised in full.&#160;Notwithstanding the foregoing, the maximum number of shares that may be subject to Incentive Stock Options
granted under the Plan shall be 3,000,000, subject to adjustment as provided in Section&#160;11.&#160;Shares of Common Stock with respect
to which Awards may be granted hereunder are subject to adjustment as set forth in Section&#160;11 herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Reversion
of Shares to the Share Reserve.</b></span>&#160;If any Award shall for any reason expire or otherwise terminate, in whole or in part,
without having been exercised in full, the shares of Common Stock not acquired under such Award shall revert to the Plan and again become
available for issuance under the Plan;&#160;<i>provided, however</i>, that in the case of Incentive Stock Options, the foregoing shall
be subject to any limitations under the Code. Notwithstanding anything to the contrary contained herein, shares subject to an Award under
the Plan shall not again be made available for issuance or delivery under the Plan if such shares are (i)&#160;shares tendered in payment
of an Option or (ii)&#160;shares delivered or withheld by the Company to satisfy any tax withholding obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any shares of Common Stock subject to an Award
that is canceled, forfeited (including as the result of shares of Common Stock subject to the Award being repurchased by the Company at
the original issuance price pursuant to a contractual repurchase right), or expires prior to exercise or realization, either in full or
in part, shall again become available for issuance under the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;Source
of Shares.</b></span>&#160;The shares of Common Stock subject to the Plan may be, in whole or in part, authorized and unissued shares,
treasury shares, or shares reacquired by the Company in any manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#160;Adjustment
Provision.</b></span>&#160;Each reference to a number of shares of Common Stock in this Section&#160;4 shall be subject to adjustment
in accordance with the provisions of Section&#160;11.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. Eligibility.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Eligibility
for Specific Awards.</b></span>&#160;Incentive Stock Options may be granted only to Employees. Awards other than Incentive Stock Options
may be granted to Employees, Directors and Consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Ten
Percent Stockholders.&#160;</b></span>A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price
of such Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock at the date of grant and the Option
is not exercisable after the expiration of five (5)&#160;years from the date of grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c)&#160;Consultants.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
Consultant shall not be eligible for the grant of an Award if, at the time of grant, a Form&#160;S-8 Registration Statement under the
Securities Act (&#8220;<b><i>Form&#160;S-8</i></b>&#8221;) is not available to register either the offer or the sale of the Company&#8217;s
securities to such Consultant because of the nature of the services that the Consultant is providing to the Company, or because the Consultant
is not a natural person, or as otherwise provided by the rules&#160;governing the use of Form&#160;S-8, unless the Company determines
both (A)&#160;that such grant (I)&#160;shall be registered in another manner under the Securities Act (<i>e.g.,</i>&#160;on a Form&#160;S-3
Registration Statement) or (II)&#160;does not require registration under the Securities Act in order to comply with the requirements of
the Securities Act, if applicable, and (B)&#160;that such grant complies with the securities laws of all other relevant jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of April&#160;7, 1999, Rule&#160;701 and Form&#160;S-8 generally are available to Consultants and advisors only if: (A)&#160;they are
natural persons; (B)&#160;they provide bona fide services to the issuer, its Parents, its majority-owned Subsidiaries, or majority-owned
Subsidiaries of the issuer&#8217;s Parent; and (C)&#160;the services are not in connection with the offer or sale of securities in a capital-raising
transaction, and do not directly or indirectly promote or maintain a market for the issuer&#8217;s securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span>&#160;<b>Option
Provisions.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Option shall be in such form and shall contain
such terms and conditions as the Committee shall deem appropriate and set forth in the Option Agreement approved by the Committee. All
Options shall be separately designated as Incentive Stock Options or Non statutory Stock Options of U.S. Participants or 3(i)&#160;Options
and Options granted under Section&#160;102 of the Ordinance (as defined under the applicable Sub Plan) for Israeli Participants at the
time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased
on exercise of each type of Option. No Option shall be treated as an Incentive Stock Option unless this Plan has been approved by the
stockholders of the Company in a manner intended to comply with the stockholder approval requirements of Section&#160;422(b)(1)&#160;of
the Code;&#160;<i>provided, that,</i>&#160;any Option intended to be an Incentive Stock Option shall not fail to be effective solely on
account of a failure to obtain such approval, but rather such Option shall be treated as a Non statutory Stock Option. The provisions
of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the
Option or otherwise) the substance of each of the following provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Procedure
for Exercise.</b></span>&#160;An Option shall be deemed exercised when the Company receives (i)&#160;written or electronic notice of exercise
in accordance with the Option Agreement from the person entitled to exercise the Option and (ii)&#160;full payment for the shares with
respect to which the Option is exercised, together with any applicable withholding taxes. Full payment may consist of any consideration
and method of payment authorized by the Committee and permitted by the Option Agreement and the Plan. The exercise price shall be denominated
in the currency of the primary economic environment of, either the Company or the Participant (that is the functional currency of the
Company or the currency in which the Participant is paid), as determined by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Term.</b></span>&#160;Subject
to the provisions of Section&#160;5(b)&#160;regarding Ten Percent Stockholders, no Option shall be exercisable after the expiration of
ten (10)&#160;years from the date it was granted, or the date set forth at the Option Agreement, as earlier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;Exercise
Price of an Incentive Stock Option.</b></span>&#160;Subject to the provisions of Section&#160;5(b)&#160;regarding Ten Percent Stockholders,
the exercise price of each Incentive Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common
Stock subject to the Option on the date the Option is granted or such other amount as may be required pursuant to the Code. Notwithstanding
the foregoing, an Incentive Stock Option may have an exercise price lower than that set forth in the preceding sentence if such Option
is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section&#160;424(a)&#160;of
the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#160;Exercise
Price of a Non statutory Stock Option.</b></span>&#160;The exercise price of each Non statutory Stock Option granted shall be not less
than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted.
Notwithstanding the foregoing, a Non statutory Stock Option may have an exercise price lower than that set forth in the preceding sentence
if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section&#160;409A
of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)&#160;Consideration.</b></span>&#160;The
exercise price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
cash and/or check payable to the order of the Company at the time the Option is exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the discretion of the Committee at the time of the grant of the Option (or subsequently in the case of a Non statutory Stock Option),
(A)&#160;by delivery to the Company of other Common Stock;&#160;<i>provided, that,&#160;</i>(I)&#160;the method of payment is then permitted
under applicable law, (II)&#160;the Common Stock, if acquired directly from the Company, was owned by the Participant for a minimum period
of time, if any, as may be established by the Committee in its sole discretion and (III)&#160;the Common Stock is not subject to any repurchase,
forfeiture, unfulfilled vesting, or other similar requirements, or (B)&#160;in any other form of legal consideration that may be acceptable
to the Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
payment in cash or by check, payable to the order of the Company, of the par value of the Common Stock to be acquired and by payment of
the balance of the exercise price in whole or in part by delivery of the Participant&#8217;s recourse promissory note, in a form specified
by the Committee and to the extent consistent with applicable law, secured by the Common Stock acquired upon exercise of the Option and
such other security as the Committee may require.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as may otherwise be provided in the applicable Option agreement or as approved by the Committee, in its sole discretion, by (A)&#160;delivery
of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the
exercise price and any required tax withholding or (B)&#160;delivery by the Participant to the Company of a copy of irrevocable and unconditional
instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any
required tax withholding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the case of a Non statutory Stock Option, by delivery of a notice of &#8220;net exercise&#8221; to the Company, as a result of which the
Participant would receive (A)&#160;the number of shares underlying the portion of the Option being exercised less (B)&#160;such number
of shares as is equal to (I)&#160;the aggregate exercise price for the portion of the Option being exercised divided by (II)&#160;the
value of the Common Stock on the date of exercise and, at the election of the Participant, less (C)&#160;such number of shares as is equal
to the withholding obligation (if any).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
any combination of the above permitted forms of payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)&#160;Transferability
of an Incentive Stock Option.</b></span>&#160;An Incentive Stock Option shall not be transferable except by will or by the laws of descent
and distribution and shall be exercisable during the lifetime of the Option holder only by the Option holder. Notwithstanding the foregoing,
the Option holder may, by delivering notice to the Company, in a form satisfactory to the Company, designate a third party who, in the
event of the death of the Option holder, shall thereafter be entitled to exercise the Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)&#160;Transferability
of a Non statutory Stock Option.</b></span>&#160;A Non statutory Stock Option shall be transferable to the extent provided in the Option
Agreement. If the Non statutory Stock Option does not provide for transferability, then the Non statutory Stock Option shall not be transferable
except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Option holder only by the
Option holder. Notwithstanding the foregoing, the Option holder may, by delivering notice to the Company, in a form satisfactory to the
Company, designate a third party who, in the event of the death of the Option holder, shall thereafter be entitled to exercise the Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)&#160;Vesting
Generally.</b></span>&#160;An Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need
not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be
based on performance or other criteria) as the Committee may deem appropriate. The vesting provisions of individual Options may vary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)&#160;Termination
of Continuous Service.</b></span>&#160;In the event an Option holder&#8217;s Continuous Service terminates (other than upon the Option
holder&#8217;s death or Disability or as a result of termination for Cause), and unless otherwise specified in the applicable Option Agreement,
the Option holder may exercise his or her Option (to the extent that the Option holder was entitled to exercise such Option as of the
date of termination) but only within such period of time ending on the earlier of (i)&#160;the date three (3)&#160;months following the
termination of the Option holder&#8217;s Continuous Service (or such shorter period specified in the Option Agreement or such different
period as the Committee may prescribe) or (ii)&#160;the expiration of the term of the Option as set forth in the Option Agreement. If,
after termination, the Option holder does not exercise his or her Option within the time specified in the Option Agreement, the Option
shall terminate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)&#160;Extension
of Termination Date.</b></span>&#160;An Option holder&#8217;s Option Agreement may also provide that if the exercise of the Option following
the termination of the Option holder&#8217;s Continuous Service (other than upon the Option holder&#8217;s death or Disability or as a
result of termination for Cause) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the
registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i)&#160;the expiration of the term
of the Option set forth in Section&#160;6(b)&#160;or (ii)&#160;the expiration of a period of three (3)&#160;months after the termination
of the Option holder&#8217;s Continuous Service during which the exercise of the Option would not be in violation of such registration
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(k)&#160;Disability
of Option holder</b></span>. Unless otherwise provided in its Option Agreement, in the event that an Option holder&#8217;s Continuous
Service terminates as a result of the Option holder&#8217;s Disability, the Option holder may exercise his or her Option (to the extent
that the Option holder was entitled to exercise such Option as of the date of termination), but only within such period of time ending
on the earlier of (i)&#160;the date twelve (12) months following such termination (or such shorter period specified in the Option Agreement
or such longer period as specified in the Option Agreement and approved by the Board) or (ii)&#160;the expiration of the term of the Option
as set forth in the Option Agreement. If, after termination, the Option holder does not exercise his or her Option within the time specified
herein, the Option shall terminate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(l)&#160;Death
of Option holder.</b></span>&#160;Unless otherwise provided in its Option Agreement, in the event (i)&#160;an Option holder&#8217;s Continuous
Service terminates as a result of the Option holder&#8217;s death or (ii)&#160;the Option holder dies within the period (if any) specified
in the Option Agreement after the termination of the Option holder&#8217;s Continuous Service, then the Option may be exercised (to the
extent the Option holder was entitled to exercise such Option as of the date of death) by the Option holder&#8217;s estate, by a person
who acquired the right to exercise the Option by bequest or inheritance, or by a person designated to exercise the Option upon the Option
holder&#8217;s death pursuant to Sections 6(f)&#160;or 6(g), but only within the period ending on the earlier of (A)&#160;the date twelve
(12) months following the date of death (or such shorter period specified in the Option Agreement and approved by the Board) or (B)&#160;the
expiration of the term of such Option as set forth in the Option Agreement. If, after death, the Option is not exercised within the time
specified herein, the Option shall terminate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(m)&#160;Termination
of Continuous Service for Cause.&#160;</b></span>Notwithstanding Sections 6 (i)-(l)&#160;above, in the event of termination of Participant&#8217;s
employment with the Company or any of its Affiliates, or if applicable, the termination of services given to the Company or any of its
Affiliates by Consultants or Directors of the Company or any of its Affiliates for Cause, all outstanding Option Awards granted to such
Participant (whether vested or not) will immediately expire and terminate on the date of such termination and the holder of Option Awards
shall not have any right in connection to such outstanding Option Awards, unless otherwise determined by the Committee. The shares of
Common Stock covered by such Option Awards shall revert to the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(n)&#160;Compliance
With Laws,&#160;etc.</b></span>&#160;Notwithstanding the foregoing, in no event shall a Participant be permitted to exercise an Option
in a manner that the Committee determines would violate the Sarbanes-Oxley Act of 2002, if applicable, or any other applicable law or
the applicable rules&#160;and regulations of the Securities and Exchange Commission or the applicable rules&#160;and regulations of any
securities exchange, inter-dealer quotation system, or other recognized securities quotation system on which the securities of the Company
are listed, quoted or traded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
Stock Grants and Restricted Stock Units.</b></span>&#160;The Committee may grant Awards in the form of shares of Common Stock, with or
without restrictions (with restrictions, &#8220;<b><i>Restricted Stock</i></b>&#8221;), and/or Restricted Stock Units. Restricted Stock
Units are a right to receive shares of Common Stock (or their then Fair Market Value) at a specified future time. Restrictions on Restricted
Stock and Restricted Stock Units may include transfer restrictions or the right of the Company to repurchase all or part of the shares
at their issue price or other stated or formula price (or to require forfeiture of the shares if issued at no cost) from the Participant
in the event that conditions specified by the Committee in the applicable Award Agreement are not satisfied prior to the end of the applicable
restriction period or periods established by the Committee for the Award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee may, in its sole discretion, impose
such conditions and/or restrictions on any Award of Restricted Stock or Restricted Stock Units pursuant to this Section&#160;7 as it may
deem advisable including, without limitation, a requirement that a Participant pay a stipulated purchase price for each share of Common
Stock or Restricted Stock Unit awarded, time-based restrictions on vesting, or holding requirements or sale restrictions placed on the
Common Stock upon vesting of any Award of Restricted Stock or settlement of any Restricted Stock Unit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless determined otherwise by the Committee,
in the event of termination of Continuous Service of a Participant, all Restricted Stock and Restricted Stock Units theretofore granted
to the Participant that are not vested on the termination date shall terminate immediately and have no legal effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the preceding provisions of this
Section&#160;7, in the event of termination of Participant&#8217;s employment with the Company or any of its Affiliates, or if applicable,
the termination of services given to the Company or any of its Affiliates by Consultants or Directors of the Company or any of its Affiliates
for Cause, all unvested Restricted Stock Awards and unvested (or vested and not settled) Restricted Stock Unit Awards granted to the Participant
will be immediately forfeited on the date of such termination, unless otherwise determined by the Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to each Restricted Stock Unit, the Committee may grant
a dividend equivalent unit to any Participant upon such terms and conditions as it may establish. Each dividend equivalent unit will entitle
the Participant, at the time of the settlement of the Award, to an additional payment equal to the dividends the Participant would have
received if the Participant had been the actual record owner of the underlying Common Stock on each dividend record date prior to settlement.
The dividend equivalent unit may be settled in cash, additional shares of Common Stock or a combination thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8.&#160;Covenants of the Company.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Availability
of Shares.</b></span>&#160;During the terms of Awards hereunder, the Company shall keep available at all times the number of authorized
shares of Common Stock required to satisfy such Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Securities
Law Compliance.</b></span>&#160;The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the
Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of Awards;
<i>provided</i>, <i>however</i>, that this undertaking shall not require the Company to register under the Plan any Award or any Common
Stock issued or issuable pursuant to any such Award under the Securities Act. If, after reasonable efforts, the Company is unable to obtain
from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale
of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise
of such Awards unless and until such authority is obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. Use of Proceeds from Stock.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proceeds from the sale of Common Stock pursuant
to Awards shall constitute general funds of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10.&#160;Miscellaneous.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Acceleration
of Exercisability and Vesting.</b></span>&#160;Subject to applicable law, the Committee in its sole discretion shall have the power to
accelerate the time at which an Award may first be exercised or the time during which a Award or any part thereof will vest in accordance
with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which
it will vest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Stockholder
Rights.</b></span>&#160;No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to,
any shares of Common Stock subject to an Option Award or Restricted Stock Unit Award unless and until such Participant has satisfied all
requirements for exercise of the Option Award pursuant to its terms or the Restricted Stock Unit Award has settled in shares of Common
Stock, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;No
Employment or other Service Rights.</b></span>&#160;Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall
confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award
was granted or shall affect the right of the Company or an Affiliate to terminate (i)&#160;the employment of an Employee with or without
notice and with or without Cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with
the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the By-Laws of the Company or an Affiliate, and any applicable
provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#160;Incentive
Stock Option $100,000 Limitation.</b></span>&#160;To the extent that the aggregate Fair Market Value (determined at the time of grant)
of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Option holder during any calendar
year (under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof
that exceed such limit (according to the order in which they were granted) shall be treated as Non statutory Stock Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)&#160;Investment
Assurances.</b></span>&#160;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award:
(i)&#160;to give assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business
matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial
and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and
risks of exercising or acquiring the Award; and (ii)&#160;to give assurances satisfactory to the Company stating that the Participant
is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or
otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be
inoperative if (A)&#160;the issuance of the shares of Common Stock upon the exercise or acquisition of Common Stock under the Award has
been registered under a then currently effective registration statement under the Securities Act or (B)&#160;as to any particular requirement,
a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable
securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as
such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends
restricting the transfer of the Common Stock. (If shares of Common Stock are held in book entry form, statements evidencing those shares
shall include a similar legend.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)&#160;Withholding
Obligations.</b></span>&#160;The Company or any Subsidiary or Affiliate may take such action as it may deem necessary or appropriate,
in its discretion, for the purpose of or in connection with withholding of any taxes that the Company or Affiliate is required by any
applicable law to withhold in connection with any Awards (collectively, &#8220;<b><i>Withholding Obligations</i></b>&#8221;). Such actions
may include, without limitation: (i)&#160;requiring a Participant to remit to the Company in cash an amount sufficient to satisfy such
Withholding Obligations; (ii)&#160;subject to applicable law, allowing the Participant to provide shares of Common Stock to the Company,
in an amount that at such time, reflects a value that the Committee determines to be sufficient to satisfy such Withholding Obligations;
(iii)&#160;withholding shares of Common Stock otherwise issuable upon the exercise of an Award at a value that is determined by the Committee
to be sufficient to satisfy such Withholding Obligations; or (iv)&#160;any combination of the foregoing. The Company shall not be obligated
to allow the exercise of any Award by or on behalf of a Participant until all tax consequences arising from the exercise of such Award
are resolved in a manner acceptable to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)&#160;Compliance
with Section&#160;409A of the Code.&#160;</b></span>It is the intention of the Company that no payment or entitlement pursuant to this
Plan will give rise to any adverse tax consequences to any person pursuant to Section&#160;409A of the Code. The Committee shall interpret
and apply the Plan to that end, and shall not give effect to any provision therein in a manner that reasonably could be expected to give
rise to adverse tax consequences under Section&#160;409A of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company makes no representations or warranty
and shall have no liability to the Participant or any other person if any provisions of or payments, compensation, or other benefits under
the Plan are determined to constitute nonqualified deferred compensation subject to Section&#160;409A of the Code but do not to satisfy
the conditions of that Section.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)&#160;Rounding
Conventions.</b></span> The Committee may, in its sole discretion and taking into account any requirements of the Code, including without
limitations Sections 422 through 424 and 409A of the Code, determine the effect of vesting, stock dividends and any other adjustments
on shares and any cash amount payable hereunder, and may provide that no fractional shares will be issued (rounding up or down as determined
by the Committee) and that cash amounts be rounded down to the nearest whole cent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)&#160;Conditions
on Delivery of Stock.</b></span> The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove
restrictions from shares previously issued or delivered under the Plan until (i)&#160;all conditions of the Award have been met or removed
to the satisfaction of the Committee, (ii)&#160;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with
the issuance and delivery of the shares have been satisfied, including any applicable securities laws and regulations and any applicable
rules&#160;and regulations of a national exchange or other recognized securities quotation system (such as the OTC Bulletin Board/OTCQB
Market), on which the Common Stock is listed or admitted to trading and (iii)&#160;the Participant has executed and delivered to the Company
such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules,
or regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)&#160;Authorization
of Sub Plans.</b></span> The Committee may from time to time establish one (1)&#160;or more Sub Plans under the Plan for purposes of satisfying
applicable securities, tax, or other laws of various jurisdictions. The Committee shall establish such Sub Plans by adopting supplements
to the Plan containing (i)&#160;any limitations on the Committee&#8217;s sole discretion under the Plan as the Committee deems necessary
or desirable or (ii)&#160;any additional terms and conditions not otherwise inconsistent with the Plan as the Committee shall deem necessary
or desirable. All supplements adopted by the Committee shall be deemed to be part of the Plan, but each supplement shall apply only to
Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants
in any jurisdiction that is not the subject of such supplement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11.&#160;Adjustment upon Changes in Stock.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Capitalization
Adjustments.</b></span> If any change is made in the Common Stock generally or the Common Stock subject to the Plan, or the Common Stock
subject to any Award, without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange
of shares, change in corporate structure, or other transaction not involving the receipt of consideration by the Company), the Plan will
be appropriately adjusted in the class(es) and maximum number of securities subject to the Plan and the share counting rules&#160;pursuant
to Section&#160;4(a), the class(es), the number of securities and price per share of Common Stock subject to such outstanding Awards and
the share and per-share related provisions and the purchase or exercise price, if any, of each outstanding Award (or substituted Award,
if applicable). The Board shall make such adjustments, and its determination shall be final, binding and conclusive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If while Awards remain outstanding under the Plan
the Company merges or consolidates with a wholly-owned subsidiary for the purpose of reincorporating itself under the laws of another
jurisdiction or for any other reason, the Participants will be entitled to acquire shares of Common Stock of the surviving company upon
the same terms and conditions as were in effect immediately prior to such merger or consolidation (unless such merger or consolidation
involves a change in the number of shares or the capitalization of the Company, in which case proportional adjustments shall be made as
provided above) and the Plan, unless otherwise rescinded by the Board, will remain the Plan of the surviving company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Dissolution
or Liquidation.</b></span> In the event of a dissolution or liquidation of the Company, then the Company shall immediately notify Participants
who hold outstanding Awards of such dissolution or liquidation. The Committee may provide a Participant thirty (30) days to exercise all
or a portion of any outstanding vested Options held by him or her at that time, and upon the expiration of such thirty (30) day period,
all remaining outstanding Options shall terminate immediately. Alternatively, the Committee may provide that all or any portion of any
vested Option shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable
tax withholdings). Except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any
other agreement between a Participant and the Company, in the case of a dissolution or liquidation of the Company all restrictions and
conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied and all Restricted Stock Units
shall automatically vest and settle.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c)&#160;Change in Control.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event of a Change in Control, then, without the consent or action required of any holder of an Option (in such holder&#8217;s capacity
as such):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b></span>Any
surviving corporation or acquiring corporation or any parent or affiliate thereof, as determined by the Committee in its discretion, shall
assume or continue any Options outstanding under the Plan in all or in part or shall substitute to similar stock awards in all or in part,
in accordance with the requirements of Section&#160;409A of the Code (or, in the case of Incentive Stock Options, Section&#160;424 of
the Code); or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b></span>In
the event any surviving corporation or acquiring corporation does not assume or continue any Awards or substitute to similar awards for
those outstanding under the Plan then: (I)&#160;all unvested Options shall expire and (II)&#160;vested Options shall terminate if not
exercised at or prior to such Change in Control; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(C)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b></span>The
Committee may, in its sole discretion, accelerate the vesting, partially or in full, in the sole discretion of the Committee and on a
case-by-case basis of one (1)&#160;or more Options as the Committee may determine to be appropriate prior to such events; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(D)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</b></span>In
the event of a Change in Control under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment
for each share surrendered in the Change in Control (the&#160;<i>&#8220;<b>Acquisition Price</b>&#8221;</i>), Participants shall be provided
a cash payment with respect to each vested Option held by a Participant equal to (I)&#160;the number of shares of Common Stock subject
to the vested Option (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Change in Control
multiplied by (II)&#160;the excess, if any, of (1)&#160;the Acquisition Price over (2)&#160;the exercise price of the Award and any applicable
tax withholdings, in exchange for the termination of such Awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence of a Change in Control, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall
inure to the benefit of the Company&#8217;s successor and shall, unless the successor determines otherwise, apply to the cash, securities,
or other property that the Common Stock was converted into or exchanged for pursuant to such Change in Control in the same manner and
to the same extent as they applied to the Restricted Stock;&#160;<i>provided</i>,&#160;<i>however</i>, that the Committee may provide
for termination or deemed satisfaction of repurchase or other rights under the Award Agreement evidencing any Restricted Stock or any
other agreement between a Participant and the Company, either initially or by amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence of a Change in Control, any surviving corporation or acquiring corporation or any parent or affiliate thereof, as determined
by the Committee in its discretion, shall assume or continue any unsettled Restricted Stock Units outstanding under the Plan or, in the
event any surviving corporation or acquiring corporation does not assume or continue any Restricted Stock Unit Awards for those outstanding
under the Plan then: all unvested Restricted Stock Units shall expire and vested Restricted Stock Units shall settle immediately prior
to such Change in Control if the Change in Control is a change in the ownership or effective control of the Company, or in the ownership
of a substantial portion of the assets of the Company within the meaning of U.S. Treasury Regulation Section&#160;1.409A-3(i)(5); <i>provided,
however,</i> that the Committee may, in its sole discretion, accelerate the vesting, partially or in full, in the sole discretion of the
Committee and on a case-by-case basis of one (1)&#160;or more Restricted Stock Units as the Committee may determine to be appropriate
prior to such events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the above, in case of Change in Control and in the event all or substantially all of the shares of the Company are to be exchanged for
securities of another Company, then each holder of an Award shall be obliged to sell or exchange, as the case may be, any shares such
holder hold or purchased under the Plan, in accordance with the instructions issued by the Board, whose determination shall be final.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the above, the Committee may, in its sole discretion, decide other terms regarding the treatment of the outstanding Awards in case of
Change in Control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#160;</b></span>Each
holder of an Award acknowledges that in the event that the Company&#8217;s shares shall be listed, quoted, or registered for trading in
any public market, the rights of such holder to sell the shares may be subject to certain limitations (including a lock-up period), as
may be requested by the Company or its underwriters, and the holder of such Award unconditionally agrees and accepts any such limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12.&#160;Shares Subject to Right of First Refusal.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span>&#160;Notwithstanding
anything to the contrary in the Certificate of Incorporation and the By-Laws of the Company, none of the Participants shall have a right
of first refusal or preemptive right in relation with any sale of shares in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;</b></span>Sale
of shares of Common Stock by the Participant shall be subject to the right of first refusal of other shareholders as set forth in the
Certificate of Incorporation and/or the By-Laws of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;</b></span>The
Committee may refuse to approve the transfer of shares of Common Stock to any competitor of the Company or to any other person or entity
the Committee determines, in its discretion, may be detrimental to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13.&#160;Amendment of the Plan and Awards.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Amendment
of Plan.</b></span>&#160;The Board at any time, and from time to time, may amend the Plan. However, except as provided in Section&#160;11
relating to adjustments upon changes in Common Stock, no amendment shall be effective unless approved by the stockholders of the Company
to the extent stockholder approval is necessary to satisfy the requirements of Section&#160;422 of the Code or any other applicable laws,
rules&#160;and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Stockholder
Approval.</b></span>&#160;The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;Contemplated
Amendments.</b></span>&#160;It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or
advisable to provide eligible Employees with the maximum benefits provided or to be provided under the provisions of the Code and the
regulations promulgated thereunder relating to Incentive Stock Options and/or to bring the Plan and/or Incentive Stock Options granted
under it into compliance therewith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#160;No
Impairment of Rights.</b></span>&#160;Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment
of the Plan unless (i)&#160;the Company requests the consent of the Participant and (ii)&#160;the Participant consents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)&#160;Amendment
of Awards.</b></span>&#160;The Committee at any time, and from time to time, may amend the terms of any one (1)&#160;or more Awards; <i>provided</i>,
<i>however</i>, that the rights under any Award shall not be impaired by any such amendment unless (i)&#160;the Company requests the consent
of the Participant and (ii)&#160;the Participant consents in writing (such consent to not be unreasonably withheld or delayed).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span>&#160;<b>Termination
or Suspension of the Plan.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Plan
Term.</b></span>&#160;The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on the
day before the tenth (10<sup>th</sup>) anniversary of the date this amended and restated Plan is adopted by the Board or approved by the
stockholders of the Company, whichever is earlier. No Awards may be granted under the Plan while the Plan is suspended or after it is
terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;No
Impairment of Rights.</b></span>&#160;Suspension or termination of the Plan shall not impair rights and obligations under any Award granted
while the Plan is in effect except with the consent of the Participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15.&#160;Tax Consequences.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;</b></span>Any
tax consequences arising from the grant, exercise, or settlement of any Award, from the payment for Common Stock covered thereby or from
any other event or act (of the Company and/or its Affiliates, or the Participant) hereunder shall be borne solely by the Participant.
The Company and/or its Affiliates shall withhold taxes according to the requirements under the applicable laws, rules&#160;and regulations,
including withholding taxes at the source. Furthermore, the Participant shall agree to indemnify the Company and/or its Affiliates and
hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation,
liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;</b></span>The
Company shall not be required to release any share certificate to (or reflect ownership of shares in a book entry system for) a Participant
until all required payments have been fully made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16.&#160;Notice To Company of Disqualifying
Disposition.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without derogating from all of the above, each
Participant who receives an Incentive Stock Option must agree to notify the Company immediately after the Participant makes a Disqualifying
Disposition of any Common Stock acquired upon the exercise of an Incentive Stock Option. A &#8220;<b><i>Disqualifying Disposition</i>&#8221;</b>&#160;is
any disposition (including any sale) of such Common Stock before the later of (a)&#160;two (2)&#160;years after the date the Employee
was granted the Incentive Stock Option or (b)&#160;one (1)&#160;year after the date the Participant acquired Common Stock by exercising
the Incentive Stock Option. If the Participant has died before such Common Stock is sold, these holding period requirements do not apply
and no Disqualifying Disposition can occur thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. Effective Date of Plan.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amended and restated Plan shall take effect
upon its adoption by the Board (the &#8220;<b><i>Effective Date</i></b>&#8221;), except that solely with respect to grants of Incentive
Stock Options this amended and restated Plan shall also be subject to approval within one (1)&#160;year of the Effective Date, by a majority
of the votes cast on the proposal at a meeting or a written consent of shareholders. Failure to obtain approval by the shareholders shall
not in any way derogate from the valid and binding effect of any grant of an Award that is not an Incentive Stock Option. Upon approval
of this amended and restated Plan by the shareholders of the Company as set forth above, all Incentive Stock Options granted under the
Plan on or after the Effective Date shall be fully effective as if the shareholders of the Company had approved the amended and restated
Plan on the Effective Date. Notwithstanding the foregoing, in the event that approval of the Plan by the shareholders of the Company is
required under applicable law, in connection with the application of certain tax treatment or pursuant to applicable stock exchange rules&#160;or
regulations or otherwise, such approval shall be obtained within the time required under the applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18.&#160;Choice of Law.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#160;Choice
of Law.</b></span> This Plan, all Awards and all documents evidencing awards and all other related documents will be governed by, and
construed in accordance with, the laws of the State of Delaware;&#160;<i>provided, that,</i>&#160;the tax treatment and the tax rules&#160;and
regulations applying to a grant in any specific jurisdiction shall be the local tax laws of such jurisdiction in addition to the Federal
income tax laws of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#160;Israeli
Participants.</b></span> Any grant of an Award to an Israeli Employee or to an Israeli Non-Employee (as each of such terms is defined
in the Sub Plan applicable to Israeli Participants) shall be made in accordance with and pursuant to the provisions of this Plan and the
Sub Plan applicable to Israeli Participants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#160;Severability</b></span>.
If it is determined that any provision of this Plan or an Award Agreement is invalid and unenforceable, the remaining provisions of this
Plan and/or the Award Agreement, as applicable, will continue in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Annex B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REVERSE STOCK SPLIT CERTIFICATE OF AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF AMENDMENT TO THE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF INCORPORATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF DARIOHEALTH CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, for the purposes of amending
the Certificate of Incorporation of DarioHealth Corp. (the &#8220;<span style="text-decoration:underline">Corporation</span>&#8221;), a corporation organized and existing under
and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration:underline">DGCL</span>&#8221;), does hereby certify that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">FIRST</span>: The Board of Directors of the Corporation
(the &#8220;<span style="text-decoration:underline">Board</span>&#8221;) duly adopted, in accordance with Section&#160;141(f)&#160;of the DCGL by unanimous written consent of
the Board on &#160;&#160;&#160;&#160;&#160;, 2025, a resolution proposing and declaring advisable the following amendment to restate Article&#160;FOURTH, Section&#160;2
of the Certificate of Incorporation of said Corporation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Except as otherwise provided by law or
by the resolution or resolutions providing for the issue of any series of Preferred Stock, the holders of outstanding shares of Common
Stock shall have the exclusive right to vote for the election of directors and for all other purposes. Except as otherwise required by
law or this Certificate of Incorporation of the Corporation, each holder of Common Stock is entitled to one vote for each share of Common
Stock held of record by such holder with respect to all matters on which holders of Common Stock are entitled to vote. Subject to the
Delaware General Corporation Law and the rights, if any, of the holders of any outstanding series of Preferred Stock, dividends may be
declared and paid on the Common Stock at such times and in such amounts as the Board of Directors of the Corporation (the &#8220;<b>Board
of Directors</b>&#8221;) in its discretion shall determine. Upon the dissolution, liquidation or winding up of the Corporation, subject
to the rights, if any, of the holders of any outstanding series of Preferred Stock, the holders of the Common Stock, as such, shall be
entitled to receive the assets of the Corporation available for distribution to its stockholders ratably in proportion to the number of
shares held by them. Upon the effectiveness of the amendment to the certificate of incorporation containing this sentence (the &#8220;<b>Split
Effective Time</b>&#8221;), each share of the Common Stock issued and outstanding immediately prior to the date and time of the filing
hereof with the Secretary of State of Delaware shall be automatically changed and reclassified into a smaller number of shares such that
each [&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ] shares of issued Common Stock immediately prior to the Split Effective Time is reclassified into one (1)&#160;share of Common
Stock. Notwithstanding the immediately preceding sentence, there shall be no fractional shares issued and, in lieu thereof, a holder of
Common Stock on the Split Effective Time who would otherwise be entitled to a fraction of a share as a result of the reclassification,
following the Split Effective Time, shall receive a full share of Common Stock upon the surrender of such stockholders' old stock certificate.
No stockholders will receive cash in lieu of fractional shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">SECOND</span>: The holders of a majority of the
issued and outstanding voting stock of the Corporation have voted in favor of said amendment at an annual meeting of said Corporation&#8217;s
stockholders duly called and held upon notice in accordance with Section&#160;222 of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">THIRD</span>: The aforesaid amendment was duly adopted in accordance
with the applicable provisions of Section&#160;242 of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">FOURTH</span>: The aforesaid amendment shall be effective as of :00
A.M.&#160;Eastern Time on , 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the Corporation has caused this Amendment to the
Certificate of Incorporation of the Corporation to be duly executed by the undersigned this the day of , 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">By: Chen Franco-Yehuda</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p></td>
    <td style="width: 50%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">Title: Chief Financial Officer, Secretary
    and Treasurer</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Annex B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INCREASE IN AUTHORIZED SHARES CERTIFICATE OF
AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF AMENDMENT TO THE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF INCORPORATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF DARIOHEALTH CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, for the purposes of amending
the Certificate of Incorporation of DarioHealth Corp. (the &#8220;<span style="text-decoration:underline">Corporation</span>&#8221;), a corporation organized and existing under
and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration:underline">DGCL</span>&#8221;), does hereby certify that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">FIRST</span>: The Board of Directors of the Corporation
(the &#8220;<span style="text-decoration:underline">Board</span>&#8221;) duly adopted, in accordance with Section&#160;141(f)&#160;of the DCGL by unanimous written consent of
the Board on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, a resolution proposing and declaring advisable the following amendment to restate Article&#160;FOURTH, Section&#160;1
of the Certificate of Incorporation of said Corporation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#160;<span style="text-decoration:underline">Classes of Stock</span>. The Corporation
is authorized to issue two classes of shares of capital stock to be designated, respectively, common stock (&#8220;<b>Common Stock</b>&#8221;)
and preferred stock (&#8220;<b>Preferred Stock</b>&#8221;). The number of shares of Common Stock authorized to be issued is four hundred
million (400,000,000), par value $0.0001 per share, and the number of shares of Preferred Stock authorized to be issued is five million
(5,000,000), par value $0.0001 per share; the total number of shares which the Corporation is authorized to issue is one hundred sixty
five million (400,000,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">SECOND</span>: The holders of a majority of the
issued and outstanding voting stock of the Corporation have voted in favor of said amendment at an annual meeting of said Corporation&#8217;s
stockholders duly called and held upon notice in accordance with Section&#160;222 of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">THIRD</span>: The aforesaid amendment was duly adopted in accordance
with the applicable provisions of Section&#160;242 of the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">FOURTH</span>: The aforesaid amendment shall be effective as of :00
A.M.&#160;Eastern Time on , 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the Corporation has caused this Amendment to the
Certificate of Incorporation of the Corporation to be duly executed by the undersigned this day of , 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">By: Chen Franco-Yehuda</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p></td>
    <td style="width: 50%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">Title: Chief Financial Officer, Secretary
    and Treasurer</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROXY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD
OF DIRECTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE UNDERSIGNED HEREBY APPOINTS<span style="text-transform: uppercase">,
EREZ RAPHAEL AND CHEN FRANCO-YEHUDA,&#160;</span>AND EACH OF THEM, AS PROXIES OF THE UNDERSIGNED, WITH FULL POWER OF SUBSTITUTION, TO
VOTE ALL THE SHARES OF COMMON STOCK OF DARIOHEALTH CORP. HELD OF RECORD BY THE UNDERSIGNED ON MAY&#160;29, 2025<span style="text-transform: uppercase">,
AT THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JULY 23, 2025 AT 4:00 P.M.&#160;LOCAL TIME AT OUR ISRAELI OFFICE, LOCATED AT 5&#160;Tarshish
STREET, 2<sup>nd</sup> FLOOR, CAESAREA INDUSTRIAL PARK, 3088900,&#160;ISRAEL, OR ANY ADJOURNMENT THEREOF.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">1.</td>
    <td style="text-align: justify">Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Hila Karah</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Dennis Matheis</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Dennis M. McGrath</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Erez Raphael</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Yoav Shaked</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Lawrence Leisure</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Adam K. Stern</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">2.</td>
    <td style="text-align: justify">To ratify the appointment by the Audit Committee of the Company&#8217;s Board of Kesselman&#160;&amp; Kesselman, a member of PricewaterhouseCoopers International Limited&#160;as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2025.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">3.</td>
    <td style="text-align: justify">To consider and vote to amend the Company&#8217;s 2020 Equity Compensation Plan, as amended.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">4.</td>
    <td style="text-align: justify">To authorize the Board to amend the Company&#8217;s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company&#8217;s issued and outstanding shares of common stock, $0.0001 par value per share (the &#8220;<b>Common Stock</b>&#8221;), at a ratio of not less than one (1)&#160;to two (2)&#160;and not greater than one (1)&#160;to twenty five (25), to be implemented no later than September&#160;15, 2025, as determined by the Board in its sole discretion;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; padding: 0.25pt; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%; padding: 0.25pt"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%; padding: 0.25pt"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">5.</td>
    <td style="text-align: justify">To approve an amendment to the Articles of Incorporation of the Company to increase the number of authorized Common Stock from one hundred sixty million (160,000,000) shares, $0.0001 par value per share, to four hundred million (400,000,000) shares, $0.0001 par value per share; and</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; padding: 0.25pt; text-indent: 0.25in"><span>&#9744;</span>&#160;FOR</td>
    <td style="width: 37%; padding: 0.25pt"><span>&#9744;</span>&#160;AGAINST</td>
    <td style="width: 30%; padding: 0.25pt"><span>&#9744;</span>&#160;ABSTAIN</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In their discretion, upon
the transaction of any other matters which may properly come before the meeting or any adjournment thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The shares represented
by this proxy, when properly executed, will be voted as specified by the undersigned stockholder(s). If this card contains no specific
voting instructions, the shares will be voted&#160;<span style="text-decoration:underline">FOR</span>&#160;each of the proposals described on this card.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Signature of Stockholder(s)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><b>Date</b></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please sign exactly as the
name appears below. When shares are held by joint tenants, both should sign. When signing as attorney, executor, administrator, trustee
or guardian, please give full title as such. If a corporation, please sign the corporate name by the president or other authorized officer.
If a partnership, please sign in the partnership name by an authorized person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>VOTE BY INTERNET &#8212;
if a registered holder by visiting www.vstocktransfer.com/proxy; if a beneficial holder by visiting www.proxyvote.com.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Use the internet to transmit
your voting instructions and for electronic delivery of information up until 11:59 P.M.&#160;Eastern Time the day before the meeting date.
Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic
voting instruction form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font-size: 10pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">PRE 14A</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-3" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-4" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-5" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-6" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-7" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-8" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-9" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-10" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-11" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-12" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-13" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-8380">0001533998</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-8381">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="drio-20250520.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5MmxidaYFRxXFiPBCpoEiYtEAYNkzcBtdNTVpFDLJv7A3WPRBMdkCUGOhAUKUX/6OedwEDHoHfLy4oHiRKOKVtnyi6VviL1HxMjsMxItKT/8BqaCeuynwUKcI+es6pqJXlxKHHuRVdTVTF0heWuiCl+1S8YpeXtCc0xMx2G2h+18M6O2ua29iZyGPeM/8BQYcP8HtW8QXRhz] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>drio-20250520.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 19 17:09:12 UTC 2025 -->
<xs:schema elementFormDefault="qualified" targetNamespace="http://dariohealth.com/20250520" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:drio="http://dariohealth.com/20250520" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="drio-20250520_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="drio-20250520_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="drio-20250520_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="AllOtherCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_AllOtherCompensation"/>
  <xs:element name="Bonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_Bonus"/>
  <xs:element name="EquityAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwards"/>
  <xs:element name="NonEquityIncentivePlanCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_NonEquityIncentivePlanCompensation"/>
  <xs:element name="NonqualifiedDeferredCompensationEarnings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_NonqualifiedDeferredCompensationEarnings"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5MmxidaYFRxXFiPBCpoEiYtEAYNkzcBtdNTVpFDLJv7A3WPRBMdkCUGOhAUKUX/6OedwEDHoHfLy4oHiRKOKVtnyi6VviL1HxMjsMxItKT/8BqaCeuynwUKcI+es6pqJXlxKHHuRVdTVTF0heWuiCl+1S8YpeXtCc0xMx2G2h+18M6O2ua29iZxLseEqgef3FJtasN9JhLzi] CSR-->
  <xs:element name="OptionAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_OptionAwards"/>
  <xs:element name="Pension" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_Pension"/>
  <xs:element name="Salary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_Salary"/>
  <xs:element name="StockAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="drio_StockAwards"/>
  <xs:element name="ChangeInPensionValueAndEquityAwardValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_ChangeInPensionValueAndEquityAwardValueMember"/>
  <xs:element name="EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
  <xs:element name="EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
  <xs:element name="EquityAwardsAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsMember"/>
  <xs:element name="EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
  <xs:element name="EquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="NetAdjustmentsForEquityAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_NetAdjustmentsForEquityAwardsMember"/>
  <xs:element name="NetAdjustmentsForPensionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_NetAdjustmentsForPensionMember"/>
  <xs:element name="OptionAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_OptionAwardsMember"/>
  <xs:element name="OptionAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="PensionAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_PensionAdjustmentsMember"/>
  <xs:element name="PensionAdjustmentsPriorServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_PensionAdjustmentsPriorServiceCostMember"/>
  <xs:element name="PensionAdjustmentsServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_PensionAdjustmentsServiceCostMember"/>
  <xs:element name="PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="PensionValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_PensionValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="StockAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_StockAwardsMember"/>
  <xs:element name="StockAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>drio-20250520_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 19 17:09:12 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5MmxidaYFRxXFiPBCpoEiYtEAYNkzcBtdNTVpFDLJv7A3WPRBMdkCUGOhAUKUX/6OedwEDHoHfLy4oHiRKOKVtnyi6VviL1HxMjsMxItKT/8BqaCeuynwUKcI+es6pqJXlxKHHuRVdTVTF0heWuiCl+1S8YpeXtCc0xMx2G2h+18M6O2ua29iZw4+Nm5NAmbiH2dbkKL/gtC] CSR-->
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <loc xlink:type="locator" xlink:label="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_StockAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_EqtyAwrdsAdjsMember" xlink:to="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_EqtyAwrdsAdjsMember" xlink:to="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember" order="2" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>drio-20250520_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 19 17:09:12 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="drio_AllOtherCompensation" xlink:href="drio-20250520.xsd#drio_AllOtherCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_AllOtherCompensation_lbl" xml:lang="en-US">All Other Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_AllOtherCompensation" xlink:to="drio_AllOtherCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_AllOtherCompensation_lbl0" xml:lang="en-US">All other compensation for the period that could not be properly reported in any other column of the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_AllOtherCompensation" xlink:to="drio_AllOtherCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_Bonus" xlink:href="drio-20250520.xsd#drio_Bonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_Bonus_lbl" xml:lang="en-US">Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_Bonus" xlink:to="drio_Bonus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_Bonus_lbl0" xml:lang="en-US">The dollar value of bonus (cash and non-cash) earned by the named executive officer during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_Bonus" xlink:to="drio_Bonus_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwards" xlink:href="drio-20250520.xsd#drio_EquityAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwards_lbl" xml:lang="en-US">Equity Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwards" xlink:to="drio_EquityAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 of all equity awards granted during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwards" xlink:to="drio_EquityAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_NonEquityIncentivePlanCompensation" xlink:href="drio-20250520.xsd#drio_NonEquityIncentivePlanCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_NonEquityIncentivePlanCompensation_lbl" xml:lang="en-US">Non-Equity Incentive Plan Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NonEquityIncentivePlanCompensation" xlink:to="drio_NonEquityIncentivePlanCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_NonEquityIncentivePlanCompensation_lbl0" xml:lang="en-US">The dollar value of (1) all earnings for services performed during the period pursuant to awards under non-equity incentive plans and (2) all earnings on any outstanding awards under such plans as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NonEquityIncentivePlanCompensation" xlink:to="drio_NonEquityIncentivePlanCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_NonqualifiedDeferredCompensationEarnings" xlink:href="drio-20250520.xsd#drio_NonqualifiedDeferredCompensationEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_NonqualifiedDeferredCompensationEarnings_lbl" xml:lang="en-US">Nonqualified Deferred Compensation Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NonqualifiedDeferredCompensationEarnings" xlink:to="drio_NonqualifiedDeferredCompensationEarnings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_NonqualifiedDeferredCompensationEarnings_lbl0" xml:lang="en-US">Above-market or preferential earnings on compensation that is deferred on a basis that is not tax-qualified, including any such earnings on nonqualified defined contribution plans, as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NonqualifiedDeferredCompensationEarnings" xlink:to="drio_NonqualifiedDeferredCompensationEarnings_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_OptionAwards" xlink:href="drio-20250520.xsd#drio_OptionAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_OptionAwards_lbl" xml:lang="en-US">Option Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_OptionAwards" xlink:to="drio_OptionAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_OptionAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 for any awards of options, with or without tandem Stock Appreciation Rights (SARs), as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_OptionAwards" xlink:to="drio_OptionAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_Pension" xlink:href="drio-20250520.xsd#drio_Pension"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_Pension_lbl" xml:lang="en-US">Pension</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_Pension" xlink:to="drio_Pension_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_Pension_lbl0" xml:lang="en-US">The aggregate pension value, as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_Pension" xlink:to="drio_Pension_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_Salary" xlink:href="drio-20250520.xsd#drio_Salary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_Salary_lbl" xml:lang="en-US">Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_Salary" xlink:to="drio_Salary_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_Salary_lbl0" xml:lang="en-US">The dollar value of base salary (cash and non-cash) earned by the named executive officer during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_Salary" xlink:to="drio_Salary_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_StockAwards" xlink:href="drio-20250520.xsd#drio_StockAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_StockAwards_lbl" xml:lang="en-US">Stock Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_StockAwards" xlink:to="drio_StockAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_StockAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 of all stock awards granted during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_StockAwards" xlink:to="drio_StockAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_ChangeInPensionValueAndEquityAwardValueMember" xlink:href="drio-20250520.xsd#drio_ChangeInPensionValueAndEquityAwardValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_ChangeInPensionValueAndEquityAwardValueMember_lbl" xml:lang="en-US">Change In Pension Value and Equity Award Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_ChangeInPensionValueAndEquityAwardValueMember" xlink:to="drio_ChangeInPensionValueAndEquityAwardValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_ChangeInPensionValueAndEquityAwardValueMember_lbl0" xml:lang="en-US">This member presents the total compensation adjustment for change in pension value and equity award value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_ChangeInPensionValueAndEquityAwardValueMember" xlink:to="drio_ChangeInPensionValueAndEquityAwardValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl" xml:lang="en-US">Adjustments For Equity Awards Failed To Meet Performance Conditions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on adjustments for equity awards that failed to meet performance conditions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="drio_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of current  year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of prior year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="drio_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5MmxidaYFRxXFiPBCpoEiYtEAYNkzcBtdNTVpFDLJv7A3WPRBMdkCUGOhAUKUX/6OedwEDHoHfLy4oHiRKOKVtnyi6VviL1HxMjsMxItKT/8BqaCeuynwUKcI+es6pqJXlxKHHuRVdTVTF0heWuiCl+1S8YpeXtCc0xMx2G2h+18M6O2ua29iZzkEzd9AcmjpL/MJPtluYEU] CSR-->
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl" xml:lang="en-US">Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Reflected In Fair Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="drio_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsMember_lbl" xml:lang="en-US">Total Equity Awards Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsMember" xlink:to="drio_EquityAwardsAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total equity awards adjustments, which may be comprised of adjustments for (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards granted in prior years that vest in the applicable year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); (iv) adjustments for equity awards that failed to meet performance conditions; and (v) dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsMember" xlink:to="drio_EquityAwardsAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl" xml:lang="en-US">Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="drio_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Equity Awards Value In Summary Compensation Table (Grant Date Value) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for equity awards value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_NetAdjustmentsForEquityAwardsMember" xlink:href="drio-20250520.xsd#drio_NetAdjustmentsForEquityAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_NetAdjustmentsForEquityAwardsMember_lbl" xml:lang="en-US">Total Net Adjustments For Equity Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NetAdjustmentsForEquityAwardsMember" xlink:to="drio_NetAdjustmentsForEquityAwardsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_NetAdjustmentsForEquityAwardsMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for equity awards, which is comprised of equity awards value from summary compensation table, net of total equity awards adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NetAdjustmentsForEquityAwardsMember" xlink:to="drio_NetAdjustmentsForEquityAwardsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_NetAdjustmentsForPensionMember" xlink:href="drio-20250520.xsd#drio_NetAdjustmentsForPensionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_NetAdjustmentsForPensionMember_lbl" xml:lang="en-US">Total Net Adjustments For Pension [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NetAdjustmentsForPensionMember" xlink:to="drio_NetAdjustmentsForPensionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_NetAdjustmentsForPensionMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for pension, which is comprised of pension value from summary compensation table, net of total pension adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_NetAdjustmentsForPensionMember" xlink:to="drio_NetAdjustmentsForPensionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_OptionAwardsMember" xlink:href="drio-20250520.xsd#drio_OptionAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_OptionAwardsMember_lbl" xml:lang="en-US">Option Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_OptionAwardsMember" xlink:to="drio_OptionAwardsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_OptionAwardsMember_lbl0" xml:lang="en-US">This member represents deduction amount for equity awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_OptionAwardsMember" xlink:to="drio_OptionAwardsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Option Awards Value In Compensation Table For The Applicable Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for option awards value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_PensionAdjustmentsMember" xlink:href="drio-20250520.xsd#drio_PensionAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_PensionAdjustmentsMember_lbl" xml:lang="en-US">Total Pension Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsMember" xlink:to="drio_PensionAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_PensionAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, which may be comprised of adjustments for service cost and prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsMember" xlink:to="drio_PensionAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_PensionAdjustmentsPriorServiceCostMember" xlink:href="drio-20250520.xsd#drio_PensionAdjustmentsPriorServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drio_PensionAdjustmentsPriorServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsPriorServiceCostMember" xlink:to="drio_PensionAdjustmentsPriorServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_PensionAdjustmentsPriorServiceCostMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsPriorServiceCostMember" xlink:to="drio_PensionAdjustmentsPriorServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_PensionAdjustmentsServiceCostMember" xlink:href="drio-20250520.xsd#drio_PensionAdjustmentsServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drio_PensionAdjustmentsServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsServiceCostMember" xlink:to="drio_PensionAdjustmentsServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_PensionAdjustmentsServiceCostMember_lbl0" xml:lang="en-US">This member presents the pension adjustments, service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsServiceCostMember" xlink:to="drio_PensionAdjustmentsServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Value And Equity Awards Value In Compensation Table For The Applicable Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the total compensation adjustment for pension value and equity awards value in compensation table for the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_PensionValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_PensionValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_PensionValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Adjustments Pension Value In Summary Compensation Table [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_PensionValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_PensionValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for pension value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_PensionValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_StockAwardsMember" xlink:href="drio-20250520.xsd#drio_StockAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_StockAwardsMember_lbl" xml:lang="en-US">Stock awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_StockAwardsMember" xlink:to="drio_StockAwardsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_StockAwardsMember_lbl0" xml:lang="en-US">Stock awards are any rights granted by the Company to Executive with respect to the common stock of the Company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_StockAwardsMember" xlink:to="drio_StockAwardsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_StockAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Stock Awards Value In Compensation Table For The Applicable Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for stock awards value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="drio_StockAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_PensionAdjustmentsPriorServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Prior Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsPriorServiceCostMember" xlink:to="drio_PensionAdjustmentsPriorServiceCostMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drio_PensionAdjustmentsServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drio_PensionAdjustmentsServiceCostMember" xlink:to="drio_PensionAdjustmentsServiceCostMember_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>drio-20250520_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 19 17:09:12 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5MmxidaYFRxXFiPBCpoEiYtEAYNkzcBtdNTVpFDLJv7A3WPRBMdkCUGOhAUKUX/6OedwEDHoHfLy4oHiRKOKVtnyi6VviL1HxMjsMxItKT/8BqaCeuynwUKcI+es6pqJXlxKHHuRVdTVTF0heWuiCl+1S8YpeXtCc0xMx2G2h+18M6O2ua29iZyjcqefNdELpSRrBou7vLrV] CSR-->
    <loc xlink:type="locator" xlink:label="ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <loc xlink:type="locator" xlink:label="StockAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_StockAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="StockAwardsValueInCompensationTableForTheApplicableYearMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="drio-20250520.xsd#drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="OptionAwardsValueInCompensationTableForTheApplicableYearMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRE 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DARIOHEALTH CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Summary<br/> Compensation<br/> Table Total<br/> for CEO</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Compensation<br/> Actually Paid <br/>
to CEO</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Summary<br/> Compensation<br/> Table Total <br/>
for Other<br/> NEOs</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Compensation<br/> Actually Paid<br/> to Other<br/> NEOs</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Value of <br/> Initial Fixed <br/> $100 <br/>
Investment<br/> Based on<br/> Total<br/> Shareholder<br/> Return</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Income<br/> (Loss)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: center">2024</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,962,084</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,678,609</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,238,304</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">3,782,931</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">45.70</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(42,747,000</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">722,187</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">274,283</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">879,232</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">576,066</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">40.13</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(59,427,000</td><td style="font-size: 10pt; text-align: left">)</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">Compensation
actually paid to our Chief Executive Officer represents the total compensation reported in the Summary Compensation Table for the applicable
fiscal year, as adjusted as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Adjustments to Determine Compensation &#8220;Actually Paid&#8221; to our Chief Executive Officer</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Total Compensation in the Summary Compensation Table</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,962,084</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">722,187</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(1,344,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under &#8220;Option Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">157,220</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">903,305</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(351,996</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(95,908</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(283,475</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(447,904</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Compensation Actually Paid to the CEO</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,678,609</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">274,283</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Adjustments to Determine Compensation &#8220;Actually Paid&#8221; to our Other Named Executive Officers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Total Compensation in the Summary Compensation Table</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,238,304</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">879,232</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(672,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under &#8220;Option Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,068,171</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">596,365</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,688,434</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(157,758</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(145,408</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,455,373</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(303,166</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Compensation Actually Paid to our other Named Executive Officers</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,782,931</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">576,066</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 1,962,084<span></span>
</td>
<td class="nump">$ 722,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">$ 1,678,609<span></span>
</td>
<td class="nump">274,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Adjustments to Determine Compensation &#8220;Actually Paid&#8221; to our Chief Executive Officer</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Total Compensation in the Summary Compensation Table</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,962,084</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">722,187</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(1,344,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under &#8220;Option Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">157,220</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">903,305</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(351,996</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(95,908</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(283,475</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(447,904</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Compensation Actually Paid to the CEO</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,678,609</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">274,283</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 5,238,304<span></span>
</td>
<td class="nump">879,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 3,782,931<span></span>
</td>
<td class="nump">576,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Adjustments to Determine Compensation &#8220;Actually Paid&#8221; to our Other Named Executive Officers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Total Compensation in the Summary Compensation Table</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,238,304</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">879,232</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(672,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deduction for Amounts Reported under &#8220;Option Awards&#8221; Column in the Summary Compensation Table</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,068,171</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">596,365</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,688,434</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(157,758</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(145,408</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,455,373</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(303,166</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Compensation Actually Paid to our other Named Executive Officers</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,782,931</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">576,066</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 45.7<span></span>
</td>
<td class="nump">40.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (42,747,000)<span></span>
</td>
<td class="num">(59,427,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Erez Raphael<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Equity Awards Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">$ (283,475)<span></span>
</td>
<td class="num">(447,904)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">157,220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(351,996)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">903,305<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(95,908)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Stock Awards Value In Compensation Table For The Applicable Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(1,344,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Option Awards Value In Compensation Table For The Applicable Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Equity Awards Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(1,455,373)<span></span>
</td>
<td class="num">(303,166)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">596,365<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(157,758)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">1,688,434<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(145,408)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Stock Awards Value In Compensation Table For The Applicable Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(672,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Option Awards Value In Compensation Table For The Applicable Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">$ (3,068,171)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=drio_StockAwardsValueInCompensationTableForTheApplicableYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=drio_StockAwardsValueInCompensationTableForTheApplicableYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any formal
policy that requires us to grant, or avoid granting, equity-based compensation at certain times. We do not grant equity awards in anticipation
of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time
the public release of such information based on award grant dates. The timing of any equity grants to executive officers or directors
in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such as an executive
officer&#8217;s commencement of employment or promotion effective date).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December&#160;31,
2024, there were no equity grants made to our executive officers during any period beginning four business days before the filing of a
periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing
of such report with the Securities and Exchange Commission that were likely to result in changes to the price of our common stock, and
do not time the public release of such information based on award grant dates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">We do not grant equity awards in anticipation
of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time
the public release of such information based on award grant dates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>30</ContextCount>
  <ElementCount>17</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="tm2515450d1_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tm2515450d1_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tm2515450d1_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>drio-20250520.xsd</File>
    <File>drio-20250520_def.xml</File>
    <File>drio-20250520_lab.xml</File>
    <File>drio-20250520_pre.xml</File>
    <File doctype="PRE 14A" isUsgaap="true" original="tm2515450d1_pre14a.htm">tm2515450d1_pre14a.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2515450d1_pre14a.htm": {
   "nsprefix": "drio",
   "nsuri": "http://dariohealth.com/20250520",
   "dts": {
    "schema": {
     "local": [
      "drio-20250520.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "drio-20250520_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "drio-20250520_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "drio-20250520_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2515450d1_pre14a.htm"
     ]
    }
   },
   "keyStandard": 17,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 7,
   "memberCustom": 2,
   "hidden": {
    "total": 16,
    "http://xbrl.sec.gov/ecd/2024": 13,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 30,
   "entityCount": 1,
   "segmentCount": 9,
   "elementCount": 268,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 52,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515450d1_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515450d1_pre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515450d1_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515450d1_pre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515450d1_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2515450d1_pre14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r96",
      "r112",
      "r147"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r183"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "drio_OptionAwardsValueInCompensationTableForTheApplicableYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://dariohealth.com/20250520",
     "localname": "OptionAwardsValueInCompensationTableForTheApplicableYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Awards Value In Compensation Table For The Applicable Year [Member]",
        "documentation": "This member presents the adjustment (deduction) for option awards value from summary compensation table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r111",
      "r146"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r107",
      "r142"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r92",
      "r108",
      "r143"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r115",
      "r150"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r110",
      "r145"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "drio_StockAwardsValueInCompensationTableForTheApplicableYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://dariohealth.com/20250520",
     "localname": "StockAwardsValueInCompensationTableForTheApplicableYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Awards Value In Compensation Table For The Applicable Year [Member]",
        "documentation": "This member presents the adjustment (deduction) for stock awards value from summary compensation table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-050983-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-050983-xbrl.zip
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MP#D)CCMN$KI5\GEY=' 3E6^\:$+J+IH\M-K63/E?@=_K;F?^.Y4WI'2_HNJ
MHI29HZS!"2-Z=+<S[8T##=M_GNUL":<*,X319AAG2I3#'035OPPNMF$TG&":
MQ4'T[?)1K;RE0#)3D,'FV/[BQ'Z-[WO/_6-K2!#^K:<X?/"68<8V#&F"&TS?
M!;)&SG]__7!"\147_3GVXI@2J-_'.!0O[4+S::-EN^S:1:>^7:$8U#N%]<3N
M[K)SL#6R.1+[#H)-]%3PZ*<54_S?R1P7"(OLHI;QY@U0@Y1+C,X,)1+\?=M[
ME+(3Y]EYSUJ^46+;I?_'<KXU>YMZNJ_6,Q]/UNY\VC3MZ=-E4L/^!E!+ P04
M    " "N@+1:!AS9'I0-  "@EP  %0   &1R:6\M,C R-3 U,C!?;&%B+GAM
M;.T=6U?;./-]?X66?8'3IKET6PK;=D\(4&YI^$A"87MZ]CBV0@R.[<IR2/CU
MGRZV8R=VXHMB&[9/$%N:&6ENFM%(_OCW=*R!"426:NB?MNIO:EL ZK*AJ/K=
MIZU^M]+LMDY/M_[^#,!O'W^O5, 7J$,D8:B P0RTC+'9E5700Y)N#0TT!MMX
MO ,J8(2QN5^M/CX^OI%)&TM6$;0,&\G0H@] I4( NB!;"%* ^Z!MZ* MS4!]
M#]1W]VM[^_4&Z/=:H%%KO.-=?ONHJ?K#0+(@('3KUJ<M'Z;I &EO#'17;=1J
M;ZMNPRW><G]*'P3:/[YEK>M[>WM5]M9K:JEA#0G8>O6F?=&51W L553=PI(N
M4P26NF^QAQ>&+&$VDVOI I$MZ*^*VZQ"'U7JC<K;^INII6SQ>0/@HR8-H'9!
M6@%&^SXR-+@"+7U==0;)VN.92=K#*8:Z N=P*61##K31Z* ,Y'9DB#]M*4@U
M_FUJ6@>/(**" '6+C=UM-T)PR)M5* -K[QHU.H(_HCM6_410+ $R7 G:2C)@
M"B4NX?]J XV) &E)I1_JE7YWZS-I"EA;X&_\D<->I+B)@G,G(=E%3_Y=0[+3
MHBH;1*Q,7 E0/T3&.,:L8V/=",DLBYQBQ9#M,=1Q@(HX4UV+F&N#S;7L:PV(
M:0'D*3 A :B0?R5,&MB: G0#@P%Y@0SR3IL!!$T#4>NDZD#29QXPS1[KP!@R
M*%U[/);0+,!.T),&&GSS;+E:8\J36'\/#-VV8BDL;YFCAC*$$2K)WLUYE3>G
M K/FL69.<-X:YF$.4ZD>D7C%T#0)@8FDV9!JP8!V -NR9(V(EE MTBOTQPZ
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M+'(3>Q-2%[HA+IPYHG>O$]52B!Y-(C,=+*N0?"(9,-A\PS78F.T[#+F88H-
M)V)J^L14]F@K+C1[$>)9"P0CF3V"ZY (!8A[(ZLSO(86)FO]0Q),=(8M&]$=
M*=Z3OH'*(0L%G!>W)*#/[AR$TI%;_4D.@UF[@*9(G&5RTP*=(7 0 8J)_G9
M @K3=2@<)> X@RV6U]K%5D-M6%C7*:UP7A90?I/3T,3Y&MI@'A'X\AG;$MO
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MD)M+#>5@Q)^#P19IG ,Q9<!@KRY8+)4A%B?CS\_ %I8C3[0M7P[[6*"<I/R
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M!2E*4^D(!%T0@L/X,D2Q*D]4D.<:Y!]0?8,XG@>1-]6:S$9B;\WR9/AUDD1
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MYJ"_I20&&O7=W(^L&G!2E1'M<U,X&15$64*>4..]9B)BXM8\\8,R?<=(GU(
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M^1?1]("W'2&SNNNE.KG,U63_]Q\17@3OS=EH?-<K<>W%1*H(%LD@#\+886N
MH*CN 9G"M>B-*< *;LLLM"(:4"P;NX74+48NF9&Q%&D7(\F;0?J<MU/S2OFJ
MXE,NG+ON;^3G]?$LGP,*7H8!6['3) Z'BE:%=#3]?RM@]>\:CAVDF@BK5P6!
M9?KX>,.8JC$S[:>8F:>8F3\=:6\AJ3H9I<@<;(ABD=7DI46D8H N834GM]\8
M!$-T4C-[*0@??$66@9+2=*F968;DS='YIC)R(1%;TH\#\LP9&6U:9;2>8;1
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M /-=I GH*ANF2DFWV^M]^%#W530Z--X$:I)B]87_"/[OUE;KV=O_^=0[0R[
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MN\NUK\7V9XW;;*(CJJ CI?4A>[_R&@,CN#134X0": EH"_0Q(FRH+?215MQ
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MQ/-(G"V?A!/+7#,DNM79'A3N+<\F-:J>S>EXS$A6BIX5NPU0:&.O\<QGP46
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M>SLW[^LG7)^/812HWX,TF/S8*>S=W6J; =\M ?X@N&+;P@' '6[@#VWFQ?V
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M'"M5W9>+ ;6<(+SH5(R*I>BT>9RJ_41&<<33,ROC<#!:R=-611/'Y,.0RV9
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MZ5QA>DT471% \;<,_Y&? 87"T%%@1CX )HS1DAS;"N9.CEBJ&HH!%\T3V!&
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M 5C8M&^EZ?^V:-;V3>^36_K9VYV7+_S=%[43O=TJFJ_-PP# ]M:VW][?^WD
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M4Z&\A\2J;NN^>_'DOKM?]]W.D_ON(<AQ'\L4W*6DGHFJF6$IXQE7\TB%IV(
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MS6FH+A.WV)T$L.04B 4K0,BIB=#3"0)XV@#Q9 F(3&$Q,2:R6ORPC!1&2[5
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MG#=K7!3'G-[N*5XAA2<GF+F9G#2M! K\6J:&F7W69@JMSCD526]S:-HL;&Q
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M&(U97GB#@DU*B8WQ#?AG^DC%SPC'9P[FU, X70B>ZA1Q)B6L%$;(.7Q!F%3
M3F,05?BPL7_'ZP#%D$G4^#K*KQ*@\$)PG@^&Q'T8S4Q&R$_5F>JJ%J+C#E#B
M\SQH%%U0(SP //PYA*_ '2,&H'B&1H:%_V'<7>)X=<=,ZQ@5)Q!.3*9TZRB?
M3K$FA<_E$H_WDGX<](3&.).B(@LI@37 +Z%EDV3Q_<ZD+UB1AFEP<.U_%]$M
M7E<DKAK1P4'A7=:L>!.E:,,31VV7\O0-9T8;%7-Z,PH1A2@K,A6 GI?%/KJ
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MX>D2IJ?NW  _((-*KUYE<7"%\*RI?R]GUL)GBL/[8Y_GPPYGOJ("4_*9.-X
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M0FL8G!BSIE<!P4W0$<_KM:0<AY<AME!B%$Z. OAQ7I\YQD<QN#65,<-7!U@
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M\_F%?6_I7=[$]77I\OVZAP+C&>[R?O/-K#%@ZOC_9$D:#._WSC[/\SQ>V40
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MYY'O1+,08VCH $VBF*:T&"OC%954'7'1$9VJZE'3WDD?%X"WJ/R-QNP93-K
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MK(NB?OU'1OUF42J.%3(=BSIW]EHMEG,Y)Y"<ZE% %'6>+!<PY5S5;<*WQN*
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MTW-:C5;'PZ^!-">1'D8S##;Q!W2VR/TEG#;@%R%CLF'F]@2L.,0/A_B;7I8
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M9V-7G\CXB$;*GF25CVC$21I'./FK69).:1>P])7K>&$KV5,PBM.<MPA_&A1
M/R#/;O*4*VERE$X@&"<@[(94<0,V/]::E#PBI]N#PD,FLS:!N$@+34\[%*;U
MCV8I$'PZBJ.24,#RPI9HCY+A;$"=;)!GP$94*P4K)PHWPAPH;,-;V0:G]HL@
MA544C(IH!J0)<[3UB&2A4:5_/_[CCS36M?Z^^\4GFP [ 5#!.*?Z\PY$7 [O
M;$MT%:%Z4 TOU<:#69_*K,TNW"0YUZ+KK<1"2U1;KV:IS)H\!W,Y8=B%D3F&
M#':0)K,A11)T4SELLDF5EKHZ.A0\"_A'+,&R4/S-H7@J"FJW(.&RT+UI<E,*
M+OML.)K*99/?F&H/73BA-DBG"I'T![,".04YS:CV<U8(Q#/<HQ%J1!O[LE=:
MR0O>(>Q&-)*2ED2CRB'606D=9#(]AZ-LPL:_L[<&-TT)@ 4NE_0Y=M5A""G/
M8&)SJAQ+!2L4G\*'KB.P&63\(I[,=.,"IS:DBG[ UTS@&.P>P8S.9$9710Y;
MD\57( 1BN23F[B2E/N75;L?[A73V>^^BQSPYU!JI+6E3#A^W3CS8\>P5OK?I
M=E!&/)#7Q/9^J7Y0+C7V6+ G8:!$/M.U9%"6\PHT"?9/SAAXH;.Y6Z7Z55VJ
M$\@!"NU3]HO61#M+$#)PP^#QA+N ?2!3!&X\3$9D@D^;12S/.K"SUN(6+:$A
M?H*N-.*U%,%LDF<_=Z10(86D;B6?@!P<_&>6,)Y*L*%=R\;#34'S"@\Q)[BI
MA9'@K3@WOL+?7,!WS*U,WOR#7['X,9H*M8,>@POXJKSUF=S@1KL104;>&?&0
M8P@%BPA1[DF.@>"UD_:CT<^-%PH>V]ZS/]7A21&Y9@QTA;PR!5%-$D5@0% C
MXRF1-T<[B&SKFD_:(6^F?">P#@*S4]7V+&5'0#-BV"8"15@$M%$RFE+H FT]
MD(9;?_57!%I8G[1/.23I<^^=C^&W4X02S6=3#8,3U(ZIX["U:]5PKRZOD<$.
M!9,+._Z2ABW%K$(#3A0?=<@TO=O'"09]A#TC^W/109@E"QX11LK&<2$Z&AX[
MJX;N'0^I.!>=C%YU>O8J+^# 4<X.\EE1^@6N$;#FP51CA9G$B*FWJ C1SR+0
M;XDB7V'=N:7*;4N5ZMZK1Q6B([\:^37Q=31H;K"9UGP5ZH)+3UJW!8ORP":J
M2BN;D^*<!#+Q(2:U<-#B_"96%5O<JJFAM1DSPOS7TG\C0>@^I#R!Y\IS 1MB
M*BIBY_MT%T@DE-=Q/"7+!0Q54(P):],#^ J51_W]A/F=0<)@]S[#S5@2#T0-
M(8N0U)#-3L^H4N1) STJRY<R<K5:4QLLL^(*Y.$?VC37G@&/UU!.B\8K04L*
MSDX39'Q#&8$>,.$@C0@!S/8X<9TNA&>@##@:&VIHOCV*S_M%G^;;IM-,$V 0
M0V/6#I,2#M5<PKS0(3?M/HETMEN!/HOKJ \6*)@#N1!$7-SP#^A-2&"N8%N(
M5C>27S/T28IT@8HAQNZ*H6+W'S$:)IQ91K8BAF.*V60Z,%Z7L!,D=QST:;-Y
M8%BV]B>541I;U0&.7L,QZBXMN0!W8-HLX8C0+P7.IRSC6I*USK\1A7K#B[^1
M'C**"=LWHH&382(]89PQ-E^48KIJ'&R_BX,]ESC8;A<'6V\^>%WWF.7#)5)#
MD1F=(YEAZY,OJ)/,D#L-8T;%/3IP47%# V4FN=;,7(MXFO>"$_3OZX04;I!;
M^DF#-"RKJ)[[2Z#H%44(3&R@]+P*4U,8\Z)8YM.ZR)RSEZR=NPD@XHC75-KR
M54Q<Z4QF4I'$6.)?^TUP3*#20=VN.K)V+=YT+:=)=:F!38?[[\;#S3,NS;D[
M+U#'-*FLAW(U0?V4(J*_;/6VMK:VJREIW1E4SN!KTQEH%^3BZU4KF<6,K'=Q
MBDFV>##%1*KS%_'6[D J!Y(V'(B.[B[!\DS6O(_R#AP)&!?EK%]%5[7N(]5(
M)(=/)66?OD[>\4(/,[<U4(39>9US$85 K<=#96J<](/=25=/>MQTTK#1LWQ6
MJ@O>MF68H/C>FL*U.A.@*=/&/6];PQ!1NK4NS W5.YN(4#AEN2;^3X4H:-ES
MTB17HB %<*%)TZ3L*@-9I>/<\[0G+KXR0Z+/*B;<1B[?(#_&P,0A.2J*!DNU
MCL;-4F*RMENS."1?W0]W"]!AJ;>',U#]N4A%#]Z$.Z;BW)/7 9"#SHD(Z71#
MFQ9+7).WWNZ\],+0^^1HI<OM?@_[=@?QMP@6B65)SC*H6K;DH*.S#4WN F=G
M%/M_[";2YIBM(MS0JB,W\]:C_;G5B5YZQ4V2KZ*3MD-=[82=RIV2IU!1RUQ=
M)65(O94.^^SVQM09\EU:"J_&WC-L=!+=\ _]DCN=D*M?L]AHRBEQ#CM690*V
M/;V'R4[H>"OF^F<@\'Q@?;$F24NX>D3>'.8ZM4]W++;*8K,:B]54N(SUP :#
M9R]T6US=XKQABTOV)R^A0S9)+ZZ]C*0JFQ46,LA(@31^S #]R)ALA3'1&^2T
M?A 6V\K$0X.<+.P11YU<STO\/:4U I>.4I4 (TL*_.&U68[EPM?Y;8RN<LN(
MJSD->GP=)J&@%[/!9F "6T(9V/V2&A93<ZS3$B(=1T&/ F6T>:;GSLY&O+FQ
MZZ<9H$="6FO'%=%@9+W7IXJ+3&N3Z<=.@:ED0#B-6! PII\FY75#B6L/TR3B
M"4VX!#XOO@^.'%7J5$MO"YU95'=ZJ=T-FG,[EMNUL#(WD!Z*](X\D_BINY_<
M:*5*OT-<0-J0_"+@%[JZF"1(GEV]HB4-S;(Y8W0,%"ZIRGZ+-"T:K(@U^HX_
M%9MEVVG@==XUJ?$NK>%\AZ5E.OM:[= D[]YE=S4Q'U(!;2UKA:"4>VT8S8()
MR &T:(%&"3V5CF\[K@U_';=H>J3) 5'IG'X3_5&.O;_,[=O;V?-\IQOP42\?
M[?SB4W!&&G0E$0W^O(D_]H+?D(^8LH+2T3%1'YY$<QOM'#IBG]3@$:SM#AO8
M,TK*&1YK(CTY',U5)FUK'4P:Y%PM&AW/L85Y32PT57=AO0O[G_J%E40\=3)8
MHI(8#\3ID.?U/N=6>7MN4.!%'<"J(<R#+H3Y7$*8>UT(<[WY5B%\2TNXY,U[
M,#?4;U'Q-9[R-;R[K \9DT[A(W<'<K-VR#1':X]*@2]:"Y%"0<'[0J"W_^=\
MI&I[")I\FI0"B(D;[YH[W#<VUC*$5",V"K"/,!]M.8>WQZZ&B+H1MN*C5CB1
M-05-83I]69TYP]*?HW(8_4>FQ71##J+_S'(]/?MQ=T[L/<(V5U<9E;8[10'X
M,FML/,]@@RL;65!^NCQ5;V=IBBUQV/OQ$_SJ?[^5SV_RO)&0 Y>06>&B5H92
MJ&?WTYB4Y$5+\Y*J%*(TIE[.@]A"H_'F1J4L4.72'E@O+90=-IO@KT-VS=T(
M.1'C"K\"-DD5EIBE-N8[5$1#IQ.=._5-:?>E4LRHEK'T\T/J*I38&CN"(AA5
M+$4]*;UN7K%T$:->44YU _8N!QN;]@?7S7_GTE3<+V6\'E1A4S -M'V;T96X
M9QL;(6_3/$?OUE6@=UR@B?)9P=JT#8:C0Q[?!L45)-!ZL)"'XB'G&7$-[?S5
M(%%,(*7)T7-)J>W>-/E;@!*O,,-Z%"'9>BD*IC3:.VGENK"!YY0$P J/ZH1J
MY!3P@$ /MAF<*(9"6[-<+6(4"U*<'T7-Q%3&Q+3S%0,3FX[6IWV/A(N]G1W/
M@N3]8%P6#$BDJ5L1Z2;?Z&BTZ7VJ'[K"'-J,*V=->@Y88^6,>B-RR-JI8;YS
M6]!X-%NC*M;WM.:;,V?7L!LT:3M5,N_MDMB;Y._/UO%);8.PMOA^RUZ':_^P
M2EU9,T:;CWH5@"L,-F52#?V?&<Q_-)<0I,$/%=&8+^WHA(NBJG3 "?9=/MJJ
M9SZMG?G'/'NEG6BJ$EVR7COGX.7(G7CH=2YU% Z<L837HX"$.UQ#&WLMK(NQ
MYIQ#S_)G<L\ITD<OC(,NM# 5VB]H\C5(.VD&4=QLK#BUGPDJGV$-3B>'<(0;
MU#?RSMD(,7^#D2QTQ-Y-,O?V9R/F*,*(76C1.)]E4^E]R3YOC/6"4H50O5Q"
M(DX[738E[/$<5$.UM[5G$$>QW--<@N#BU=];.&!>=1RAOVC#<U?ZXU1K9S>=
MW1?@2J5#WJB"RE[(%KB%?HM6V;S"8/$*"3.89R*Y0%AY'EDD! ;[A*-"\,I[
M?%]+GST#V%B;Q.L*XHI3A*Z<R'NDG:M8$&8\TD/_CM4B+$X![T'_U6['PZH\
M;-;$PY0!1@_N*[MT.E"S_&KQ=2,YFJLQCN.I8M%D^\=36:-#M5=8*\LA,=:A
M$'FE-)0FHJ\,]G:V XW(6HDV=#11I8F;&DV(C%DF3T(JPR0+$$%1F^73$KK*
M]H%^R?/-&Y7%'C5CLAL-1G4:S'(G?5L_Z>5NNEJ0RQ %7F^%RE^]/";16S6<
M;E7(=J"ZRQSBMY9#5 L0D2M,NP$*>1TQCE>-BAUV4;'G$A7;[Z)BZ\W%YJU<
M;"5L<%L1W8^GMPCC7('0<'141LX(8G1U$D"+R2=CMR"BMG&K$,RM\1/D- 8Y
M,LY><(8H:558<NO!<SR1"[Y@>.R+XJE/0AQ_M!$''^$2E*'U4C)@.8%=>]G*
MN_0/0EVQ+M+0#9'PL K579P+:[P.1!-_I#O16I^7:%/9TV3W40O4G87_=M/*
M7!P"%VF W2>@M?2+_"M<?S <$DIT=5XN;2R4ZC*2N%1Q9B*R/K8)G+T&0>0:
MPT7#M$\KOX7GV5NKNY7 YQKPP=!71P!B.K\UGP*_:04*0Q8S2!&Y@;N2<*@:
M5IR9$7A*WL03B:#2[O2"$V]K#8BDVS@GFA(6((-,<"4(Q7:UYR\CT'6LWAA-
M-4;^,#<%'.8Z-555F%&P@%-8<62:K"@<MKM!M0XH_<H-<JM[5N>&# AY3V:H
M7&88M#)#EI;=25:[H@R\DX1]7B9Y$8ZJO2&MF[C(_K(,^\BA$L(N?)@5'2S\
MMSN06BN4(1Q(11!9W[[?:J;BW3?22BX4\C#,?BGKZ2]6*70;2G:G4>L?$B]S
M&O8<:*GTU\9>0"T'%MP66.%QAP5!7<S\JHKES(=*?8TACBHYB2UQ5T,CU=D6
M#]998>1RW^9FK<W\&!4E)C3]\L7OU4>K_(!T*>F)&T>%I/6 Q$QCQ7%0K-(A
MC&3.>0'-+F),0^+9DD+$VI@N:0"Y2^C;Z!$9 !DC>/?"8BSQH=NIE/%T*A5*
M:A"5UV$+UW)@25T\8:IWMIBFI&ZO/$KD%9#5VA=VE%M##[]:P!C=9F??Q?*"
MY5B>:F1YK7Q.FB +MW,GV[E-'@XLZ]IC;7XL_&X=L_+"$NC7.CK@0+ODU6%"
MS/_HU-%[85B;L[3I)_>J=;(E3KLOML3I:5"I_NW>(*<Y:(M&L*SVW^UT#7OJ
MJ[?3)H=L&:__PWH&5<6EUX]A*[*'< Y6)D;5 Q7'F^G\3*DOU;DNZT,,'LR'
MJ-I]B+FSLJ7\B<$R_D0G>[#B4U0K^A2=D1K]BL&+\RNN&K\^ZN+7SR5^?=#%
MK]=;?J7IIC*@!<D;G1_#*#%> G@U^9N1;!CDH]'DZ6R<1<!Y8U=ON 19^5DD
MX87MCK%"2 2#%R1G-[B;G-.]ZC;S@B)5" NG6Y'2R:6;=7%MFP.AZ6W$]C:)
M[?N+:T' ,4 9:T$I_3>[H$P(?BYK$ST^P)>_MH<-IPOI^7O5Y$.K4/^EYQ:4
MMNDN8+&H6$X7.:[@,YU73;8^0V-3&<.DB'5;1:)HPCQN]D(RB-* ZOKJ3U22
M#XVBASV5T@6EC&M!_0\;+A8*^8Q<I+0U8"M1A@$C(UX4>B66V=#-Z;85[9RS
MSP780!=EZ=1Q*D>TK4.KGD="(YCFRB)6UAQF4I$C6RD70."?TO8KI./\Y*DH
M7R,2&U=@7.>W;-2R#Z/ZPFMU2SA]H.YRDTC/[8^_)JG4\G*UD)<"$5K+<;ZJ
M9\?=9H,LCDTA%_J>2:G?Q.;6&DJ!Y*:.D-!)\H*T7#<SF> ^3J<LTW7UFQ>9
M=86\=N7PQ+.9!H&LNG6DR+-:!"PP;%G+=A"F8:1;%O),7_.>Y%CTSU!_"[W?
M=L\<8(E0M2%+Q-] X<#^G@PX@.,AS #WX-(H64['6%W%+.^1>7>31+:M=7E-
M@D&/JXO<:.2;N$3-1=GS9F^C:>@<AWJQN&-8'U2O\\;?\.YQ,1J>M;3DIEU<
MAZ90#P=!4&,<A$Y6S&+) A'A;*OY#6/0->5S*NBL7%%3Y<[<HE(<D$S-.9H(
M7LA.Y8!+<V[RK[%J+]BANCW\;.3K>C[&KVEW:XB8R /[1K,XPF#F("^P)% W
MMX-_AD$NG<XQ[H@L [U$H-YD@[D>49<V2.UE)=I.'XZPQ79&,(VF/S6<)=Z7
M1 >MT%@ 7H6Q#W)@(9+R!*Z7(,41WH'^G,*V?W,)@P /6A,Z?F!"!@JV82>?
MILI!@O]M)RJ77[#OT"4NSX,H@'S$Z=?B'&X>Z!A@_Z,9B)("U,G PES25:?6
MCG HJ+C'0/^C2HU?2"\DQ'](KI@"841-C J\(3-&_*V"NN*AK,5!/-0Y+% (
M-8)O[!0A)%2JW8\7%-M2TD9[I=YZ[/Y#<2.\!L)ZYO645A?22X/\"$53KZ%\
M"-.I*JDB3>#OHB:93HH6T;CA6PT@/4H@J1FGAZ(KR4C'X:^99]+]8V#KTL_F
MP!42"FJ17%U/2Y:" \3.CMN>S$'"7T4NV SV-8(7D0PE\@F6 6-J+3/@*(9!
MP*!'V8R&3?0M0'PI!J^MZM2:48?5Y9$,5E%:Y@W9(TV?I>Z6:Z)!WGR'Y/78
M"2$1S41&HDAU*)F:#)1.EX'2RR)SK!H_84A;(P8JERY#K4=%4B@+G5O#<M!R
M(12K"B11DH,N:HPJA$.[1E S)\:J'[J*,Z0P['?IX29I))72L9,K?=?=.4WR
M%(%_RQ=%,JN&#8^[L.%S"1L>=F'#Y\AI[\%J@<>2^:=]W65-KM5$O<=<23!:
MTY(2A-WN/#KA@I(@L/>YV#34?IL'FH*$OT+G+_;,>#5,I"=T-,2U$;S*BV)K
MK;;/M\?2N8W?P?83,F:]R90%623-EUTX/SG+9&H!';6*[OD+J*<:<4.M2-:L
M5F4,)/S@.IS8XQR8$?FA8FN5SXY=K10%,9Y6SI\7?7(P+37DJ8U_,.QINVL'
MG13YE+6G/J-X,9Q7M9VV\O @Z>)F(U JIFTXEVL5^L=J-_$DON-.77*'JH&H
M%[_41PH%R7]@(W]A\N[9HJ=+'6@U&K&-Y'(1B-<$M[ _$*%AQ?#&MLYAD 3"
MQCZY&Q7;ZHY.N#:!N1^G^>UFJ#2$$UFZ$DK@N@5#!]6:!0E-DX-:.M*+*RHO
M3-!+U[/R16:_%5B0V,VHCV4-NCL<-R143>'-4.YD)CV=S:UL]QZ&-B2*,] ?
MD=[0L_[ "7C/]8ON<#>Q$H;D,QT$T-+.MV'@,#$3>;7MJ$Q0!)A.SI(=")9Y
MC'%XW\ED*#E?K#E*M<2:H%K T84>9A\]TP6^&/5S=/]7(_WLD*>W)2(@4(>6
MJNJ;[(:'>\'[ZCQ<0&'\M/8R($6 FL7_IOQ2=%Y6(]XA?&R(_Y]HE'8A]6F.
MG??&^8VA?K5!VT;M"L60Q9Z3#(<9ZK;1(!UNS2"4$-L78Y=KN8J802MA1['I
MX4TTB#*T)<T9\JA#$^9P>F=Y<1 I_@-!Y8<J,5'(K',<_9N)'W[&R(JYR(49
MWW0N= X*84 +H+ A<P2\;+=YL+&SJ9.E:!3:>37+HBP98\M$<:14OF4;B6(H
M4_!!@2+)T24TI$N0G!$6S9[BE4DV0[^2YG+J*P*"2EZ4>1Z!ZJ]TP'22D*<"
MCH!#MQ()%@>:9F-"SQ<^<W,S&4Q(UI34F= 9;@@-T- QS$;%^/BI_8+<UL4Q
M,4XJSX:S@=E<@\V)931L'3C.&]0HE5$BUT%G>*S8*,@;>Z-0.<O+A#D^Y@U4
M.S]\GL'Y#> Z7!815\IHJ7LRY9-DWF99N/OV1+\]I;=#G4YE<J<<F'?E ;LC
M Z<>4V,4?(9[@R 8LQN_@HY9*]H2(O)Q,8G5.GXP:5T@G0QR:1_7V )CBKNC
MEQ'5,H1$U%#;U92%G<L_M%KA B4;<-\R;,(ZKT*XJG_:+*,2KK;%V3<"WQ4,
M#N:^O8^^B'9THA6T(,+\T7I\\WIXGXT: A\C#ZFQ[G.;I:,U&'=0VFI'U6H&
MQU1N 5X/9H*[<X6N^#C1JB"[XKD&?01_P,UE.\0!_L!/WL#M&\*YM8#_Z?@[
M^11D%3A;>5Q5'M<:IP66]K;:%?TP%X/\BO."27,6SST(RB!OOZPTP!7=M#"'
MSDW[3-RT1YV;]KFI#2#>]WK\S0O.U:OH=>)360MGP^,DD].^J2\Q(OC?F2!<
MLU6KHBX:D*+"((U7!<O?]H1*C12A51ZE>Q\(Y+\6^O)>C #C$AVVPV.-\V%X
M='P8'NSOM 'Q""BDL1ZU(2T?0C7<J?%4P&_B;!@5P3R.0,3')OW\73P@-4$<
M']LAXC,=A,V_/VSY_5'+[X]IFK4_J9VMW2V2LYEKRMZUK7:[RN2;K4$YL"4H
M=XZ0E.5,L*6<P(6BJ,1[RFQ[AP$&>.1M5"*H/ZL.S5VMJNL"8[\6_(4Q_(H;
MH%.G<;8'Q$(34-X$Q(]4Q64!/:-Y)=*T;!!-$BS&V>!&U;FDPSKMF:@\J/U%
M(*$D-9&#X:8)$DBZA7,S_!=M,F]CFS@<P@%/ 36)I"$*:/)-VW3=),-SIE-4
MU5/LQ]2RC!=1YGH8V0XSZU ;HO#',K$]U=VOEK;<*DCSB$ &]8?UHG@IB@QU
M9\> 1R"S +:4ZWY('DPX;97122N=>ITL;DNJ#6'\RO;2RI6LW"P4-5S,RQ3)
M <HT3MA,%(=%J7R5T[FPI^);,IZ-ZQ?&@]>QHJ>E_[)JT;@-H>V&6UM;]/]>
MU86)W:'I:1P:U:;PV]N^**R2@1N*5"9M77AW);G#P.F3YM\ZES(FU@GCUB<C
MQLF+TLZ?M$CG2RP7#2^LG)EN/$-4W"J4ST=. C,3STCN$DHW./'XVP29C2[*
M)^^##E2R]YO0J *+1F6K":ZC&[P&Y$NOW1F^#RWB@NRZ@=<?AH2L.U%T"A<^
MWB0QRRO$/N (N(INHB0U\5%DW>0I\&]-4R.[AAPYWPO:VAC=N_229.;?:=Q=
MUTWHIA(-8[+)/38"S[.1+DNEB#WC%&2(BB"W+,D,@);W,=DT^HJJ< K:9]DP
M(&#L\-6\8^0C3V&YF$Q0L?)]U0KIS;2BTLQ->CDQB5!NE.(*5)M=:L,^\I)\
M+QYJ3_IUG#:Q<_05E-@K!G^,OO&C(%A(SS*IA^O /;!@\FYX2'WB'#H&/0@#
M!W&*5 U'.HH3*I2R*:CBA(119^ET.01*6V3#&D$1@_(UN([*NKR-N"L/*/I7
M5(1I*(HKBOR(!%/V8(K:IAV3!?IF*%'T!"=G6J;:X@[L5 L[]H=H/-P637,;
M+N5@_J2#@PZC:"-[G]37@88>&(M6VW[4^M6*GV;S;SG"(J;"6D2S?'$M1^3X
MLTQT<AX_5%.47;-"7Q8B'/DV_$6+E0JA2BT/YUEW)UT#N34EXUIM4Y]U3+A^
MVH335\3&>8R7^VX;,6NRVQH!_JSRJ%;O_@KJ[3H<;__-?B\XHX@ 9;YWWJE%
MWBEGHQ2R^ NJ($T&8K8TJ,;-"E[5ON&@MY,9WM.&D /?U6;%U1/AS3"A$Q="
M)F<;8*YWF&*["U,\ES#%<1>F6&_>J/T'EW&F&F"0REX-@^HD:(%,<NQ)AZ&U
MEQ,Z #$^QH#2GGI;F@A63!HC^"$&VZ]!):>:4 \-R85#>A\E1? ;YR80*W%S
MN:P;GRM)A^+WY_"#3C24=D&ZUZWC';7M2L@2,<E](USAQKYL*/OZ3?=C[R,O
MBGLOD9CK"Z:UT$ >-QGW1#G-K+UK8]([="X74Z6+C9U@0]NI4QDJ5(7)->_S
M0CHH7[PZPK;)-OWT8@HD2+Y68]&JA3VIO;&J+:EU^H<UFLFK?L4@4&)XD]4_
M&J'&SS^441JW.-N5$YK0\31GD\!&QU1'$VR*IC,+5EKJAN%<M$*#FS<3[>5V
MW&>FW!S3"F5D_S5E.JC3IR*-$\5Q!C</R[C0Q9AT\J:XU[ . \CTO6T-72ZH
MS5!;[Z% "EZ[R!O1U,$Q"3;.K;N,[2-] NQGBS)60*5PV'HRJN<.IQWWKGHA
M8P]2EDQ6H:9=U4Q-A!R[<:YGXG2)YQ!5X;[5.@.$CBV&G U=S5RKY*NI^NNU
M#D,> $EUUVA\?--\P2&]-+HM368HAY+B-+[!]_X-SY3#-6JZ\EAYDB<4-3P!
M69[RB@[#8/OX^#AT,O,.M[;IE'R&Y=3<%K'/6QP9PSY^S%A%RXBLKV3TLP=0
M0P,H_^J6KUV:B.?ZYH(ZGD4@O8<N(V$^04XE3'^&CW+#L9)_T-G&K_);]+T;
MX.!$7$W^WY7[=\VT>&P3:^3A&<IIX]2!VC%S\BN :M4&AM%J)NM0-8'12!SS
M51$E""NIX%)F9320X# U4J?QAV1TIG/VMYF?=+T2K2ZAJ ,AW)"2I:5595%V
M"NMP7QY4\SZHNQO@MZ)U&K?:VNA3;K]3(ZTT!CB5TB$%FHQ@I"[%2=)-*&:U
M8CL'3,G!"N,QW;"RU>R=]B'TQDU#TYM><)*FZE,U@Z.,)U'!"2G#N(1U4G\+
MF%.;OP@N1SML"C&$WWL7/1?_@-[9-3$T[2S"]>BW_/"_[]W<VM%<YE,!>@^Y
M13<BC*>-*%9HY;"3TZT!B#?I-I^7103*J#\IUJY45>W,AB2!!^BU&,%H4^%6
M[)-'O51OF?L,U9.YK]PF0A;LRA]9EWW536Q"32K//&PO2KMBH,&1[J0*>U^C
MO"FE-].A+6&@8C8_1B1,55B%8I23R5)-)O& P+#$,Y/ZD:J:XV;#\/@4 ?-S
M]2L(PCM@O]O4<PLBW!3.1C7(4?"<ONWNK!8" %E+902261XW<&0FX3I3Z(V7
ME+N(GD5E'0O6^R0V.%E.UA@&_1FHBQ$I6Z[9WWA8"RX2USSY4*&&[O2M:82%
MY"G$-1;% 5*X.M/K(I]=75-AG-.E8.2&&*16J#]W@A[,<92-<!NS89//' N^
M.+CNMX7@@A_"<'9%P8L7 X_CV =Q.8B'0&/DUC\3?E 7L"=9C;9JZ5Q4R^/>
M7TD5*VU&@ZY PUAT"K1?Y%DR0*)*Y"!EL+:X5$T &2^1U*=2UXO4+^!TWR0=
MT>1*4&Q; W%J14P8)R7/U=!%G:&2TLO9RZ^X_([F2K%[*Q_<I(II] W#'._=
M3S.6(M=>V&P_ZJ[!M9D,'3J]SH<N=*@3R6V$>[;HJ_+GNOP6EQT7?5[6_(GN
M:6<YIRT-E4[FH23A@:FRA3?&F%@3P]SAV0$<QDT")RR=\T+7MZ%)1/;<Q2_:
MT)D7=)MGV4#R;"N?4Y4AS)^3S#DK=V!T9T3)<)-P46T-6"64_:)XQ:KQH9TN
M/O1<XD/;6UV :+UEK T0%>.Z1)4*&74WK,.^&0DK+0J2(BV!)$(AJ$GJ)4(P
M"J7RQO;6@A!,,@UN(V,\&0!%^INU%,6+7)4TQ'-AT#3ITH/:$\&T_J4^%Z(0
MM5H4K02U!$[(2@2EZE%&HW(O-';Z[',30S#*O "DTXIE^>"C:LQXTR9"9LG1
MU]),LHD82>R<EHHC"\%A '/=K,K6O&)5*4]H-_UP>.KE$&75?4P9QH3Q$]'5
M7G6XV*H=!&Q@P\B+\"IG?14H_:@L9V-C/GD &9RESON0:TO6VMJ2$ZRC+PLH
M"3OQ1'4CNKOA;0F #3=\D5W>F C:<AG;AS$44KN8ZF$N9G,JZK(7LZ?N*/U9
MM$4/?+U44DN@^)'7:^OXQ':/Z>Y5_5[%3AZ%,9<;KXVJ7QL_I670P/ZCNML#
M3<BPTI/ ,[0=NY])-BZ#"MP, C^QGZKL.O'<]9_S3&'G$]S#G]#O?1VC&SN:
MZ_ F%T@,.3G:+YZPF1XM?IMUN%"/%HOFVA,'?K.*ZE7-I?&2;IP=WQ &228N
M!D1KF%CM_'TS5"8ZW9_;,BH_'87 9(C?NG>ZU9>O3RAY8_) <+"ZATUC\)@+
M+J@KSAU/H]O0R>*H"D5.L-"\Q82$C6EE\FG0MN*0N$:[<EQ7)%$0C(O*7QEG
MFP1#@LAL#$ ?.KJLP<!J<@W"[F,@'F,.[NF2:_2\=2$Z;:E2BF<+C4(E!5*S
M(L;DG-$L1>RU>.AA[O,IE0FP_*CP@C3T9Y-F( 4E_#A%.0D2_2I*?=>H5_H;
M#0;QA#PFRM*'@;I<AYO^P%?][5P94L\"8K,,%T=<-ER&S8;&_0OG>=.J&TJ
M3%\$ZB8X-_=,;(=^E.J03H/5V5#-%+@L00,8-K5;B <YB'52MK _$7(9(.98
MF@TQ("W7-%A0,-^9[DO\*LICE2%0^H9_^>J:!N%*^_V5W$"%<JQ520>9U^/W
M2/IRC=:#QA^XB\O9-^0)&FK3)A^ZF(0BCYQ#U*=@(B6<N]B:[Q"V<-40GS0"
M3).JE.\F!3;KX@]R*9Y)U" P"[ALT^@K%8$3N!?03#*]10,&N!WVJM<0J#@H
MD?9DFM9$8SD;C;"/ HH1&),RM.#>40REH4,=,W7=.ZA:$>QP:'/O&N1573IC
M>>J$(287K5IQ!Z.!P'CG]U^V9F:1:(S.-M@-:&K1A[C1;1OPHF[8JL&AW2XX
M]&R"0]M=<.C92:;':2\&YNVRME!857<B)W5""A"RV)3<Z/Z@M=1]R@:RB 4F
M6JZ\-D+Y+!T:M!^OA66M%IE$56H]6L"K'7M19"F#'=AT$0H,&&E"N@X/K.S
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MCU\_QG_.64=RA$MM(UF(^/XARI"3K"Y6\HS359BT[;=F,4,V= _A2DM*C:A
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MN/J(-'6=0.N^&'34M=.9DW@_-CYQUF!%L%AO>'5'7QL-P^NV8'[;U'*A);I
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MDJH*AQJP(JFCH%.P>NBWJ=X3C,A![,G9K49&-!X*;Q.QLALQ)VX\_QVQ$&J
M0ENQ:'ZAJHYH[QBU8MX-+7F_;3O51LG51DG0-L6W:1O,!R 4;DM76&5 K-*$
M46.1*QN67TZ0OL\PM!6?J;K%KO\YVHJ+JI:NT72-)F?65[Q&2V];HVYLOJ^(
MY+.K]+D@3_\BS6(S'&,1$WE@))8#B6?1 FM/F!=/A+/[DD-\Z1Y9+T?!S5IP
MLQ7"=0R?R@?),IA*.@8D@(B/%(O='LLA;$R,=/7CZC*06%NX1^ D"KX7^04L
MM 7+N/A0*/^1=9(Q)E.-HHVH%&E6\UKHJ5/;9YSDRVY*5  Y)0!!RHMU(I:H
MKV+GVBLTN+'((25#=4R2E2KO.5.H2W&EJ]"R2S1^7>V^K<GWU\/KC@T]BD-$
MZ&OC/$.03+\E\#,0Y!F.%4Y#,S?=>BB_T7I@ , T12Q<>ICGVEK/I((P>%[,
M"=1'&(VNAA(;?8F#@?1*BNJ\E#[H90["++B9@]QP>-90H!NR/S$S.@GQ-4U]
M1,-E;7=;Z:::;JJK%)DUFH(-G0?\>;9JEJ:&TMH!-*;65\P9"[Y3V ,'"H E
M&V,I?2P,H)J89XI@H&Q+H7K$#SN/J.K*5UCA.E-1K!;U1N61O8&W&.;N8*)C
M:? I_$6/&0P9@U  C/DB"UQ4=8^!3A)>UH6B9>G!6"*?@;E&)^CY4GX_6'_L
M"0V.WCC"8PDO,F_A"<>!A,WPW&1"<6WI+%M9#\;="M)_6TT"NN)]Z\N!';49
M]N?4L&0-#U$@=.16Y: +O+-K+VNSX2HZG 7W]&M+)O!MV 2.3GY[5:\BD^EZ
M-'IXQJJS]P(2NCHB*^YTR.!?&Z\PSDZVN0-_>PYWQ^GA+CW<O;O4OF%?O]+H
M(0FW7=BLP3S"8A#439K1X?R%QS%5!N/H5M6,QSWA!G=WOJ/B=:B#)/,5';]
M0$<0ZRP(DHW@+11< YMV/H1_TD)*\#',D:FK8# P$\$PLV!.38B.2#<R_1'V
M<<M6U0P86_<SV$H)CGK*^GN/%Y\4+H."=3B0.]10"%0S<[^@(Z3X-?PAG IQ
M@-SX0'N&4 \PUBRA=J'OJ,AR5DP*-BWC&<W65<R F@:;YXCCON<N#3S.>NVA
MH]K0$VPKT@RZLZ'0:/>E;EOJTROS?.%C!A&8_$YVCMM"2\I9A)IPCX^/>P_4
M &1I<,!WL,/WJ7WYD4(X@33J*LP(IJ,_T0!]FV)UP;?)J"T8S>P!O^(@-.Q!
M97<ER+<)L3,+O("(L(Q=\#>:/V4:.AF!_:K!HF*@1P2!SR?L:F4VY<E4^?Q)
M^=B7.!@H7>(4-8\X+"D4@*:.M8%H?^C4,$N>8 D0Z H]-,!##+9@7A)5>%1O
M855QU"96A(T/U#<.!"6ZQ<, :YKAO['AP:,1=:'@VO/&&7%00$Y,-G@Q/EU3
M>LWFSU'.!U?1!/%(K:'564/O:9#XIDPAUE23%R=P^,:S\5]D?C)696#4J2!D
MZ$]$ 07E_ 1OM6<3(#:BQW9@3E>]^[0S@ODARJ<=]O+N'1@>N_ KW"V!A$I.
MJL9HAO<J6-P!K)2N).1+XE_[@1:!ADNDYN!T!:@4EZGD'2KJ2#D1E:]] R^-
MQ8F] VJ.L.]FEK(CS"URHA/MTPZH"1SH?I#0Z4NT2\NT"^NB75ZF75P7[<-E
MVJ5UT3Y>IEU>%^U\A$@?K([X2]0+R]0/UT<]8M*/UD<]8MJ/UT:]D(]0,KD5
MDG^)?I226Z&6>Y%^A*++KU#3O4C_((+^"K7=RQN9MVM)B!VYJ,"^9<I: PSU
M^:6Z8-TC\X?=H^(1;++HYRL7B\?'1TO[V>LIN97R:II\'Z"0WSF]DS5+C=PL
M]_T;-"-'Z[NB_6:=_J41_=N)-1JK$QEH"G/Z\]A$\HI)C%V,&,J5"[F].>4=
M?6S##OUIQZ*11SO[C(.^-ATB%MCG\+,PGVBZ!;-EV].3_7T\JLUO36W/,._W
M"[E<<1_M<BP^"7.!#\@)YX'S(1LK,(--#9A'[#4*V[DXI;]R?TE/].AD )L-
M1Z4&"%OJ:._>>-BO-"Z#LQ+^V"6U'Z+EHP]'>F(H(?HP%-/&>]!3X%QI-Y>'
M_YQ&O&<";]XW%L7[*%_8+>8]RNR)OS<N99S? ,^>9V%^\UA8_!D6%G\?"POO
MP4*/->H]:@#?X/DC!3HRQXJMQ&ZQ= D%K'X=J[:&->*<6#NGN+9/J$-#?(1C
MN45KUS5T?\1T'X\F-</LCU71+08[5&63$6"]7:+[$UV3Z'4@>5 K,$GWAKE@
M7<1'5ZKQ6FJNA#@L2MSJ+::BMRVB%S>M5TJ0Z+'KJI7+7B+D+FXJKYS*W5;(
M7=STW4$RY Y_-30E7:F9('&=.^F[O1 ?0?[.3=U60/X>3&5H=F:VI>CWHJX,
M] ?+5EX6@T3(7-QTW6$J<XF7N;CIN:/DR-RU9>OW53M2ZD#,X+$K?"_-?R)$
M+6[J[3@5M:2*6MRT6IY?%2="V"IC_;ZA<UD+;YOAS?7*-(>FM2VW)'%3<?E\
M*G?;('>QTW>%9,J=:'7N^%[;N:,BYLK=6_;8A$A=[+1=,96ZY$M=['1=Z1VD
MCD9B_G/3NC[X]Y_/H^EL/M3+Q\J/PX?[X4(?5&>/YX?F\>%EX>N@O["TPX?1
MCYQV8>_;E</*PY=ZY^)K;R!=W ZUWH_<WY-^7OPQ&E^*7^_+XO?K"V)<-\JM
MR9PH\K#6G7^ND:NSRM20R-"6Q&'[VX_1F:VT^]?36K5Y\7 H%F^NNF<MY5ME
M<-X9BX/+P>?]@XZJ/$K5NE&_:RY*1IUT+SN7U[:^( ?7#Z29K\];7ZW6O&%?
M]O>/SK[+%76VT!\'EZ/&GZIU,/U^\5F;7];KL^ZUTK_NUW)C]69&*MJ?^=[1
M<*I^MBNCW+PU+YP7QG_FCUH'G<),+AR3+XOS*[4%#?X]'%T=U>V;H[\_=\<_
M_A4JO>[N[N]=KNZ*A&<OFAV)6(>QT_[E!&G_[1.GV*GU@X2(TX9$-[0-'>2O
M_:((;HLV.TS%;XO$+W;:[RA)XA?S0(=4]05E[SB5O6V1O;CIO4*2'#5Q#GI(
M=5Y0[I+DJ$GE;G/T79(<-3&,@DC57%#<DN2A2<4M]MKM/5PSOTO<XAW^D"JZ
MH.0ER1F12MXFZ;RD^"WB'@21:KR@W"7%89'*W6;INZ1X*M[-[9\JLJ! )<7]
ML*T"]7X:"LLZ!:4)ZSN=^KL_464$%3\EEE$JY ]/!KVJTYCSB'73^2VVZ10T
MXO6+V(].Q4.W0"+_\]90%EC5?&Q/M-/_ U!+ 0(4 Q0    ( *Z M%I3&>R&
M1 8  "(I   1              "  0    !D<FEO+3(P,C4P-3(P+GAS9%!+
M 0(4 Q0    ( *Z M%KGG)4%M ,  ,L+   5              "  7,&  !D
M<FEO+3(P,C4P-3(P7V1E9BYX;6Q02P$"% ,4    " "N@+1:!AS9'I0-  "@
MEP  %0              @ %:"@  9')I;RTR,#(U,#4R,%]L86(N>&UL4$L!
M A0#%     @ KH"T6M!4AI!( P  ?P@  !4              ( !(1@  &1R
M:6\M,C R-3 U,C!?<')E+GAM;%!+ 0(4 Q0    ( *Z M%I,0WLG+F<! #:
M"P 6              "  9P;  !T;3(U,34T-3!D,5]P<F4Q-&$N:'1M4$L%
3!@     %  4 3 $  /Z" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2515450d1_pre14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:drio="http://dariohealth.com/20250520"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="drio-20250520.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:StockAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">drio:OptionAwardsValueInCompensationTableForTheApplicableYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-102">DARIOHEALTH CORP.</dei:EntityRegistrantName>
    <ecd:PeoName contextRef="c0" id="ixv-1143">Erez Raphael</ecd:PeoName>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="c0" id="ixv-5000">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We do not have any formal
policy that requires us to grant, or avoid granting, equity-based compensation at certain times. We do not grant equity awards in anticipation
of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time
the public release of such information based on award grant dates. The timing of any equity grants to executive officers or directors
in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such as an executive
officer&#x2019;s commencement of employment or promotion effective date).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December&#160;31,
2024, there were no equity grants made to our executive officers during any period beginning four business days before the filing of a
periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing
of such report with the Securities and Exchange Commission that were likely to result in changes to the price of our common stock, and
do not time the public release of such information based on award grant dates.&lt;/p&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMethodTextBlock contextRef="c0" id="ixv-8328">We do not grant equity awards in anticipation
of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time
the public release of such information based on award grant dates.</ecd:AwardTmgMethodTextBlock>
    <ecd:PvpTableTextBlock contextRef="c0" id="ixv-5034">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal Year&lt;/td&gt;&lt;td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Summary&lt;br/&gt; Compensation&lt;br/&gt; Table Total&lt;br/&gt; for CEO&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Compensation&lt;br/&gt; Actually Paid &lt;br/&gt;
to CEO&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Summary&lt;br/&gt; Compensation&lt;br/&gt; Table Total &lt;br/&gt;
for Other&lt;br/&gt; NEOs&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Compensation&lt;br/&gt; Actually Paid&lt;br/&gt; to Other&lt;br/&gt; NEOs&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Value of &lt;br/&gt; Initial Fixed &lt;br/&gt; $100 &lt;br/&gt;
Investment&lt;br/&gt; Based on&lt;br/&gt; Total&lt;br/&gt; Shareholder&lt;br/&gt; Return&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net Income&lt;br/&gt; (Loss)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 22%; font-size: 10pt; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,962,084&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,678,609&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,238,304&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;3,782,931&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;45.70&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(42,747,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;722,187&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;274,283&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;879,232&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;576,066&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;40.13&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(59,427,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; "&gt;Compensation
actually paid to our Chief Executive Officer represents the total compensation reported in the Summary Compensation Table for the applicable
fiscal year, as adjusted as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;Adjustments to Determine Compensation &#x201c;Actually Paid&#x201d; to our Chief Executive Officer&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Total Compensation in the Summary Compensation Table&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,962,084&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;722,187&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under the &#x201c;Stock Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,344,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under &#x201c;Option Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;157,220&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;903,305&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-6"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(351,996&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-7"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(95,908&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(283,475&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(447,904&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Compensation Actually Paid to the CEO&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,678,609&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;274,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;Adjustments to Determine Compensation &#x201c;Actually Paid&#x201d; to our Other Named Executive Officers&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Total Compensation in the Summary Compensation Table&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,238,304&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;879,232&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under the &#x201c;Stock Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(672,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-8"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under &#x201c;Option Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,068,171&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-9"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;596,365&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-10"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,688,434&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-11"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-12"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(157,758&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-13"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(145,408&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,455,373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(303,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Compensation Actually Paid to our other Named Executive Officers&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;3,782,931&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;576,066&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c0" decimals="0" id="ixv-8329" unitRef="usd">1962084</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c0" decimals="0" id="ixv-8330" unitRef="usd">1678609</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="0" id="ixv-8331" unitRef="usd">5238304</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="0" id="ixv-8332" unitRef="usd">3782931</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c0" decimals="2" id="ixv-8333" unitRef="usd">45.7</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-8334" unitRef="usd">-42747000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c1" decimals="0" id="ixv-8335" unitRef="usd">722187</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c1" decimals="0" id="ixv-8336" unitRef="usd">274283</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c1" decimals="0" id="ixv-8337" unitRef="usd">879232</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c1" decimals="0" id="ixv-8338" unitRef="usd">576066</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c1" decimals="2" id="ixv-8339" unitRef="usd">40.13</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c1" decimals="0" id="ixv-8340" unitRef="usd">-59427000</us-gaap:NetIncomeLoss>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c0" id="ixv-5131">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;Adjustments to Determine Compensation &#x201c;Actually Paid&#x201d; to our Chief Executive Officer&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Total Compensation in the Summary Compensation Table&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,962,084&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;722,187&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under the &#x201c;Stock Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,344,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under &#x201c;Option Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;157,220&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;903,305&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-6"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(351,996&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-7"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(95,908&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(283,475&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(447,904&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Compensation Actually Paid to the CEO&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,678,609&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;274,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c0" decimals="0" id="ixv-8341" unitRef="usd">1962084</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c1" decimals="0" id="ixv-8342" unitRef="usd">722187</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c2" decimals="0" id="ixv-8343" unitRef="usd">-1344000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c6" decimals="0" id="ixv-8344" unitRef="usd">157220</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c8" decimals="0" id="ixv-8345" unitRef="usd">903305</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c11" decimals="0" id="ixv-8346" unitRef="usd">-351996</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c13" decimals="0" id="ixv-8347" unitRef="usd">-95908</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c14" decimals="0" id="ixv-8348" unitRef="usd">-283475</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c15" decimals="0" id="ixv-8349" unitRef="usd">-447904</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c0" decimals="0" id="ixv-8350" unitRef="usd">1678609</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c1" decimals="0" id="ixv-8351" unitRef="usd">274283</ecd:PeoActuallyPaidCompAmt>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c0" id="ixv-5239">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"&gt;Adjustments to Determine Compensation &#x201c;Actually Paid&#x201d; to our Other Named Executive Officers&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Total Compensation in the Summary Compensation Table&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,238,304&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;879,232&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under the &#x201c;Stock Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(672,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-8"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deduction for Amounts Reported under &#x201c;Option Awards&#x201d; Column in the Summary Compensation Table&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,068,171&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-9"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Remain Unvested as of Year End, Determined as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;596,365&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-10"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase for Fair Value of Awards Granted During Fiscal Year that Vested during Applicable Fiscal Year, Determined as of Vesting Date&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,688,434&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-11"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that were Outstanding and Unvested as of Applicable Fiscal Year End&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-12"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(157,758&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Increase/deduction for Awards Granted During Prior Fiscal Year that Vested During Applicable Fiscal Year&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-13"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(145,408&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,455,373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(303,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Compensation Actually Paid to our other Named Executive Officers&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;3,782,931&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;576,066&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="0" id="ixv-8352" unitRef="usd">5238304</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c1" decimals="0" id="ixv-8353" unitRef="usd">879232</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c16" decimals="0" id="ixv-8354" unitRef="usd">-672000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c18" decimals="0" id="ixv-8355" unitRef="usd">-3068171</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c20" decimals="0" id="ixv-8356" unitRef="usd">596365</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c22" decimals="0" id="ixv-8357" unitRef="usd">1688434</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c25" decimals="0" id="ixv-8358" unitRef="usd">-157758</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c27" decimals="0" id="ixv-8359" unitRef="usd">-145408</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c28" decimals="0" id="ixv-8360" unitRef="usd">-1455373</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c29" decimals="0" id="ixv-8361" unitRef="usd">-303166</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="0" id="ixv-8362" unitRef="usd">3782931</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c1" decimals="0" id="ixv-8363" unitRef="usd">576066</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">PRE 14A</dei:DocumentType>
    <ecd:AdjToCompAmt
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c5"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c7"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c9"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c10"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c12"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c17"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c19"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c21"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c23"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c24"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c26"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-8380">0001533998</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-8381">false</dei:AmendmentFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
